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Hypertension (HT) is a highly prevalent condition, although under diagnosed, in patients with 
obstructive sleep apnea (OSA). These conditions are closely related and 24-hour ambulatory 
blood pressure monitoring (ABPM) seems to be the most accurate measurement for diagnosing 
hypertension in OSA. However, this diagnostic tool is expensive and time-consuming and, 
therefore, not routinely used. On the other hand, although continuous positive airway pressure 
(CPAP) is considered the gold standard treatment for symptomatic OSA, its lowering effect on 
blood pressure (BP) seems to be modest and, therefore, concomitant antihypertensive therapy is 
still required. Data on antihypertensive drug regimens in patients with OSA are scarce and 
specific therapeutic guidelines for the pharmacological treatment of hypertension in these 
patients remain absent. The use of animal models of CIH, which mimic the HT observed in 
patients with OSA, is extremely important since it is imperative to identify preferred 
compounds for an adequate BP control in this group of patients. However, studies aimed at 
investigating the antihypertensive effect of antihypertensive drugs in this animal model are 
insufficient, and most reports on CIH animal models in which drugs have been tested were not 
designed to respond to pharmacological issues. Moreover, when testing antihypertensive drugs 
(AHDs) it becomes crucial to ensure the selection of a non-invasive and stress-free method for 
drug delivery. Although gavage is effective and a widely performed technique for daily dosing 
in laboratory rodents, it comprises a sequence of potentially stressful procedures for laboratory 
animals that may constitute bias for the experimental results. 
The overall goal of the present translational research was to contribute to identify more effective 
AHDs for the treatment of hypertension in patients with OSA and investigate underlying 
mechanisms of systemic effects associated with OSA, as well as its modulation by AHDs. The 
specific aims were: first, to find new predictors based on anthropometric measures to identify 
patients that misclassify themselves as non-hypertensive, and thereby promote the selective use 
of ABPM; second, to investigate a hypothetical association between ongoing antihypertensive 
regimens and BP control rates in patients with OSA, before and after CPAP adaptation; third, to 
determine, in a rat model of CIH-induced hypertension, the efficacy of carvedilol (CVD), a 
nonselective beta-blocker with intrinsic anti-α1-adrenergic activity and antioxidant properties; 
fourth, to explore the effects of CIH on the pharmacokinetics profile of CVD and fifth, to 
investigate an alternative method to gavage, for chronic administration of AHDs to laboratory 
rats.  
For that, in the first phase of this project, we used a sizeable sample of patients with OSA 
(n=369), that attended a first visit at Centro Hospitalar Lisboa Norte, EPE Sleep Unit, and 






ongoing antihypertensive medication profile registration. In the second phase, a rat experimental 
model of HT induced by a paradigm of CIH that simulates OSA was used. 
The main findings of this work were: first, body mass index (BMI) and neck circumference 
(NC) were identified as independent predictors of hypertension misclassification in patients 
suspected of OSA; second, in patients with OSA, BP control is independent of both the 
antihypertensive regimen and the number of antihypertensive drugs, either before or after CPAP 
adaptation; third, although the doses of 10, 30 and 50 mg/Kg of CVD promoted a significant 
reduction in heart rate, no decrease in mean arterial pressure was observed; fourth, the S/(R+S) 
ratios of CVD enantiomers, between rats exposed to CIH and normoxic conditions, were 
different and fifth, voluntary ingestion proved to be an effective method for a controlled daily 
dose administration, with a define timetable, that is independent of handling and restraint 
procedures. 
In conclusion, the clinical study showed that BP control in OSA patients is independent of both 
the antihypertensive regimen and the number of antihypertensive drugs. Additionally, our 
results highlight the lack of validity of self-reported hypertension and suggest that all patients 
suspected of OSA with undiagnosed hypertension and with a BMI and NC above 27 Kg/m
2
 and 
39 cm should be screened for hypertension, through ABPM. The results attained in the rat 
model of HT related to CIH suggest that the blockade of the sympathetic nervous system 
together with the putative pleiotropic effects of carvedilol is not able to revert hypertension 
induced by CIH and point out that the pharmacokinetic changes induced by CIH on S/(R+S) 
ratio are not apparently responsible for the lack of efficacy of carvedilol in reversing this 
particular type of hypertension. Finally, the results here presented support the use of voluntary 
oral administration as a viable alternative to gavage for chronic administration of a fixed dose of 
AHDs. 
 
Key words: ambulatory blood pressure monitoring, antihypertensive drugs, carvedilol, chronic 
















A hipertensão arterial (HA) é uma patologia altamente prevalente, embora claramente 
subdiagnosticada, em doentes com síndrome de apneia obstrutiva do sono (SAOS). Estas duas 
patologias apresentam uma estreita relação e a monitorização ambulatória  da pressão arterial 
(MAPA),  por um período de 24 horas, parece ser o método mais preciso para o diagnóstico de 
hipertensão em doentes com SAOS. No entanto, esta ferramenta de diagnóstico para além de ser 
dispendiosa e envolver um número acrescido de meios técnicos e humanos, é mais morosa e, 
por conseguinte, não é utilizada por rotina no contexto do diagnóstico da SAOS. Por outro lado, 
apesar da aplicação de pressão positiva contínua nas vias aéreas (CPAP – Continous Positive 
Airway Pressure)  ser considerada a terapêutica de eleição para os doentes com SAOS, o seu 
efeito no abaixamento da pressão arterial (PA) parece ser modesto,  exigindo, por conseguinte, a 
implementação concomitante  de terapêutica anti-hipertensora. Acontece que são escassos os 
dados relativos aos regimes de fármacos anti-hipertensores utilizados em doentes com SAOS e, 
acresce ainda que, as guidelines terapêuticas para o tratamento farmacológico da HA, neste 
grupo particular de doentes, permanecem, até ao momento, inexistentes. A utilização de 
modelos animais de hipóxia crónica intermitente (CIH), que mimetizam a HA observada em 
doentes com SAOS, revela-se extremamente importante, uma vez que se torna imperativo 
identificar fármacos que promovam um controle adequado da PA neste grupo de doentes. No 
entanto, estudos concebidos com o intuito de investigar o efeito anti-hipertensor dos fármacos 
neste modelo animal revelam-se insuficientes e, por outro lado, os escassos estudos que 
testaram fármacos anti-hipertensores neste modelo não foram desenhados para responder a 
questões de natureza farmacológica. Acresce ainda que se torna imprescindível  garantir  a 
escolha de um método para administração destes fármacos que seja não invasivo e que 
minimize o stress do animal. Embora a gavagem seja uma técnica indiscutivelmente eficaz e 
amplamente utilizada para a administração diária de fármacos a animais de laboratório, ela 
compreende uma sequência de procedimentos geradores de stress para os animais e, que podem 
por conseguinte, constituir um viés na interpretação dos resultados obtidos. 
O objectivo global da presente investigação translacional foi contribuir para a identificação de 
fármacos anti-hipertensores mais efectivos para o tratamento da HT nos indivíduos com SAOS 
e investigar mecanismos subjacentes aos efeitos sistémicos associadas à SAOS bem como a sua 
modulação por fármacos anti-hipertensores. Os objectivos específicos foram: em primeiro lugar, 
encontrar novos critérios, baseados nas medidas antropométricas, que permitam a identificação 
de doentes com suspeita de SAOS, que erroneamente se auto-classifiquem como não-
hipertensos, e desta forma promover um uso mais criterioso do MAPA; em segundo lugar, 
investigar a existência de uma hipotética associação entre os esquemas de fármacos anti-





em terceiro lugar, avaliar a eficácia do carvedilol (CVD), um fármaco bloqueador β-adrenérgico 
não selectivo com actividade antagonista α1 intrínseca e propriedades anti-oxidantes num 
modelo animal de hipertensão induzida pela CIH; em quarto lugar, explorar os efeitos da CIH 
sobre o perfil farmacocinético do CVD; e, em quinto lugar, investigar um método alternativo à 
gavagem para a administração crónica de fármacos anti-hipertensores a animais de laboratório. 
Com este intuito, na primeira fase deste projecto, fizemos uso de uma amostra com um número 
apreciável de doentes com SAOS (n=369), que acorreram, pela primeira vez, à consulta de 
Patologia do Sono do CHLN e que foram submetidos a um estudo polissonográfico do sono, à 
MAPA e que preencheram um questionário que contemplava a obtenção de informação relativa 
ao perfil da medicação anti-hipertensora em curso. Numa segunda fase, utilizámos um modelo 
experimental de HT no rato induzida por um paradigma de CIH. 
Do nosso trabalho resultaram os seguintes resultados principais: em primeiro lugar, o índice de 
massa corporal (IMC) e o perímetro do pescoço (PP) foram identificados como preditores 
independentes de “auto-classificação errónea” da HA em doentes com suspeita de SAOS; em 
segundo lugar, não encontramos qualquer associação com significado estatístico entre os vários 
esquemas de fármacos anti-hipertensores bem como  o número de fármacos incluídos nesse 
esquemas, e o controle da PA (antes e depois da adaptação do CPAP); em terceiro lugar,  apesar 
das doses de 10, 30 e 50 mg/kg de carvedilol terem promovido uma redução significativa da 
frequência cardíaca, não foi observado qualquer decréscimo na PA no nosso modelo animal; em 
quarto lugar, as razões S/(R+S) dos enantiómeros do CVD nos animais expostos à CIH e a 
condições de normóxia revelaram-se diferentes; e, em quinto lugar, a administração oral 
voluntária mostrou ser um método eficaz para a administração diária controlada de fármacos 
anti-hipertensores e que é independente da manipulação e contenção do animal. 
Em conclusão, os resultados obtidos através do estudo clínico revelaram que o controle da PA, 
antes e após a adaptação do CPAP, em doentes com SAOS é independente, quer do esquema de 
fármacos anti-hipertensores, quer do número de fármacos incluídos num determinado esquema. 
Os nossos resultados salientam ainda a falta de validade da chamada self-reported hypertension 
e sugerem que em todos os doentes com suspeita de SAOS, com HA não diagnosticada e com 
um IMC e um PP acima de 27 kg/m
2
 e 39 cm, respectivamente, a confirmação do diagnóstico de 
HA deverá ser realizada através da MAPA, ao invés de outros métodos que com maior 
frequência são utilizados com este propósito. Os resultados obtidos no modelo animal de HA 
induzida pela CIH sugerem que o bloqueio do sistema nervoso simpático, juntamente com os 
supostos efeitos pleiotrópicos do CVD, não parece ser a estratégia mais adequada para reverter 
este tipo particular de hipertensão e indicam que as alterações farmacocinéticas induzidas pela 
CIH no ratio S/(R+S) não justificam a falta de eficácia anti-hipertensora do CVD observada 






viabilidade da utilização da administração oral voluntária, em alternativa à gavagem, para a 
administração crónica de uma dose fixa de fármacos anti-hipertensores. 
 
Palavras-chave: Administração oral voluntária, apneia obstructiva do sono, carvedilol, 












































The present thesis is divided into five main chapters, enumerated with Roman numbers, whose 
content is summarized below. 
 
Chapter I is a general introduction to the thesis, summarizing the most relevant topics of 
literature in chronic intermittent hypoxia-related disorders, namely obstructive sleep apnea, and 
its close linkage with hypertension. Special focus is given to the efficacy of pharmacological 
interventions to revert hypertension related with chronic intermittent hypoxia conditions in both 
animals and humans. The content of this chapter has been included in the publication of a 
review article. 
In Chapter II, we summarize the starting points for the establishment of the main goals of our 
research line. The general and specific research aims that will be addressed in this thesis are also 
listed in this chapter.  
Chapter III contains the description of the general methods used during both clinical and 
experimental studies. 
In Chapter IV, we present the results of this thesis, published or submitted to international 
peer-reviewed journals. Section 1 comprises two original articles regarding the results of the 
study performed in humans. Section 2 includes one original article concerning the results 
attained in the animal model of hypertension induced by chronic intermittent hypoxia and the 
other relating to an alternative method to gavage, for chronic administration of antihypertensive 
drugs to laboratory animals. 
Chapter IV summarizes the main conclusions and limitations of our work and presents the 
future perspectives concerning the non-pharmacological and pharmacological management of 























































































Chronic intermittent hypoxia-related disorders 
Is is well established that intermittent hypoxia (IH) affects control of breathing, the autonomic 
nervous system and the cardiovascular system (Foster et al., 2007). Chronic intermittent 
hypoxia (CIH) is a feature that is present in interstitial lung disease (Fletcher et al., 1992a) and 
sleep-disordered breathing (SDB), and it has also been shown to occur in patients with 
hepatopulmonary syndrome (Tanné et al., 2005; Ogata et al., 2006; Palma et al., 2008). Since 
several years ago, there has been growing interest concerning CIH due to the high relevance of 
the part assumed to be played by sleep-related breathing disorders in chronic diseases. 
Sleep apnea/hypopnea disorders include centrally originated diseases and obstructive sleep 
apnea (OSA). Central sleep apnea (CSA) is characterized by a lack of drive to breathe during 
sleep, resulting in insufficient or absent ventilation and compromised gas exchange (Eckert et 
al., 2007). In CSA, the cessation of respiration during sleep is not associated with ventilatory 
effort and there is sleep fragmentation due to arousals associated with reflexes activated by the 
ensuing hypoxemia (Paiva and Attarian, 2014). The major manifestations of CSA include high 
altitude-induced periodic breathing, idiopathic CSA, narcotic-induced central apnea, obesity 
hypoventilation syndrome, and Cheyne-Stokes breathing in heart failure (Eckert et al., 2007). 
While the precipitating mechanisms involved in the several types of CSA may diverge, unstable 
ventilatory drive during sleep is the principal underlying feature (Eckert et al., 2007). CSA is 
diagnosed in approximately 5% of the patients who undergo a polysomnographic study (Khan 
and Franco, 2014). On the other hand, OSA is briefly characterized by repetitive episodes of 
airflow cessation (apnea) or airflow reduction (hypopnea) caused by an obstructed or collapsed 
upper airway during sleep. Unlike CSA, obstruction occurs in OSA despite the central drive to 
breathe and inspiratory muscle activity (Levitzky, 2008). An appreciable number of factors are 
known to be linked to upper-airway collapse, namely reduced airway dilator muscle activity 
during sleep, upper-airway anatomy, obesity, decreased end-expiratory lung volume, ventilatory 
control instability, and rostral fluid shifts (Kapur, 2010). The repetitive episodes of apnea and 
hypopnea characteristic of OSA are closely associated with CIH, hypercapnia and an increase in 
intrathoracic pressure, leading to recurrent arousals and significant changes in sleep 
architecture. OSA is affecting a growing proportion of the common population, and the 
estimated prevalence in the 1990s was 9% for women and 24% for men among middle-aged 
adults (Young et al., 1993). In addition, CSA can occur concomitantly with OSA. This last 
condition, recently labeled complex sleep syndrome, is observed in approximately 15% of the 
patients following treatment with continuous positive airway pressure (CPAP) (Paiva and 
Attarian, 2014). In a few words, complex sleep syndrome is a form of sleep-disordered 
breathing in which CSA persists or emerges when obstructive events have disappeared using a 





apneas are observed in polysomnograms of patients with OSA, they are normally ignored 
because we do not presently understand their potencial clinical relevance.  
Nowadays, it is well known that the outcomes of these sleep-related breathing disorders can 
lead to vascular diseases, contributing to a considerable increase in overall cardiovascular risk. 
The desaturation-reoxygenation sequence, a typical pattern coupled with the majority of 
respiratory events, is thought to be responsible for most of the associated cardiovascular 
morbidity (Lévy et al., 2012). Although OSA has been associated with several cardiovascular 
conditions, it has been more closely etiologically connected to systemic HT (Kapa et al., 2008), 
and the link between HT and OSA is now widely accepted and supported by different findings. 
Most episodes of OSA are coupled with sleep disruption, which per se increases sympathetic 
nerve activity and blood pressure (Morgan et al., 1996). In addition, the occurrence of arousals 
appears to enhance the pressor effects of asphyxia during OSA (Morgan et al., 1998), 
contributing synergistically to blood pressure increase. In any case, studies in both animals and 
humans underline the major role of hypoxia itself in promoting an increase in blood pressure 
(Brooks et al., 1997b; Tamisier et al., 2011). 
Regarding CSA, this SDB, like OSA, is strongly linked to cardiac disease and cardiovascular 
outcomes (Brenner et al., 2008). Indeed, the majority of patients with CSA have underlying 
cardiovascular disease, primarily heart failure, which is considered the most common risk factor 
for CSA, followed by atrial fibrillation (Bradley et al., 1992). Moreover, like OSA, CSA has 
been implicated in heart failure pathophysiology (Mehra, 2014) and occurs in 30–50% of 
patients with left ventricular dysfunction and heart failure caused by HT, cardiomyopathy and 
ischemic heart disease (Bradley and Floras, 2003). Thus, CSA has significant co-morbidity with 
many cardiac conditions, which clearly contributes to an increase in the associated mortality and 
morbidity. 
Besides systemic HT, chronic intermittent alveolar and systemic arterial hypoxia-hypercapnia 
can cause pulmonary HT (PH). SDB has also been found to be associated with PH, being 
considered one of the potential etiologies of PH (Galie et al., 2009). During episodes of OSA, 
the subsequent oscillations in PaO2 lead to a cyclical pattern of vasoconstrictions and 
relaxations in the pulmonary circulation responsible for the marked fluctuations observed in 
pulmonary arterial pressure (Dempsey, 2010). The perpetuation of this pattern leads to fixed 
elevations in pulmonary pressure (Dempsey, 2010). Some data suggest that even slight changes 
in pulmonary function, in the absence of lung disease, are able to induce PH in patients with 
OSA. Furthermore, it is important to bear in mind that PH could also be a cause of abnormal 
arterial blood gases during wakefulness (Dempsey, 2010) and that OSA itself can lead to PH 
(Sajkov and McEvoy, 2009). The major consequence of the increased pulmonary artery 




















erythropoietin subsequent to hypoxemia), is the occurrence of right ventricle hypertrophy 
leading to cor pulmonale (Levitzky, 2008). The prevalence of this chronic cardiopulmonary 
condition among patients with SDB is estimated to range from 17% to 52% (Minic et al., 2014), 
and 20–30% of untreated OSA patients suffer from PH (Dumitrascu et al., 2013). Even if PH in 
this group of patients is typically not severe (Badesh et al., 2010), OSA patients with PH have a 
higher mortality rate than OSA patients without PH (Minai et al., 2009). A recent meta-analysis 
shows that CPAP is associated with a mild but statistically significant reduction in pulmonary 
artery pressure in OSA patients (Sun et al., 2014). This decrease might translate into a better 
outcome in patients with PH secondary to OSA. However, more studies are needed to confirm 
this assumption. 
 
OSA and Hypertension: How relevant is this linkage? 
Since 2003, OSA has formally been recognized as a frequent and important secondary cause of 
HT and is one of the first causes to be screened mainly in patients with a suggestive phenotype, 
refractory HT and a non-dipping profile (Chobanian et al., 2003; Mancia et al., 2007). More 
recently, OSA has been identified as an independent risk factor for HT (Lavie et al., 2000; 
Peppard et al., 2000; Marin et al., 2012), as one of the major clinical conditions that favors 
poorly controlled HT (Oliveras and Schmieder, 2013), and as the most common condition 
associated with resistant HT (Pedrosa et al., 2011). OSA and HT are two prevailing risk factors 
for several cardiovascular events (Wang and Vasan, 2005; Baguet et al., 2009). Due to their 
high prevalence and cardiovascular morbidity (Wolf et al., 2007; Malhotra and Loscalzo, 2009), 
OSA and HT are now acknowledged as public health problems. Epidemiological data show that 
the estimated overall prevalence of HT among patients with OSA is approximately 50% and an 
estimated 30–40% of hypertensive patients are diagnosed with OSA (Calhoun, 2010), 
confirming the bidirectional relationship between OSA and HT. Moreover, OSA and HT are 
chronic diseases mostly diagnosed in active adults and because of the associations between 
OSA and obesity and advancing age, the public health burden of OSA related to cardiovascular 
disease is expected to rise in the coming years (Dempsey et al., 2010). The use of both 
antihypertensive drugs (AHDs) and CPAP in these patients is for life and consequently 
treatment is associated with a high impact both in terms of costs and in patients’ quality of life. 
Indeed, OSA generates an impressive economic burden, including medical costs, when 









OSA and Hypertension: What is the problem? 
CPAP is considered the gold standard treatment for mild, moderate and severe OSA due to its 
remarkable ability in providing pneumatic splitting of the upper airway and effectiveness in 
reducing the apnea-hypopnea index (AHI), symptoms, and cardiovascular morbidity and 
mortality (Hla et al., 2002; Pepperell et al., 2002; Wolf et al., 2007; Epstein et al., 2009; 
Mannarino et al., 2012). Besides preventing hypoxemia, sleep disturbance and apnea episodes, 
CPAP reduces sympathetic activity, systemic inflammation and oxidative stress (Yorgun et al., 
2014). However, the results found for the effectiveness of CPAP on blood pressure (BP) control 
are still controversial. Table 1 summarizes the results of original studies in which the effect of 
CPAP on BP has been analysed.  
Whereas some studies and meta-analyses (Bakker et al., 2014; Varounis et al., 2014) have 
reported modest effects for CPAP in lowering BP, others tend to support the beneficial effect of 
CPAP treatment on BP reduction and attenuating the risk of developing HT. In any case, 
although the lowering effect of CPAP on BP is relevant in terms of overall cardiovascular risk 
reduction, this effect is very limited when compared to the performance of AHDs in patients 
with essential HT (Pépin et al., 2010). Thus, treating HT in patients with sleep apnea is proving 
to be a dificult task and there is consensus that the use of AHDs is mandatory. In spite of this, 
data on AHDs regimens in patients with OSA are scarce and there is a lack of specific 
therapeutic guidelines for the pharmacological treatment of HT in these patients. Furthermore, 
the effects of antihypertensive agents on OSA patients are not consistent (Parati et al., 2012) 
and there are no data on the efficacy of specific AHDs regimens when associated with CPAP.  
A new treatment for OSA patients is the oral appliance/mandibular advancement device 
(Guralnick and Bakris, 2012). Oral appliance therapy is an important alternative to CPAP for 
some patients with mild to moderate OSA (Iftikhar et al., 2013). Despite a recent study (Andrén 
et al., 2013) and a recent meta-analysis (Iftikhar et al., 2013) which have shown some beneficial 
effects of this device in reducing blood pressure measurements, larger and longer randomized 
control trials are needed to confirm the effects of oral appliance therapy on BP control. 
Clearly, more studies are required to identify first-line AHDs regimens for optimal BP control 
in this particular group of hypertensive patients (Tsioufis et al., 2010; Parati et al., 2013). 
Moreover, HT related to OSA needs to be managed as a specific entity and an earlier diagnosis 






















Table 1. CPAP effect on blood pressure 


















194 12 wks 100 Yes 5 
 3.1 mmHg MBP 
 3.2 mmHg DBP 
 3.1 mmHg SBP (NS) 
Martinez-Garcia 
et al., 2013 
RCT; parallel 
group 
118 4 wks 10 Yes 4.9  3.3 mmHg 24h MBP 




48 4 wks 79 Yes 5.1 
 5.2 mmHg DBP 
 3.8 mmHg SBP (NS) 
Zhao et al., 2012 
Prospective 
randomized trial 
32  9 wks 66 Yes 5.5 
 ± 10 mmHg MBP 
 ± 10 mmHg DBP 
 ± 10 mmHg SBP 
(During both day and 
night-time) 










91 5 yrs 100 Yes NA 
 
NS on 24h BP, SBP and 
DBP 




40 6 mon 100 Yes 6.01 
 Awake SBP (6.5 mmHg) 
and DBP (4.5 mmHg) 
NS nocturnal SBP and 
DBP 





98 1 yr 100 Yes 6.3 
 5.6 mmHg MBP 
(resistant HT group) 
 0.8 mmHg MBP 
(controlled BP group) 
Dernaika et al., 
2009 
RCT; crossover 28 8 wks 100 Yes 4.8 
 2.1 mmHg 24h MBP 
(CPAP group) 
 9.1 mmHg 24h MBP 
(valsartan group) 
Pépin et al., 2010 
Prospective 
cohort study 
86 6 mon 55 Yes 4.8  4.92 mmHg 24h MBP 




24 12 wks 0 No NA  5.3 mmHg 24h MBP 




196 6 mon 85 Yes NA 
 2.7 mmHg DBP 
 2.1 mmHg SBP 




340 12 wks 100 No 4.5 
 1.5 mmHg MBP 
 1.3 mmHg mean DBP 










35 10 wks 100 Yes 5.2 NS on overall 24h MBP 





495 3.4 yrs 40.4 Yes NA 
 Occurrence of systemic 
arterial HT 




44 13.2 wks 100 Yes 5.1 
Additional  in office BP 
and ambulatory BP 
monitoring (CPAP+ 3 
AHDs) 
Litvin et al., 2013 
RCT, 
multicenter 
359 1 yr 100 Yes 4.7 
 2.19 mmHg DBP NS 
 1.89 mmHg SBP NS 
Barbé et al., 2009 
RCT 36 3 mon NA No 5.2 
 2 mmHg office DBP 
 5 mmHg office SBP 
 5 mmHg 24 h DBP  
 5 mmHg 24 h SBP  




64 3 mon 100 Yes > 5.8  
 6.98 mmHg 24h DBP 
 9.71 mmHg 24h SBP 
Lozano et al., 
2010 
AHDs, antihypertensive drugs; BP, blood pressure; CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; HT 
(%), percentage of hypertensive patients; MBP, mean blood pressure; NA, information not available; NS, no significant effect; 





What models are available to study Hypertension related to OSA? 
Due to the high complexity and heterogeneity associated with OSA, considerable variability can 
be observed between reports addressed at the study of this disease. In addition, the scarcity of 
opportunities for patient investigation, in particular at the cellular level, has compromised 
progress in understanding the pathophysiology of OSA and the development of novel and 
specific treatments for this disorder. To overcome some of these limitations, several animal 
models and more recently, a model of OSA in healthy human volunteers (Tamisier et al., 2009; 
Tamisier et al., 2011) have been developed. Animal models, especially of IH, mimic OSA more 
easily than human models. The small size of rodents allows more rapid and intense changes in 
SaO2 (arterial hemoglobin oxygen saturation) whereas humans require longer periods of 
hypoxia to induce arterial oxyhaemoglobin desaturation (Foster et al., 2007). The combination 
of these two approaches is certain to contribute to the consolidation of prevention strategies and 
the development of more suitable treatments for OSA patients. 
 
ANIMAL MODELS 
The major advantage of the use of animal models is that they allow single components of the 
disease to be evaluated, accurately controlling the triggering events in terms of both severity 
and duration, and providing homogeneous populations (Lévy et al., 2012). These models also 
provide an excellent opportunity to explore the underlying mechanistic pathways of HT related 
to OSA and their consequences under controlled conditions. Moreover, animal models have 
enabled the study of parameters that have proved difficult to assess in humans, particularly due 
to the need for organ harvesting to explore the mechanisms underlying the consequences of IH 
at the molecular level (Dematteis et al., 2009). Thus, studies with animal models are good tools 
for overcoming some confounding factors present in human studies (e.g., the presence of 
comorbidities, disease duration, and behavioral and environmental variables) (Badran et al., 
2014), and for providing more specific information concerning the efficacy of drugs to be 
tested.  
In 2009, Dematteis et al. used the terminology homologous (sharing the cause or 
pathophysiology of the human disease), predictive (responding to treatment similarly to the 
human disease) and isomorphic (displaying symptoms similar to those of the human disease 
although their cause and pathophysiology may differ) to categorize sleep apnea models 
(Dematteis et al., 2009). According to these categories, most sleep apnea models are only 
partially isomorphic, focusing on a specific aspect of the human disease. As a matter of fact, 
none of the currently available animal models reproduce all aspects of human sleep apnea and 
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brought out most of the available knowledge in this field and furthermore, almost all 
cardiovascular diseases known to be present in patients with OSA have been replicated in these 
models (Dumitrascu et al., 2013). 
The effective use of animals to study sleep apnea implies recognition of the natural similarities 
and differences between animals and humans to ensure the reliability of the experimental 
results. For instance, as rodents are nocturnal animals, the stimulus must be applied during the 
sleep-dominant phase of the diurnal cycle. Moreover, in humans the circadian distribution of 
sleep tends to be consolidated and normally monophasic, with a daily sleep duration of 7–8 
hours, whereas it is polyphasic, relatively fragmented and with a duration of 12–15 hours in 
rodents (Toth and Bhargava, 2013). Another issue is related to the fact that rodents sleep in the 
prone position (Golbidi et al., 2012); it is well known that supine OSA is the dominant 
phenotype of OSA syndrome and that the supine position favors upper airway collapse in 
humans (Joosten et al., 2014). Furthermore, additional care must be taken to minimize external 
factors (e.g., light exposure, photoperiod, noise, disruptions in the home environment, and post-
surgical care in studies, for instance requiring implantation of telemetric devices) able to 
influence sleep in animals used in experimental research (reviewed in Toth and Bhargava, 
2013).  
The experimental animal models developed to mimic OSA have recently been reviewed 
(Dematteis et al., 2009; Golbidi et al., 2012; Davies and O’Donnell, 2013; Toth and Bhargava, 
2013) and assembled taking into account the main injuries triggered by OSA. Despite attempts 
to use large animals (e.g., dogs, lambs and pigs) to simulate upper airway obstruction, most 
research on the cardiovascular consequences of OSA has been performed in rodents. Alternative 
models (e.g., cell cultures incubated in specific devices that perform oxygen fluctuations 
mimicking sleep apnea-related IH), mainly relevant to signaling investigation (Kumar et al., 
2003; Gozal et al., 2005; Ryan et al., 2005), represent a complementary approach to the most 
widely used sleep models. However, in spite of the recommendations to refine, reduce and 
replace (the 3Rs programme), these alternative models cannot replace animal models in the 
study of HT. 
The natural models of sleep apnea include the English bulldog, the historic natural model of 
spontaneous obstruction (Hendricks et al., 1987), the sleep-related central apnea models (e.g., 
Sprague-Dawley rats (Carley et al., 2000), spontaneously hypertensive (SH) rats (Carley et al., 
1998), C57BL/6J (Julien et al., 2003; Liu et al., 2010)), and the Zucker obese rat in which 
apnea is obesity-related (Ray et al., 2007; Lee et al. 2008; Iwasaki et al., 2012). The 
experimentally-induced models (e.g., the sleep deprivation model, induced airway obstruction 
and the CIH model) are the most widely used. Due to model limitations and lack of extensive 





model. Special focus will be given to the CIH model, based on the assumption that IH is the 
most effective paradigm to induce HT related to OSA and probably the most relevant stimulus 
regarding the cardiovascular sequelae of OSA. 
 
Induced airway obstruction models 
Briefly, the airway obstruction model involves surgical intervention (an endotracheal tube), 
which is an invasive procedure, or alternatively the use of a specific chamber with a latex neck 
collar that induces recurrent airway obstruction. This latter procedure, developed by Farré et al. 
(Farré et al., 2007), is associated with high levels of stress due to the restriction of animal 
movement. In both approaches, the degree of obstruction is adjustable (Golbidi et al., 2012) and 
in the case of induction of obstruction through endotracheal tube, the PaCO2 can be adjusted to 
mimic human sleep apnea (Golbidi et al., 2012). Many experiments using this method have not 
monitored the sleep state of the animals, but more recent studies have incorporated sophisticated 
apparatus that is able to detect sleep-awake states and allow close coordination between the 
initiation of airway obstruction and sleep onset (Schneider et al., 2000). 
This model allows the study of the potential consequences of strenuous breathing against an 
obstructed airway and can be used to study the cardiovascular consequences and risk factors of 
OSA (e.g., systemic inflammation and coagulation), and to investigate the mechanisms that 
underlie OSA (Salejee et al., 1993; Nacher et al., 2007; Almendros et al., 2008; Nacher et al., 
2009; Othman et al., 2010; Almendros et al., 2011). However, to the best of our knowledge, no 
study has yet shown that this obstruction model is able to mimic HT related to OSA. 
Furthermore, when testing AHDs, it became crucial to ensure the selection of a stress-free 
paradigm as it has been shown that any source of external stress on rodents can significantly 
increase heart rate and blood pressure (Brown et al., 2000; Kramer et al., 2000; Balcombe et al., 
2004; Bonnichsen et al., 2005) and therefore contribute to confounding the experimental results. 
Finally, as the rat models of obstruction or asphyxia were developed in restrained or 
anesthetized rats, they are not good models for chronic administration of oral drugs, particularly 
AHDs.  
 
Sleep deprivation models 
In the last few years, several approaches have been used to trigger sleep deprivation in different 
animals, the rat being the animal of choice to date (Colavito et al., 2013). In the “multiple 
platform technique”, the animal is aroused from sleep when the characteristic loss of muscle 
tone that accompanies paradoxical sleep causes it to fall off the platform (Suchecki and Tufik, 
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interaction with the experimenter, who actively keeps the animal awake through the use of 
external stimulation (e.g., mild noises, tapping or gentle shaking of the cage, or by direct contact 
with the animal either using a soft brush or by hand), or by the introduction of novel objects or 
nesting material in the cages, which typically leads to active exploratory behavior (Colavito et 
al., 2013).  
These models are most often used to evaluate the neurophysiological aspects of OSA (Van 
Dongen et al., 2003; Haack and Mullington, 2005; McKenna et al., 2007; Ward et al., 2009; 
Nair et al., 2011) due to the high similarity between the structures of the nervous systems of 
rodents and humans (Badran et al., 2014), and to illustrate some mechanistic pathways induced 
by this trigger (McGuire et al., 2008; Tartar et al., 2010; Liu et al., 2011; Perry et al., 2011). 
Nevertheless, some studies have also aimed to evaluate the cardiovascular outcomes induced by 
this OSA feature and have suggested that sleep fragmentation may have a far more important 
role in cardiovascular changes observed in OSA patients (Golbidi et al., 2012). Even so, sleep 
deprivation studies have produced mixed results regarding BP outcomes.  
In 1997, Brooks et al. suggested that sleep fragmentation, triggered by auditory stimulus, 
induced only acute changes in BP and did not affect daytime BP (Brooks et al., 1997a; Brooks 
et al., 1997b). In the same way, Bao et al.’s results showed that sleep fragmentation in rats, 
using acoustic stimuli for 35 days, did not elicit an increase in BP, probably due to some 
adaptation behavior (Bao et al., 1997). However, more recent studies have shown that sleep 
deprivation leads to increased plasma concentrations of epinephrine and norepinephrine 
(Andersen et al., 2005), ET-1/2 levels (Palma et al., 2002), and increased heart rate and systolic 
blood pressure (Anderson et al., 2004; Perry et al., 2007). In addition, sleep fragmentation 
enhances plasma inflammatory cytokines (e.g., TNF-α, IL-6, IL-1α, and IL-1β), leading to 
increased oxidative stress and inflammation (Yehuda et al., 2009). These results add further 
evidence demonstrating that sleep deprivation may lead to serious cardiovascular consequences 
and may aggravate hypertensive features. However, despite the potential of the sleep 
deprivation model to induce HT related to OSA, it does not exactly mimic sleep fragmentation 
and presents one major shortcoming regarding the evaluation of AHDs efficacy that should be 
taken into account. Sleep deprivation is a stressful method and it is still unclear whether the 
method is itself a stressful stimulus (Palma et al., 2002). Thus, in conclusion, sleep deprivation 
models are useful tools for unveiling various aspects of sleep function, studying the effects of 
sleep loss on subsequent brain function at the molecular, cellular and physiological levels, and 
evaluating cognitive impairment, but should be used with caution whenever stress can act as a 







IH is now established as the dominant model of sleep apnea. Generally, this model makes use of 
specific ventilated chambers in which the animals are housed and cyclically exposed either to 
normoxia/hypoxia or room air to mimic the most relevant consequences of OSA. Hypoxic 
conditions can also be achieved by surgical intervention (an endotracheal tube) or by the use of 
a mask, which involves animal restraint and consequently high levels of stress (Golbidi et al., 
2012). In either case, animals breathe nitrogen-enriched air alternating with oxygen or normal 
air (Dematteis et al., 2009). Thus, as with O2, nitrogen plays an important role in this model as 
the flushing of the chambers with this gas allows the gradual lowering of O2. The duration of 
the hypoxic and normoxic phases of the IH cycle, as well as the slopes of FiO2 (fraction of 
inspired oxygen), decrease and increase, and are dependent on cage/chamber size and the gas 
flows and mixtures (Dematteis et al., 2009). 
The standard animal model of OSA was that described in the landmark study of Fletcher and 
Bao (Fletcher and Bao, 1996). Despite the presence of some drawbacks, this model has 
successfully been employed to study the changes in systemic arterial pressure and the impact of 
IH on a wide range of cardiovascular outcomes. One of the major limitations pointed to in this 
model is the absence of recurrent upper airway obstruction, abolishing the acute hemodynamic 
changes due to the negative intrathoracic pressure (Badran et al., 2014). Marked negative 
intrathoracic pressure induces acute hemodynamic changes that are probably the starting point 
for chronic cardiovascular diseases (Bonsignore et al., 1994). Despite the absence of upper 
airway occlusion, some respiratory efforts (intermittent tachypnea) occur, corresponding to a 
fluctuating hyperventilation that follows the IH cycles (Dematteis el al, 2009). However, this 
disadvantage allows the evaluation of CIH effects, namely chronic blood gas exchanges, 
without the interference of the mechanical aspects of OSA.  
This model also fails to reproduce the transient hypercapnia, or at least eucapnia, which occurs 
in humans determined by airway occlusion. The first question concerning this issue should be: 
is PaCO2 (partial pressure of carbon dioxide in the blood) relevant in humans? Hypercapnia is 
not a standard parameter analyzed in polysomnographic recordings in patients and therefore 
there is no consensus on the impact of PaCO2 in arterial blood pressure in patients with OSA. In 
clinical studies of patients with moderate OSA, the changes in PaCO2 have seemed to be 
irrelevant (Epstein et al., 2001) or have shown a slight increase (Tilkian et al., 1976) during the 
apneic events. However, a PaCO2 increase may contribute to the severity of the cardiovascular 
consequences of OSA (Cooper et al., 2005). The results shown by Fletcher et al. in rats suggest 
that the exposure to hypercapnia during IH is not a critical factor as the effect of IH on diurnal 
BP is similar, independently of the lower or higher levels of CO2 (Fletcher et al., 1995). 
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acute BP increase than hypocapnic IH (Bao et al., 1997). Similarly, Lesske et al. showed 
comparable changes in BP between two groups submitted to IH with or without hypercapnia 
(Lesske et al., 1997). On the other hand, based on the results of different CIH experimental 
protocols in rodents, Kanagy concludes that the level of PaCO2 influences the magnitude of an 
increase in BP (Kanagy, 2009). Concretely, eucapnic hypoxia induces a faster and greater 
increase than hypocapnic hypoxia (Kanagy, 2009), through mechanisms that presently remain 
unknown. Moreover, the greatest increases in BP have been observed in studies in which 
hypocapnia was prevented by CO2 administration (Morgan, 2009). Likewise, Tamisier et al., in 
a study performed in humans, reported that hypercapnic hypoxia leads to greater sympathetic 
activation than hypocapnic hypoxia (Tamisier et al., 2009). In line with these findings, the 
presence of hypocapnic or eucapnic hypoxia conditions leads to an underestimated increase in 
BP that must be taken into account. In conclusion, although some data suggest that PaCO2 may 
influence physiological responses to IH, further studies are needed to evaluate the combined 
effect of IH and hypercapnia. Another drawback that could be attributed to the IH paradigm is 
the fact that it is not accompanied by sleep fragmentation and does not incorporate monitoring 
of sleep.  
Each group of researchers has applied its own specific paradigm and these discrepancies may 
compromise the straightforward comparison of the results. The several paradigms of CIH, 
which simulate the cyclical pattern of hypoxia experienced by patients with OSA, diverge in 
some respects, namely in the animal species involved, e.g., Sprague-Dawley rats (Fletcher et al., 
1995; Kanagy et al., 2001; Tahawi et al., 2001; Allahdadi et al., 2005; Chen et al., 2005; 
Phillips et al., 2005; Lai et al., 2006), Wistar rats (Dunleavy et al., 2005; Lefebvre et al., 2006), 
C57BL/6J mice (Julien et al., 2003), and CF-1 mice (Rosa et al., 2011), the severity of hypoxia, 
the number of hypoxic episodes per hour of sleep, the number of days of hypoxic exposure 
(exposure duration), and CO2 manipulation. Table 2 summarizes the variability observed in the 
CIH models. 
These models typically create moderate to severe oxygen desaturation, thereby mimicking 
severe forms of OSA and may therefore not be applicable to mild and moderate clinical OSA 
(Dematteis et al., 2009). CIH models with cycles of FiO2 of 5% or less usually mimic severe 
forms of OSA in humans and produce maximal changes in BP and heart rate (Dematteis et al., 
2008). However, higher FiO2 (8–10%) has been used in rodent models of CIH (Soukhova-









Table 2. Reports on the effects of CIH on blood pressure 
Species 
Hypoxia cycle, Nadir FiO2, 




Effect on BP  Reference  
Sprague-Dawley 
rats 
20 cycles (90 s each) of 21–5% O2 and 
0–5% CO2/hour; 7 h/day; 35 days; Yes 
Tail-cuff method 
 MAP (25-28 
mmHg) 




80 cycles (6 min each) 21–10% O2/ day; 
8 h/day; 7 days; No 
Telemetry  MAP (7-10 mmHg) Knight et al., 2011 
Sprague-Dawley 
rats 




No changes in MAP 
Iturriaga et al., 
2010 
Wistar rats 
10% O2 for 4 h/day and 21% O2 for 20 
h/day; 56 days; Yes (PCO2 < 0.02%) 
Arterial 
catheterization 
No differences in 
systemic pressure 
Kalaria et al., 2004 
Sprague-Dawley 
rats 
2/3–20.9% O2 (3–6 s +15-18s; 2 
cycles/min); 6–8 h/day; 35 days; No 
Telemetry  MAP (16 mmHg) Tahawi et al., 2001 
C57BL/6J mice 




 Systemic BP (7.5 
mmHg) 
Campen et al., 
2005 
SHR + Wistar 
rats 
21–10% O2 (1 min cycles: 20 s + 40 s); 





development in SHR 
+ NS in Wistar rats 
Belaidi et al., 2009 
Sprague-Dawley 
rats 
2/3–20.9% O2 (3-6 s + 12 s; 2 
cycles/min); 6–8  h/day; 35 days; No 
Telemetry  MAP (10 mmHg) 
Fletcher et al., 
2000 
LCR and HCR 
21–10% O2 (3 min cycles); 8 h/day; 7 
days; No 
Telemetry  MAP in both groups Sharpe et al., 2013 
Sprague-Dawley 
rats 
20 cycles (90 s each) of 21–5% O2 and 
0–5% CO2/hour; 8 h/day; 11 days; Yes 
Arterial 
catheterization 
 MAP (30 mmHg) Kanagy et al., 2001 
Sprague-Dawley 
rats 
48 cycles (45 s + 30 s) 20.9–2/6% O2/ 
hour; 6 h/day; 30 days; No 
Telemetry  MAP (19.3 mmHg) Lai et al., 2006 
C57BL/6J mice 
21–5.7% O2 (alternating every 6 min); 
12 h/day; 90 days; No 
Arterial 
catheterization 
 MAP (19.8 mmHg) Lin et al., 2007 
Sprague-Dawley 
rats 
21–10% O2 for 5 s every 90 s; 10 h/day; 
4 weeks; No 
Tail BP telemeter  MAP (37 mmHg) Liu et al., 2013 
SHR 
21–10% O2 (alternating every 90 s); 12 
h/day; 30 days; No 
Tail-cuff method 
 SBP and DBP (NA 
mmHg) 
Soukhova-O'Hare 
et al., 2008 
Sprague-Dawley 
rats 
21–4/6% O2 (every 60 s); 8 h/day; 5 
days/week; 5 weeks; No 
Tail-cuff method  MAP (12 mmHg) Chen et al., 2005 
Wistar rats 
1 min cycles with 30 s of a 5% FiO2; 8 




Rapidly  MAP (NA 
mmHg) 












20.8–6% O2 (9 min cycles: 5 min Nx); 8 
h/day; 10 days; No 
Arterial 
catheterization 
 MAP (12 mmHg) 
 SBP (9 mmHg) 
 DBP (8 mmHg) 
Zoccal et al., 2009 
Wistar- 
Hannover rats 
21–10% O2 (2 min + 2 min); 1000–
1600 h; Yes (PCO2 < 0.01%) 
Arterial 
catheterization 
No differences in 
MAP 
Perry et al., 2011 
Sprague-Dawley 
rats 
10 cycles (6 min each) of 21–6% O2 
and 0–5% CO2/hour; 8 h/day; 28 days; 
Yes 
Telemetry 
 SBP (39 mmHg) 
 DBP (33 mmHg) 
Dyavanapalli et al., 
2014 
C57BL/6J mice 
21–7% O2 (120 s each cycle); 5 
days/week; 8 h/day; 6 weeks; No 
Telemetry Significant  MAP Schulz et al., 2014 
Sprague-Dawley 
rats 
21–10% O2 (cycle duration: NA); 8 
h/day; 7 days; No 
Telemetry 
 MAP that persisted 
after CIH exposure 
Bathina et al., 2013 
BP, blood pressure; CIH, chronic intermittent hypoxia; DBP, diastolic blood pressure; h, hour; HCR, high aerobic capacity rats; 
HT, hypertension; LCR, low aerobic capacity rats; MAP, mean arterial pressure; NA, information not available; NS, no significant 
effect; Nx, normoxia; min, minutes; s, seconds; SBP, systolic blood pressure; SHR, spontaneously hypertensive rats; , increase.  
 
 
The duration and frequency of hypoxic/normoxic periods are adjustable; usually, the higher the 
frequency the shorter the IH cycles (Golbidi et al., 2012). There is a sizeable discrepancy 
regarding the duration of IH cycles, ranging from 120 cycles/h (30 second cycle; Fletcher et al., 
1992a; Julien et al., 2003; Dematteis et al., 2008), 80 cycles/h (6 min cycle; Knight et al., 
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cycles are often used, reducing the number of cycles/h (Zoccal et al., 2007; Silva and 
Schreihofer, 2011) of daytime exposure, from 4 h/day (Kalaria et al., 2004), 6 h/day (Lai et al., 
2006), 7 h/day (Fletcher et al., 1992a), 8 h/day (Chen et al., 2005; Belaidi et al., 2009; Zoccal et 
al., 2009; Knight et al., 2011; Silva and Schreihofer, 2011; Dyavanapalli et al., 2014; Schulz et 
al., 2014), 10 h/day (Liu et al., 2013) to 12 h/day (Lin et al., 2007). The exposure duration of 8 
h/day seems to be that on which there is the greatest consensus (see Table 2). The duration of 
exposure seems to affect the study outcomes more than the hypoxic nadir or the rate of hypoxic 
cycling (Davis et al., 2013).  
An advantage of CIH models is they allow exposures that can be extended over months, 
enabling the investigation of chronic consequences that might occur in humans (Toth and 
Bhargava, 2013). The number of days necessary to induce an increase in BP seems to be 
dependent on the CIH paradigm. Some authors suggest that the BP increase triggered by CIH 
represents a time-dependent effect (Prabhakar et al., 2001; Hui et al., 2003; Dematteis et al., 
2008; Zoccal et al., 2009). Moreover, both the time and severity of hypoxia have been shown to 
play an important role in the cardiovascular response (Li et al., 2007; Perry et al., 2007). It has 
recently been shown that a period of 14 days is not long enough to induce structural changes in 
cardiovascular structures, but these are already apparent after 35 days of incubation (Dematteis 
et al., 2008). Moreover, Iturriaga et al. report that the exposure of rats to CIH for 14 days 
enhanced the ventilatory response to hypoxia and produced a significant shift in heart rate 
variability, but these cardiorespiratory alterations occurred without noticeable changes in mean 
arterial BP until 21 days of CIH exposure (Iturriaga et al., 2010). Whereas some short-term 
protocols (7–14 days) cause a significant increase in BP (Belaidi et al., 2009; Knight et al., 
2011; Silva and Schreihofer, 2011; Bathina et al., 2013), others show an increase in BP that 
occurs only after long-term exposure (35 days) to CIH (Prabhakar et al., 2001; Chen et al., 
2005; Prabhakar et al., 2005; Zoccal et al., 2009) (see Table 2). Finally, most IH paradigms in 
rodents do not include CO2 supplementation (Lin et al., 2007; Fletcher et al., 2009; Iturriaga et 
al., 2010; Perry et al., 2011; Bathina et al., 2013). In fact, only some authors have manipulated 
the CO2 levels (Ooi et al., 2000; Kantores et al., 2006; Dyavanapalli et al., 2014) and fixed the 
values along the protocol (see Table 2). 
Independently of the paradigm used to induce HT related to OSA, previous reviews are 
unanimous in reporting the development of mild HT, despite the divergent changes in arterial 
blood gases (Kanagy, 2009) (see Table 2). The exceptions found in this review (Kalaria et al., 
2004; Belaidi et al., 2009; Iturriaga et al., 2010; Perry et al., 2011) are all related to the method 
used for BP measurement. It is apparent that arterial catheterization is not an accurate method of 
measuring BP in CIH models. The methods most often used for BP measurement in IH models 





O’Hare et al., 2008; Totoson et al., 2008; Belaidi et al., 2009), radiotelemetry (Fletcher et al., 
2000; Tahawi et al., 2001; Lai et al., 2006; Knight et al., 2011; Bathina et al., 2013; Sharpe et 
al., 2013; Dyavanapalli et al., 2014; Schulz et al., 2014), and arterial catheterization (Kanagy et 
al., 2001; Kalaria et al., 2004; Campen et al., 2005; Lin et al., 2007; Belaidi et al., 2009; Zoccal 
et al., 2009; Iturriaga et al., 2010; Perry et al., 2011; Silva and Schreihofer, 2011; Totoson et 
al., 2013).  
The tail-cuff method is the most frequently used indirect method for monitoring BP (Kurtz et 
al., 2005). In spite of this, in the context of chronic disease animal models, this method presents 
several disadvantages, such as the inability to assess the average level of BP throughout the day 
and night over the course of a study (Kurtz et al., 2005). Moreover, this method induces 
significant stress, disturbing multiple aspects of the cardiovascular system (Kurtz et al., 2005). 
Finally, its accuracy is dubious and most tail-cuff methods are not well suited to measuring 
diastolic pressure (Kurtz et al., 2005).  
Regarding radiotelemetry, the availability of this technique has represented an enormous 
advance in HT research. This method allow BP measurements to be taken in conscious freely 
moving laboratory animals and also provides the ability to measure BP at any time of the day or 
night and for extended periods of time (Kurtz et al., 2005). The major limitations of 
radiotelemetry relate to the expense of acquisition and further maintenance of the telemetric 
devices, the need for surgical skills and training to perform the introduction of the catheter into 
the abdominal aorta or femoral artery, and also the risk of infection after the surgical 
intervention (Kurtz et al., 2005).  
Arterial catheterization allows direct measurement of BP with a fluid-filled external catheter. 
Like telemetry, it is accurate and reliable and permits assessment of BP lability and diurnal 
variations in BP (Kurtz et al., 2005). This technique can be used effectively for acute studies in 
anesthetized animals or for long-term, continuous monitoring of arterial pressure in conscious 
animals (Kurtz et al., 2005). However, the maintenance of catheters in chronic studies can be 
labor intensive and meticulous care of the catheters is required to avoid infections and to 
prevent failure during long-term experiments (Kurtz et al., 2005).  
Finally, the studies performed with CIH models have been very useful for elucidating 
mechanistic issues and also showing that in spontaneously hypertensive rats (SHR), IH 
accelerates the BP increase, with higher BP values after 14 days of exposure (Belaidi et al., 
2009). In contrast, in animals that are not prone to HT, IH has been found to trigger a rapid but 
moderate BP elevation (Campen et al., 2005; Fletcher et al., 1992a; Lai et al., 2006; Lin et al., 
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BP increase in rats seems to be predominantly diastolic (Dematteis et al., 2008). The same 
finding was also reported in the early study of Fletcher et al. (Fletcher et al., 1992a).  
 
HUMAN MODELS 
The variety of models of IH in healthy human subjects is much less impressive than that 
observed for animal models of sleep apnea. In terms of the exposure time, these models are 
usually divided into short-term and chronic (Foster et al., 2007). In short-term IH models, 
generally the exposure time (20–60 min) and the duration of the hypoxia or voluntary apnea 
period (30 s) are very limited. The protocols of Cutler et al. and Tamisier et al. are good 
examples of short-term models (Cutler et al., 2004; Tamisier et al., 2009). In contrast, Foster et 
al. made use of a chronic model, exposing healthy human volunteers to an hour of IH (5 min 
hypoxia alternating with 5 min normoxia) daily for two weeks (Foster et al., 2005). As in the 
animal models of IH, only some studies have controlled the level of CO2 (Foster et al., 2005), 
whereas others have not (Tamisier et al., 2009). Regardless of the protocol followed, exposing 
humans to CIH implies careful supervision.  
In 2001, Xie et al. exposed nine healthy human subjects during wakefulness to 20 min of 
isocapnic hypoxia (arterial O2 saturation, 77–87%) and 20 minutes of normoxic hypercapnia 
(end-tidal PCO2, 15.3–8.6 Torr above eupnea) on two separate days. The subjects breathed 
through a leak-free nasal mask and the neurocirculatory and ventilatory responses to these two 
stimuli were further evaluated (Xie et al., 2001). These authors found that hypoxia induced a 
sympathetic activation that outlasted the chemical stimulus, whereas hypercapnia evoked a 
short-lived sympathetic activation (Xie et al., 2001). Years later, in a study performed with a 
larger sample (n=31), Cutler et al. used a model of IH induced by voluntary apnea (30 s of 
hypoxic apnea every 1 min – simulating an AHI of 60/h – for 20 min) to determine if the 
cessation of breathing is important in prolonged sympathetic activation (Cutler et al., 2004). 
This study also included two other groups that were exposed to intermittent hypercapnic 
hypoxia and to intermittent isocapnic/hypoxia, respectively (Cutler et al., 2004). Their results 
support the hypothesis that short-term exposure to intermittent hypoxic apnea results in 
sustained elevation of postganglionic muscle sympathetic nerve activity and that hypoxia is the 
primary mediator of this response (Cutler et al., 2004). The data reported by Leuenberger et al. 
one year later were in line with these results. They also found, in a study that enrolled 26 
patients, a sustained sympathetic activation and also a transient elevation of BP following 30 
min of voluntary end-expiratory apneas primed with a hypoxic gas mixture and lasting for 20 s 
in each minute (Leuenberger et al., 2005). 
Foster et al. carried out three main studies in healthy human volunteers. The first aimed to 





of IH (Foster et al., 2005). This study involved 18 patients randomly assigned to short-duration 
IH (1 hour of 12% O2 separated by 5 min of normoxia) or long-duration IH (30 min of 12% O2). 
Both groups had 10 exposures over 12 days. Their findings show a rise in mean arterial blood 
pressure (MAP) that occurs throughout the daily exposure to short-duration IH but not during 
exposure to long-duration IH; moreover, they demonstrate that the vascular processes required 
to control blood flow and O2 supply to cerebral tissue in a healthy human are delayed following 
exposure to 12 days of isocapnic IH (Foster et al., 2005). In 2009, the same group reinforced the 
enrollment of IH on the pathogenesis of cardiovascular and cerebrovascular disease in patients 
with OSA (Foster et al., 2009). They exposed 10 healthy subjects to IH (2 min of hypoxia: 
nadir PET,O2 = 45.0 mmHg, alternating with 2 min of normoxia: peak PET,O2 = 88.0 mmHg 
for 6 h) for 4 consecutive days and concluded that IH alters BP (MAP increased by 4 mmHg) 
and induces an increase in cerebral vascular resistance (Foster et al., 2009). More recently, 
Foster et al. have assessed the role of the type I angiotensin II receptor in mediating an increase 
in arterial pressure associated with a single 6-hour IH exposure (Foster et al., 2010). For that, 
they exposed nine healthy subjects to sham IH, IH with placebo medication, and IH with the 
type I angiotensin II receptor antagonist (losartan). Their findings demonstrate a significant 
increase in arterial pressure after exposure to isocapnic IH (Foster et al., 2010). Furthermore, 
since this increase is prevented by the blockade of AT1 receptors, these results suggest an 
important role for the rennin-angiotensin-aldosterone system (RAAS) in the pathophysiology of 
HT related to OSA (Foster et al., 2010). 
Tamisier et al. have developed a novel model of nocturnal CIH in healthy humans, which 
represents an important step forward in the field, designed to overcome some of drawbacks and 
confounding factors that are present in studies of both animals and OSA patients (Tamisier et 
al., 2009). To investigate the effects of CIH on sleep, BP and ventilatory control, these authors 
make use of altitude tents to mimic the cyclical arterial oxygen desaturations-resaturations of 
sleep apnea. They delivered O2 for 15 s every 2 min during sleep while subjects breathed 13% 
O2 in a hypoxic tent to create 30 cycles/h of cyclic desaturation-reoxygenation (SpO2 range: 95–
85%), and exposed subjects overnight for 8–9 h/day for two or four weeks (Tamisier et al., 
2009). Among other results, they show that waking normoxic arterial pressure increased 
significantly at two weeks for systolic and for diastolic at four weeks, that patients developed a 
sustained BP increase during the day and exhibited a steeper BP decrease at night compared to 
baseline BP values, and finally, that this model produces clinically relevant fluctuations in SaO2 
(Tamisier et al., 2009). Although undoubtedly relevant, the authors recognize the presence of 
several respects in which their model does not mimic sleep apnea, e.g., no negative intrathoracic 
pressure development, higher percentage of sleep time at < 90% SaO2 and poikilocapnia 
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pattern of IH more akin to OSA features. The same group further used this model in 2011 to 
shed light on the profile of the BP increase previously described to determine if it is sustained 
and to explore potential underlying physiological mechanisms. The authors found that only 2 
weeks of severe IH exposure produces a sustained daytime BP increase in the setting of 
sympathetic activation and blunted vascular sympathic baroreflex gain in healthy volunteers 
(Tamisier et al., 2011). 
In conclusion, to date, only a small number of studies have been conducted using healthy 
human models of IH and these have primarily been aimed at elucidating the role of IH in 
sustained sympathetic activation and cerebrovascular regulation. Only a few studies have 
evaluated BP outcomes (Foster et al., 2009; Tamisier et al., 2009; Foster el al, 2010; Tamisier et 
al., 2011) and none of these models have truly been used to assess the efficacy of AHDs in the 
treatment of HT related to OSA. In fact, in the later work of Foster et al., losartan (the 
angiotensin II AT1 receptor antagonist) was used only to demonstrate a mechanistic pathway 
rather than to evaluate its efficacy (Foster et al., 2010). Thus, future research in this field is 
clearly needed. 
 
What are the mechanisms involved in the pathogenesis of Hypertension 
related to OSA? 
Fletcher et al. were pioneers in demonstrating the hypertensive effect of CIH (Fletcher et al., 
1992a) and the role of the sympathetic nervous system, peripheral receptors and rennin-
angiotensin system in this response (Fletcher et al., 1992b, 1999, 2000, 2002). This group also 
showed that surgical denervation of peripheral chemoreceptors, adrenal demedullation and 
chemical denervation of the peripheral nervous system prevented the increase in BP in response 
to CIH stimulus (Fletcher et al., 1992b; Bao et al., 1997). After Fletcher et al.’s first work, 
many reports enabled confirmation of the relationship between IH and BP increases and 
contributed to elucidating the underlying mechanisms. Kanagy et al. reported increased plasma 
endothelin-1 levels in rats exposed for 11 days to CIH, which also demonstrated an appreciable 
increase in MAP (Kanagy et al., 2001). In 2006, Lai et al. suggested that chronic IH-induced 
sustained HT was associated with the facilitation of cardiovascular sympathetic outflow 
followed by decreases in baroreflex sensitivity in conscious rats (Lai et al., 2006). Along the 
same line, the work undertaken by Zoccal et al. provided strong evidence to support the idea 
that rats submitted to CIH show an increase in sympathetic activity, which seems to be essential 
in the maintenance of high BP values in the CIH model (Zoccal et al., 2007). Another group 
revealed that although elevated sympathetic nerve activity (SNA) may contribute to CIH-
induced HT, reduced adrenergic vascular reactivity buffers the cardiovascular impact of 





indicated that CIH induces an increase in FosB/ΔFosB in autonomic nuclei and suggested that 
activator protein-1 (AP-1) transcriptional regulation may contribute to stable adaptative changes 
that support chronically elevated BP (Knight et al., 2011). Also in 2011, Liu et al. demonstrated 
that CIH activates the HIF-1α/endothelin system, through CIH-NADPH oxidase-mediated ROS 
production, and this enhances the development of resistant vasoconstriction and elevates BP in 
rats (Liu et al., 2011). The study undertaken by Bathina et al. revealed that the knockdown of 
tyrosine hydroxylase in the nucleus of the solitary tract (NTS) reduces the CIH-induced 
persistent increase in MAP, suggesting that noradrenergic A2 neurons in NTS play a role in the 
cardiovascular responses to CIH (Bathina et al., 2013). More recently, Schulz et al. have shown 
that NADPH oxidase 2 (NOX2) knockout blocks the development of HT induced by CIH, 
suggesting that this type of HT is mediated by reactive oxygen species (ROS) derived from the 
activation of NOX2 within cells located outside the cardiovascular system (Schulz et al., 2014).  
The mechanisms involved in the genesis of HT related to OSA have recently been reviewed 
(Lavie and Lavie, 2009; Bosc et al., 2010; Sunderram and Androulakis, 2012; Zhang and Si, 
2012; Lévy et al., 2013) and broadly include the following: sympathetic nervous system 
stimulation mediated mainly by the activation of carotid body chemoreflexes, decreased 
vascular responses to nitric oxide, increased plasma concentrations of endothelin, and elevation 
of proinflammatory cytokines (TNF-α, IL-6, VEGF). While for some of these mechanisms (e.g., 
activation of the RAAS, endothelial dysfunction, systemic inflammation, metabolic anomalies, 
and genetic contribution) the relationship with OSA and subsequent cardiovascular morbidity 
remain partially unclear and there is a need to gather more evidence, for others (e.g., the 
increase in sympathetic activity and acute effects of negative intrathoracic pressure), there 
seems to be more agreement on the linkage and it is well-documented (Parati et al., 2013). In 
fact, based on data attained from patients with OSA, it is widely accepted that sympathetic 
activation, inflammation and oxidative stress play major roles in the pathophysiology of this 
particular type of HT. In addition, the use of animal models has revealed that CIH is the critical 
stimulus underlying sympathetic activity and HT, and that this effect requires the presence of 
functional arterial chemoreceptors (Fletcher, 2000). However, it should be also mentioned that 
HT related to OSA probably results not only from increased carotid chemoreflex but also from 
decreased baroreceptor activity (Dumitrascu et al., 2013). It is also important to highlight the 
potential role of obesity as an intermediate factor in the pathway of HT related to OSA 
(O’Connor et al., 2009; Young et al., 2007).  
The mechanisms involved in the pathogenesis of HT can be summarized in relation to two main 
pathways: sympathetic nervous system stimulation mediated mainly by activation of carotid 
body (CB) chemoreflexes and the systemic effects of chronic intermittent hypoxia (CIH), 
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hypothesized pathways by which intermittent hypoxia leads to HT. Briefly, repetitive 
obstructive apneas or hypopneas lead to increased intrathoracic pressure, sleep fragmentation, 
recurrent hypercapnia, and IH. This last phenomenon plays a pivotal role in triggering several 
intermediary mechanisms and molecular pathways that contribute to the initiation and 
progression of cardiac and vascular pathology. First, IH enhances sympathetic nervous system 
activity, leading to vasoconstriction and systemic hypertension through RAAS activation, and 
an increase in catecholamine secretion and plasma level of vasoconstrictive ET-1. Episodic 
hypoxia also favors the stabilization of HIF-1α and the production of ROS, which is followed 
by increased expression of NF-κB and decreased NO bioavailability, the most important 
vasodilatory molecule synthesized by the endothelium. Angiotensin II (AT II) and ET-1 both 
seem to be implicated in vascular remodeling and ROS formation, which is increased through 
the activation of vascular NADPH oxidase and xanthine oxidase. ROS molecules induce a 
cascade of inflammatory pathways linked to an overexpression of adhesion molecules and pro-
inflammatory cytokines, and oxidative stress may trigger sympathetic hyperactivation and vice 
versa. ROS production is required for HIF-1α induction and HIF-1α induction is required for 
ROS production. In addition, HIF-1α promotes the expression of ET-1 and transcriptional 
activation of VEGF and other growth factors. Activation of NF-κB also seems to be central in 
inflammation induced by IH due to its regulatory role in the production of pro-inflammatory 
mediators (e.g., TNF-α, IL-6, IL-8, ICAM-1, and CRP). These signaling pathway proteins, 
combined with RAAS, decreased expression of eNOS, and increased ROS production and 
stabilization of HIF-1, participate in the molecular mechanisms underlying the endothelial 
dysfunction induced by IH. Together, these mechanisms progress to fluid retention, changes in 
cardiac output and vascular tone, and vascular remodeling, leading to systemic HT, one of the 








Figure 1: Schematic diagram summarizing the pathways by which intermittent hypoxia 
leads to hypertension. 
 
AT II, angiotensin II; CA, catecholamine levels; CRP, C- reactive protein; CB, carotid body; ET-1, 
endothelin 1; HIF-1α, hypoxia-inducible factor α; IH, intermittent hypoxia; IL, interleukin; ICAM-1, 
intercellular adhesion molecule; NADPH, nicotinamide adenine dinucleotide phosphate; NO, nitric 
oxide; eNOS, endothelial nitric oxide synthase; NF-κB, nuclear factor-κ-light chain enhancer of activated 
B cells; RAAS, renin-angiotensin-aldosterone system; ROS, reactive oxygen species; TNF- α, tumour 
necrosis factor α; VEGF, vascular endothelial growth factor. 
 
 
What is already known concerning the efficacy of AHDs? 
 
HUMANS 
Despite the considerable number of studies involving OSA patients, only a few have 
investigated the efficacy of different AHDs and in general, they tend to be individual drug 
studies. Moreover, most of the studies only take into account the number of drugs taken by 
patients to adjust this variable and are difficult to interpret as most of the patients were already 
under AHDs regimens. This lack of information could be attributed to the large number of 
possible different AHDs regimens observed in OSA patients. Table 3 summarizes the most 
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Table 3. Studies of the efficacy of AHDs in OSA patients 
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NIF:  24.2 mmHg mean SBP 
and  18.7 mmHg mean DBP 
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 10 mmHg MBP (vs.  4.3 
mmHg MBP for placebo) 
Grote et 
al., 1994 
ABPM, ambulatory blood pressure monitoring; AHDs, antihypertensive drugs; BP, blood pressure; CAR, carvedilol; CIL, 
cilazapril; CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; DOX, doxazosin; EN, enalapril; HCTZ, 
hydrochlorothiazide; MBP, mean blood pressure; MET, metoprolol; NA, information not available; NEB, nebivolol; NIF, 
nifedipine; NS, no significant effect; RCT, randomized controlled trials; SBP, systolic blood pressure; SD, standard deviation; TSP, 





In a study undertaken by Pelttari et al., the AH effects of four different AHDs (atenolol: a beta-
blocker; isradipine: a calcium channel blocker; hydrochlorothiazide: a diuretic; spirapril: an 
angiotension-converting enzyme inhibitor) in obese patients with OSA and HT were compared 
using ambulatory blood pressure monitoring (ABPM) (Pelttari et al., 1998). This study revealed 
that although daytime HT was quite easily controlled by the single use of these drugs 
(especially with atenolol and isradipine; diuretics did not significantly lower BP) none of the 
AHDs were able to produce a significant decrease in nocturnal BP (Pelttari et al., 1998). Mayer 
et al. carried out another comparative study between cilazapril (an angiotension-converting 
enzyme inhibitor) and metoprolol (a beta-blocker) (Mayer et al., 1990). Their findings showed 
that despite the short period of therapy (one week), both metoprolol and cilazapril lowered 
nighttime BP in OSA patients (Mayer et al., 1990). 
A multiple crossover study examined the BP-lowering effect of the five major AHDs classes 
(atenolol: beta-blocker; amlodipine: calcium channel blocker; enalapril: angiotension-
converting enzyme inhibitor; hydrochlorothiazide: diuretic; losartan: angiotensin II receptor 
blocker) and showed that atenolol induced the most pronounced effect in lowering BP (Kcraiczi 
et al., 2000). Atenolol was more efficient in reducing mean nighttime diastolic and systolic BP 
(measured by ABPM) compared to amlodipine, enalapril, hydrochlorothiazide, and losartan 
(Kcraiczi et al., 2000). Salo et al. investigated the effects of four AHDs (atenolol; isradipine: a 
calcium channel blocker; hydrochlorothiazide; spirapril: an angiotension-converting enzyme 
inhibitor) on cardiovascular autonomic control and reactivity in HT OSA patients (Salo et al., 
1999). This group reported that of the four drugs, only atenolol effected BP variability (Salo et 
al., 1999). Thus, the results of these two pilot studies are in line with those arguing the 
involvement of the sympathetic system in the pathophysiology of HT related to OSA, 
suggesting that beta-blockers, in particular atenolol, may have beneficial effects beyond BP 
reduction in patients with OSA. However, both studies presented low levels of causation, which 
could have limited the ability to detect differences between classes. 
Nevertheless, it has been advanced that angiotension-converting enzyme inhibitors (ACEi) 
treatment could exacerbate OSA by inducing upper airway inflammation (Cicolin et al., 2006). 
The comparison between chronic treatments of ACEi and angiotensin AT1 receptor antagonists 
in terms of AH efficacy and levels of inflammatory markers has never been performed either in 
humans with OSA or in animal models. More recently, other study compared the effect of 
doxazosin (an α1- adrenergic receptor antagonist) and enalapril (an angiotensin-converting 
enzyme inhibitor) on nocturnal BP control and concluded that the former has a proportionally 
poorer effect than the latter (Zou et al., 2010). In 1994, Grote et al. performed a study aimed at 
assessing the effectiveness of cilazapril (an angiotension-converting enzyme inhibitor) in 
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results suggested that cilazapril is effective in reducing BP in all sleep stages (Grote et al., 
1994). In another small study, Heitmann et al. evaluated the effect of nebivolol (a third 
generation beta-blocker) on BP reduction and sleep apnea activity in HT patients with mild to 
moderate OSA in comparison with valsartan (an angiotensin II receptor blocker) and concluded 
that the effect of these AHDs were similar (Heitmann et al., 2010). Despite the same 
limitations, these studies highlight the role of the RAAS in the pathophysiology of HT related to 
OSA 
In two past studies (Lozano et al., 2010; Litvin et al., 2013), patients either received CPAP in 
combination with AHDs or alternatively, the pharmacological treatment alone, allowing the 
evaluation of the effects of CPAP and AHDs independently or in conjunction. In the study 
undertaken by Lozano et al., patients were under an AHDs regimen with at least three drugs at 
adequate doses, including a diuretic (Lozano et al., 2010). The authors noted a significant 
decrease in the mean 24-h diastolic BP in patients who received CPAP in addition to 
conventional treatment, suggesting that resistant HT treated with both CPAP and AHDs 
provides greater BP reduction than AHDs alone (Lozano et al., 2010). However, in patients who 
used CPAP less than the average (5.6±1.52 h/night) and for those treated with conventional 
treatment alone, there was no significant difference in the 24-h ambulatory BP values (Lozano 
et al., 2010). These findings are in line with those reported by Litvin et al., attained with 
patients who received stepped dose titration of AHDs treatment (valsartan 160 mg + amlodipine 
5–10 mg + hydrochlorothiazide 25 mg) for three months before CPAP was added (Litvin et al., 
2013). These findings seem to suggest that the best strategy to treat HT related to OSA involves 
the combination of OSA treatment with CPAP and the use of AHDs. This combination is likely 
to be more effective in lowering both daytime and nighttime BP than either treatment alone 
(Phillips and O’Driscoll, 2013). In addition, Pepin et al. explored RAAS inhibition using 
losartan in a crossover randomized control trial. In this study, the authors compared the efficacy 
of CPAP and valsartan in reducing BP in HT patients with OSA never treated for either 
condition (Pepin et al., 2009). They reported that although the BP decrease was significant with 
CPAP treatment, valsartan induced a fourfold higher decrease in mean 24-h BP than CPAP in 
this specific sample (Pepin et al., 2009). 
In an earlier report, 74 of the 393 OSA patients using AH medications on a regular basis for 
more than six months were deemed to have been treated “ineffectively” (Lavie and Hoffstein, 
2001), but the characterization of these medications was not reported. The same limitation is 
found in the study of Deleanu et al., which aimed to study the effect of medication-controlled 
HT on OSA patients (Deleanu et al., 2014). The authors suggested that controlled BP abates 





These findings could be much more interesting if the regimens responsible for these effects 
were revealed. 
In a recent study, Kario et al. aimed to evaluate the effects of bedtime dosing of vasodilating 
(nifedipine, a calcium channel blocker) vs sympatholytic (carvedilol, a nonselective β-
blocker/α1-blocker) AH agents on the sleep BP profile in HT OSA patients (Kario et al., 2014). 
For this, they made use of a new BP monitoring method, the trigger sleep BP monitoring (TSP) 
method, which is based on the automated fixed-interval measurement function with an 
additional oxygen-triggered function that initiates BP measurement when oxygen desaturation 
falls below a set variable threshold continuously monitored by pulseoximetry (Kario et al., 
2014). The BP lowering effects of nifedipine on the mean and minimum sleep systolic BP were 
stronger than those of carvedilol; moreover, sleep systolic BP surge (the difference between the 
hypoxia peak systolic BP – SBP – measured by the oxygen-triggered function and SBP within 
30 minutes before and after the peak SBP) was only significantly reduced by carvedilol (Kario 
et al., 2014). Thus, both drugs are effective in decreasing sleep BP (Kario et al., 2014) but the 
effect of carvedilol seems to be related more specifically to the hypoxia stimuli than nifedipine. 
Finally, Cichelero et al. recently published the protocol of their randomized double-blind 
clinical trial, which seeks to compare the efficacy of chlorthalidone (a diuretic) with amiloride 
(also a diuretic) versus amlodipine (a calcium channel blocker) as a first drug option in patients 
older than 40 years of age with stage I HT and moderate OSA (Cichelero et al., 2014). The 
findings of this study have not yet been reported. 
In summary, individual drug studies find that the blockade of β1-adrenergic receptors (e.g., 
atenolol and nebivolol) and the renin-angiotensin-aldosterone (RAA) pathway, including both 
ACEi and angiotensin AT1 receptor antagonists, might be helpful. Spironolactone (a 
mineralocorticoid receptor antagonist) has been proposed has a very useful tool in cases of 
resistant HT (Ziegler et al., 2011a, 2011b), a very prevalent condition in OSA patients (Oliveras 
and Schmieder, 2013; Solini and Ruilope, 2013) in which aldosterone levels are generally 
elevated, as well as for severe OSA patients (Ziegler et al., 2011a). Moreover, a study 
performed by Gaddam et al. (Gaddam et al., 2010) has provided preliminary evidence that 
treatment with this drug substantially reduces the severity of OSA and improves BP in patients 
with both OSA and resistant HT (Gaddam et al., 2010). These results seem promising but need 
to be confirmed in further larger studies. In contrast, despite volume overload appears to play a 
large role in the development of OSA (Owen and Reisin, 2013), diuretics, namely thiazide, have 
not been very effective AH agents in OSA patients without fluid retention (Ziegler et al., 
2011b). Calcium channel blockers, although effective in lowering BP, seem to present an effect 
less related to hypoxia stimuli. Moreover, Nerbass et al. reported that the use of these drugs 
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reported that the use of calcium channel blockers was associated with significant reduction in 
total sleep time and lower sleep efficiency (Nerbass et al., 2011). Thus, their prescription can be 
questionable in these patients.  
Despite the findings of these studies, they present some limitations and important data are 
missing. The major limitations comprise the following: the variability of subjects included in 
the studies as most of them were performed in non-AHDs naïve patients; the severity and 
chronicity of HT, which were not taken into account and consenquently the clinical relevance of 
BP reduction is questionable; the drug effectiveness in reducing nocturnal BP, which was not 
assessed in some studies; the confounding risk factors for HT that might be present in OSA 
patients (e.g., obesity) and were not properly addressed in most studies. Furthermore, we can 
point out several questions that are still unanswered, e.g.: how many OSA patients are 
controlled under monotherapy with beta- blockers, angiotensin-converting enzyme inhibitors 
(ACEis), and angiotensin II receptor blockers (ARBs)? Beta-blockers or RAAS blockers are 
apparently effective, but should they be used alone or in combination? How many OSA patients 
remain uncontrolled despite the use of two or more AHDs? How do different AHDs behave 
when included in an AHDs regimen? In addition, the impact of these studies in clinical practice 
is unknown because epidemiological studies designed to investigate the AH medication profile 
in OSA patients are lacking. In addition, the more recent recommendations for the management 
of patients with OSA and HT are inconclusive regarding the use of AHDs and recognize the 
lack of strong evidence for the establishment of a first-line AHDs regimen for these patients 
(Parati et al., 2013). Other authors support the idea that as there is no clear evidence for 
prefering a specific class of AHDs, the selection should primarily be guided by the patient’s 
cardiometabolic profile and associated comorbidities (e.g., obesity, metabolic syndrome, 
diabetes mellitus, and cardiovascular diseases) (Tsioufis et al., 2010). Moreover, these authors 
recommend that due to the lack of relevant trials focused on the use of associations of AHDs in 
OSA patients, the choice should rely on current HT guidelines and the adverse effects of AHDs 
also need to be considered (Tsioufis et al., 2010). The limited evidence base restricts the ability 
to make informed treatment choices. Thus, larger scale observational and clinical studies are 
needed to address these and possibly other limitations and bring new insights to the field. 
Another problem concerning the studies carried out in humans is that HT is frequently not 
recognized in patients with OSA (Baguet et al., 2009), and it is important to highlight that 
patients with elevated BP who do not carry the diagnosis of HT may be misclassified as non-HT 
(Wang and Vasan, 2005). Consequently, aggressive control of BP must be warranted in OSA 
patients and an accurate method for BP measurement should be used in the early diagnosis of 
clinically suspected OSA patients. Taking into account the advantages and limitations of the 





measurement and home BP monitoring in diagnosing HT in patients with suspected OSA 
(Parati et al., 2012). 
 
ANIMALS 
As previously stated, a rather wide variety of animal models has been used to evaluate the 
cardiovascular consequences of OSA and to study the cause-effect mechanisms in OSA. As 
CIH causes a moderate increase in BP, drugs can be tested further to modulate this effect. 
However, studies aimed at investigating the AH effect of drugs on animal models are scarce. 
Table 4 summarizes the studies that have evaluated the effects of AHDs on BP in animal 
models of CIH.  
In a study undertaken to clarify the role of renal sympathetic nerve activity and plasma renin 
activity (PRA) in the diurnal BP response to chronic IH, Fletcher et al. demonstrated that the 
pharmacological blockade of the RAAS with losartan prevented the rise in BP induced by CIH 
(Fletcher et al., 1999; Fletcher et al., 2002). Losartan and other angiotensin antagonists (A-779, 
an Ang-(1–7) antagonist; ZD7155, an AT1 antagonist; PD123319, an AT2 receptor antagonist) 
were further used by da Silva et al. (da Silva et al., 2011) to investigate the role of endogenous 
angiotensin peptides within the hypothalamic paraventricular nucleus (PVN) neurons to control 
BP in a rat model of CIH-induced HT. These authors concluded that endogenous angiotensin 
peptides acting in the PVN contribute to IH-induced increases in MAP observed in this rat 
model. In 2013, losartan was used once again to test the role of the brain RAAS in CIH HT 
(Knight et al., 2013). The work of this group provided evidence that brain RAAS contributes to 
HT related to CIH and that brain RAAS appears to be critical for the development and 
maintenance of the sustained HT during normoxia (Knight et al., 2013). 
Other groups have found that the systemic administration of endothelin (ET) receptor 
antagonists in rodents prevents the increase in BP during CIH exposure (Kanagy et al., 2001; 
Allahdadi et al., 2008; Belaidi et al., 2009). The data provided by Allahdadi et al. showed that 
an endothelin receptor antagonist (ETA: BQ-123) acutely decreased the MAP dose dependently 
in rats exposed to IH but not sham rats, suggesting that targeting ETA receptors may be a 
selective and effective treatment of HT related to OSA (Allahdadi et al., 2008). Belaidi et al. 
used SH rats and bosentan, a mixed endothelin receptor antagonist (Belaidi et al., 2009). Their 
results showed that the administration of bosentan during chronic IH prevented the increase in 
BP and reinforced the idea that endothelin antagonists could be useful therapeutic tools in HT 
related to OSA (Belaidi et al., 2009). The same effects were reported by Kanagy et al. for 
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BP measurement  






2/3- 20.9% O2 (3-6 s 
+15-18s; 2 
cycles/min); 6-8 
h/day; 35 days 
Losartan (15 mg/kg); 
gavage; 35 days 
Telemetry 
Significant  MAP 
(98.2  61.7 to 85.9 
 62.7 mm Hg) 















delivered into PVN; 
14 days. 
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20.9-10% (180 s 
cycles); 10h/day; 35 
days 
Losartan (15 mg/kg); 
p.o. (syringe 
technique); 35 days 
NA (arterial 
catheterization?) 




80 cycles (6 min 
each) 21-10% O2/ 
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20 cycles (90s each) 
of 21-5% O2 and 0-
5% CO2/hour; 
7h/day; 14 days 
BQ-123 (10 to 1,000 
nmol/kg in bolus or 
100 nmol/kg/day for 
chronic 
administration); iv or 















21-10% O2 (1 min 
cycles: 20s+40s); 
8h/day; 14 days 
Bosentan (100 
mg/Kg/dia); mixed in 
chow; 14 days 
Tail-cuff method +  
Arterial 
catheterization 
Prevented MAP Belaidi et al., 2009 
SHR 
21-10% O2 (every 
90 seconds); 12 
h/day; 30 days 
Nifedipine (5 mg/Kg) 
and SOD mimetic 
(MnTMPyP; 10 
mg/Kg); s.c.; 30 days 
Tail-cuff method 
Nifedipine: 
attenuate SBP and 
DBP 
SOD mimetic:  






21-5% O2 (every 60 
s); 8h/day; 14-21 
days 
Melatonin (10 
mg/Kg); i.p.; 14 or 21 
days (30 min before 
hypoxic exposure) 




20 cycles (90s each) 
of 21-5% O2 and 0-
5% CO2/hour; 
7h/day; 14 days; 
Tempol (1 mM); 
drinking water; 14 
days 
Telemetry  MAP (17 mmHg) 
Troncoso-Brindeiro 




12 cycles (300s 
each) of 21-5% 
O2/h; 8h/day; 21 
days 
Ascorbic acid (1.25 
g/L); drinking tap 
water; 21 days 
Arterial 
catheterization 




9 cycles (5 min+ 
15s) of 21-5% 












20 cycles (90s each) 
of 21-5% O2 and 0-
5% CO2/h; 8h/day; 
11 days 
PD145065 (ET 
receptor antagonist in 
cumulative drugs: 0.3, 
3.0, 30, 300, 1000 




Dose dependent  
MAP 




21-5% O2 (12 
times/h); 8 h/day; 14 
days 
Ebselen (specific 
ONOO- scavenger; 10 
mg/kg/day); osmotic 
mini-pumps; 7 days 
Telemetry  elevated BP Moya et al., 2014 
AHDs, antihypertensive drugs; BP, blood pressure; CIH, chronic intermittent hypoxia; DBP, diastolic blood pressure; ET, 
endothelin; h, hour; HT, hypertension; i.p., intraperitoneal; MAP, mean arterial pressure; NA, information not available; min, 
minutes; p.o., per os; PVN, hypothalamic paraventricular nucleus; s, seconds; SBP, systolic blood pressure; SHR, spontaneously 






Soukhova-O’Hare et al., designed a study based on the assumption that reactive oxygen species 
and altered L-Ca
2+
 channel activity may underlie the postnatal programing of exaggerated BP 
and cardiac remodeling (Soukhova-O’Hare et al., 2008). To test this hypothesis, these authors 
used nifedipine, an L-calcium channel blocker, and a superoxide dismutase mimetic 
(MnTMPyP pentachloride); both attenuated BP (Soukhova-O’Hare et al., 2008). Their results 
suggested that Ca
2+
 and reactive oxygen species-mediated signaling during IH are critical 
mechanisms underlying postnatal programing of an increased severity of HT in SHR. Kumar et 
al. reported similar results for the same superoxide dismutase mimetic (Kumar et al., 2006). A 
year before, Troncoso Brindeiro et al. used another superoxide dismutase mimetic, tempol, and 
showed that scavenging superoxide prevents both the increase in ET-1 production and vascular 
ROS levels induced by CIH exposure (Troncoso Brindeiro et al., 2007). The later work of Del 
Rio et al., using the antioxidant ascorbic acid, showed that this substance prevented the 
increased plasma peroxidation and nitrotyrosine formation within the carotid body, as well as 
HT (Del Rio et al., 2010), supporting the essential role of oxidative stress in the generation of 
carotid body chemosensory potentiation and systemic cardiorespiratory alterations induced by 
IH (Del Rio et al., 2010). 
More recently, Hung et al. tested the hypothesis that melatonin, previously shown to ameliorate 
oxidative injury and inflammation, could have a protective effect against IH-induced HT and 
endothelial dysfunction. This assumption was confirmed as melatonin promoted a decrease in 
systolic BP and prevented endothelial dysfunction with ameliorated levels of nitric oxide, 
endothelial-dependent relaxation, and expressions of eNOS and antioxidant enzymes (Hung et 
al., 2013). 
Based on the studies described, we can conclude that most reports on CIH animal models in 
which drugs have been tested were not designed to respond to pharmacological issues: they 
have been used solely as pharmacological tools to address physiological mechanisms. The 
experiments evaluate prevention but not the effectiveness of treatment. They must be planned 
first to induce HT and then evaluate the efficacy of cumulative doses of drugs because the 
translation of the results to humans obtained with simultaneous induction of HT and drug 
administration is not relevant. Other limitations of the pharmacological approaches included in 
these works are the absence of dose-response curves and comparison of the effectiviness of 


































































































Which were the starting points for the design of the present study? 
1) Close linkage between obstructive sleep apnea (OSA) and hypertension, highlighted by 
the extremely high prevalence of hypertension (HT) among patients with OSA. 
2) Scarce effect of continuous positive airway pressure (CPAP), the gold standard 
treatment, on sustaining blood pressure (BP) control, which implies that the use of 
antihypertensive drugs is still required for patients with both OSA and HT.  
3) Lack of specific guidelines for the pharmacological treatment of HT in patients with 
OSA. 
4) Limited data on antihypertensive drug (AHDs) regimens in these patients.  
5) Inconsistent effects of antihypertensive drug in patients with OSA. 
6) Higher clinical prevalence of CIH conditions than acute or chronic sustained hypoxia. 
7) Less explored mechanisms and consequences of chronic intermittent hypoxia (CIH) 
than for chronic sustained hypoxia. 
8) Lack of experiments specifically planned and performed to evaluate the efficacy of 
cumulative doses of antihypertensive drugs in CIH conditions. 
 
Facing these facts, the general aim of this thesis is to contribute to identify more effective 
AHDs for the treatment of hypertension in patients with OSA and investigate underlying 
mechanisms of systemic effects associated with OSA, as well as its modulation by AHDs. For 
that, we will use a sizeable sample of patients with OSA and, in order to surpass some 
confounding factors that might be present in the human study and to attain more specific 
information concerning drugs efficacy, a rat experimental model of hypertension induced by a 
paradigm of CIH that simulates OSA. 
 
The specific aims of the present work are the following: 
1) To highlight the relevance of Ambulatory Blood Pressure Monitoring (ABPM) in 
diagnosis and therapeutic decision-making for patients suspected of having OSA. 
2) To find new predictors based on anthropometric measures to identify patients that 
misclassify themselves as non-hypertensive, and thereby promote the selective use of 
ABPM. 
3) To characterize the phenotypic characteristics and, specifically, the patterns of AHDs 
used in patients with OSA. 
4) To investigate a hypothetical association between ongoing antihypertensive regimens 
and BP control rates in patients with OSA, before and after CPAP adaptation. 
5) To determine, in a rat model of CIH-induced hypertension, the efficacy of carvedilol, a 






6) To investigate an alternative method to gavage, for chronic administration of AHDs to 
laboratory rats, since when testing these drugs it becomes crucial to ensure the selection 
of a non-invasive and stress-free method for drug delivery. 




















































































All patients were fully informed about the study and gave written consent (attachment #1) in 
accordance with the Declaration of Helsinki. The study protocol was previously approved by 
Centro Hospitalar Lisboa Norte’s Ethics Committee (Ethical approval: 11
st
 November 2009) 
and registered at ClinicalTrials.gov (NCT01803815). 
 
Subjects and Study Design 
Three hundred and sixty-nine consecutive patients clinically suspected of having OSA, aged 
above 18 years, who were attending their first visit at the Centro Hospitalar Lisboa Norte, EPE 
(CHLN) Sleep Unit, following referral by their general practitioner or other specialist, were 
assessed for eligibility. Patient inclusion started in April 2010 and was completed in July 2012. 
Exclusion criteria included severe psychiatric disease or an inability to understand the 
information required for informed consent.  
At baseline (first visit) all patients were invited to undergo an overnight polysomnography, 24-h 
ambulatory blood pressure monitoring (ABPM) and completed a data collection form that 
included ongoing medication profile registration.  
Predictors of HT misclassification 
Patients with ABPM, sleep data and no prior diagnosis of hypertension were included in the 
cross-sectional study designed to evaluate the validity of self-reported hypertension and to find 








Figure 1: Predictors of HT misclassification: patient eligibility and follow-up.  
ABPM: Ambulatory Blood Pressure Monitoring; HT: hypertension. 
 
Of the 369 patients consecutively included, ABPM and/or sleep recordings were missing for 48, 
due to technical problems or because they did not attend the ABPM or sleep study. One hundred 
and twenty-two patients who were not taking antihypertensive medication answered  “No” to 
the question “Have you ever been told by a doctor that you have high blood pressure?” and the 
remaining 199 answered yes or were under antihypertensive medication. Of the 369 only 122 
patients were considered eligible for the study (misclassified non-hypertensive patients n=53; 
non-hypertensive patients n=69). 
Association between antihypertensive medication and BP control 
Once the diagnosis of OSA and hypertension was established, the criteria for treatment with 
CPAP confirmed and baseline ABPM measured (second visit), patients were scheduled for 
CPAP titration. Four to five weeks after CPAP adaptation (third visit), the device data were 
checked and patients with a CPAP mean daily use of at least 4 hours were scheduled for 























changed their antihypertensive medication since the first evaluation. If any changes in either 
type of medication or dose had occurred, the patient was excluded from the study. 
For this prospective cohort study, additional inclusion criteria were subsequently defined. 
Only patients with an apnea-hypopnea index > 5 events/hour, diagnosis of hypertension, a 
CPAP mean daily use of at least 4 hours and ambulatory 24-h ABPM recordings, performed at 
baseline and 1-3 months after checking CPAP adherence, were considered eligible for the study 
of the association between antihypertensive regimens and BP control, before and after CPAP 
adaptation (Figure 2).  
Briefly, of the 369 patients consecutively included, 68 were patients with no diagnosis of OSA 
and 48 with no diagnosis of hypertension. The ABPM and/or sleep recordings were missing for 
48 patients due to technical problems or because they did not attend the ABPM (n=41) or sleep 
study (n=7). Forty had no indication for CPAP therapy. One hundred and sixty-five were 
scheduled for CPAP adaptation; however, 7 refused CPAP, CPAP data were missing in 6 
patients and 51 had no compliance. Of the 369, only the data from 90 patients were used to 
investigate the association between ongoing AH regimen and BP control rates after CPAP 
adaptation. 
 
Figure 2: Association between antihypertensive medication and BP control: patient 
eligibility and follow-up.  
AHI: Apnea-Hypopnea Index; ABPM: Ambulatory Blood Pressure Monitoring; BP: blood pressure; 





Data collection form and clinical assessment 
Socio-demographic and anthropometric data, as well as smoking habits, comorbidities and 
ongoing medication profiles, were registered (attachment #2 and #3).  
All patients were assessed for weight, height, neck circumference (NC) and waist circumference 
(WC) using standardised protocols. Weight was measured, with lightweight clothing and 
without shoes, to the nearest 100 g and height was assessed, with no shoes, to the nearest 0.5 
cm, in both cases using calibrated instruments. Body mass index (BMI) was calculated as body 
weight in kilograms divided by the square of height in metres (kg/m
2
). Neck circumference, 
measured in the middle of the neck, at the level of the cricothyroid membrane (in men with a 
laryngeal prominence it was measured just below the prominence), to within 0.1 cm, with the 
patient’s head positioned in the Frankfort horizontal plane, and WC, assessed at the level of the 
umbilicus to within 0.1 cm, were also recorded using a flexible non-stretchable measuring tape.  
Regarding smoking habits, patients were classified as non-smoker, ex-smoker, and smoker 
(defined as those who smoke at least one cigarette per day over the previous year). 
Comorbidities, with a focus on hypertension, were assessed. Hypertension was defined as self-
reported hypertension (answer “yes” to the question “Have you ever been told by a doctor that 
you have high blood pressure?”) or use of antihypertensive medication. Information about 
diabetes mellitus, dyslipidaemia, arrhythmias, asthma, chronic obstructive pulmonary disease 
(COPD), depression and anxiety, history of cardiovascular disease and hypothyroidism was also 
collected.  
The ongoing medication profile (drug name (International Non-proprietary Name: INN) and 
dose) was recorded using the “Brown-Bag” medication review (a method in which patients are 
asked to bring all of their medications to each visit) (Caskie et al., 2006). We analysed the use 
of antihypertensive drugs by regimen: 1-with angiotensin-converting enzyme inhibitors (ACEi); 
2-with angiotensin II receptor blockers (ARAs); 3-with β-blockers; and 4-others (including 
diuretics and calcium channel blockers), and the number of antihypertensive drugs (1-one, 
monotherapy; 2-two or more, polytherapy) included in each patient regimen. In all patients, 
antihypertensive drugs were taken for at least six months without changing the medication 
profile until the end of the follow-up. 
 
Sleep Evaluation 
Patients underwent an overnight in-laboratory polysomnography or, as an alternative for the 
diagnosis of OSA in patients with a high pretest probability of moderate to severe OSA, a 
cardiorespiratory sleep study (Collop et al., 2007). In-laboratory polysomnographic studies 























Broomfield, CO, USA) and ambulatory recordings were made using a validated portable digital 
recording unit (type 3) with sensors for the registration of airflow, saturation, respiratory 
movements of the chest, body position and snoring sounds (Embletta PDS device; Embla 
Systems Inc, Broomfield, CO, USA). Sleep recordings were manually scored, based on standard 
criteria (Collop et al., 2007), by trained technicians. Apnea was defined as a complete cessation 
of airflow for at least 10 s, associated with oxygen desaturation of 3%. Hypopnea was defined 
as a discernible reduction in airflow of at least 50% for 10 s or more, with an accompanying 
desaturation of at least 3% or an arousal. The number of apneas and hypopneas per hour of 
sleep was calculated and, for both in-laboratory and ambulatory recordings, the apnea-hypopnea 
index (AHI) was considered. Respiratory effort related arousals (RERAs), scored in laboratory 
polisomnography sleep staging, were not considered in order to minimize the differences 
between the results of the two diagnostic approaches. OSA was categorized according to current 
AHI cut-offs of < 5 (non-diagnostic), 5 ≥ and < 15 (mild), 15 ≥ and < 30 (moderate) and ≥ 30 
(severe) (Berry et al., 2012; Collop et al., 2007). 
 
Twenty-four-hour ambulatory blood pressure monitoring (ABPM) 
Twenty-four hour ABPM was performed at baseline, on a different day to that of the sleep 
evaluation, and 1-3 months after CPAP adaptation. All participants were instructed to continue 
their usual daily activities. Screening BP measurements were performed in accordance with the 
recommendations of the European Society of Hypertension (ESH) and of the European Society 
of Cardiology (ESC) guidelines (Mancia et al., 2007), using appropriately-sized arm cuff, on 
the non- dominant arm, with a non-invasive portable validated BP recorder (Spacelabs Model 
90217; Spacelabs Healthcare, Redmond, WA, USA).  
The equipment was programmed for cuff inflation every 20 minutes during the daytime period 
and every 30 minutes during the night-time. Daytime and night-time were individually 
predetermined depending on the participants’ usual awake and sleep schedule. The data were 
considered valid when a minimum of 70% of the measurements was recorded without errors. 
BP recordings were analysed for the overall 24-hour period, daytime and night-time periods. 
Additionally, 24 h BP profile was assessed and patients were classified as showing a dipping or 
a non-dipping profile. A dipping profile was defined as a reduction in the average systolic and 
diastolic BP at night that was higher than 10% compared to daytime values. The data were 
analysed by an experienced cardio-respiratory technician. 
Uncontrolled BP was defined according to ESC and ESH guidelines (Mancia et al., 2013). BP 
was considered uncontrolled for systolic BP (SBP) values of 135 mm Hg or above, diastolic BP 
(DBP) values of 85 mm Hg or above, or both during daytime and systolic BP (SBP) values of 





time (Mancia et al., 2013). Isolated nocturnal hypertension was defined, in accordance with the 
established BP thresholds for ABPM, as night-time SBP values of 120 mm Hg or DBP of 70 
mm Hg or above, and isolated daytime hypertension as diurnal SBP of 135 mm Hg or DBP of 
85 mm Hg or above. When both conditions were present, subjects were classified as having 
combined day-night hypertension (Mancia et al., 2013). 
 
Continuous Positive Airway Pressure (CPAP) therapy 
CPAP titration was performed using self-adjusting CPAP devices (autoCPAP) (REMstar PR1 
Auto, S8 AutoSet Spirit- Resmed Ltd), AutoSet Spirit S9 - Resmed Ltd). These devices 
automatically titrates the amount of pressure delivered to the patient to the minimum required to 
ensure an unobstructed airway, allowing optimal pressure settings. During the initial setup of 
the machine, the minimum (Pmin: 4 cm H2O) and maximum (Pmax: 16 cm H2O) pressures 
were set. All patients were followed-up 4-5 weeks after CPAP adaptation, in order to check for 
any side effects or problems with the treatment and, if required, for CPAP pressure adjustment.  
CPAP adherence, as well as residual AHI, leak and pressure data, were assessed from the device 
counter. Optimal pressure was determined visually from the raw data by analyzing the pressure 
curve that included the periods with a leak lower than 0.4 L (90
th
 percentile leak). Data were 
analysed by experienced technicians using appropriate software (attachment #3). 
 
Statistical Analysis 
An exploratory analysis was carried out for all variables. Categorical data were expressed as 
frequencies and percentages, and continuous variables as mean or median, standard deviation 
(SD) or inter-quartile range (25th percentile-75th percentile). Univariable analysis was 
performed using Student's t-test and nonparametric (Fisher's exact test, χ2 and Mann-Whitney 
U) tests as appropriate. Welch’s t-test was used as an adaptation of Student’s t-test whenever 
unequal variances were obtained. Wilcoxon test and Sign test were used to compare ABPM data 
measured at baseline and after CPAP adaptation. The McNemar test was applied to compare the 
proportion of uncontrolled patients before and after CPAP adaptation. Finally, the Spearman’s 
rho rank correlation was used to investigate the association between the anthropometric 
variables. 
For the categorization of NC and BMI, the minimum p-value approach was applied 
(Mazumdar and Glassman, 2000). Based on a systematic search for the "best" cut point, this 
method obtains the point from a grid of marker values that is associated with the minimum p-
value which corresponds to the maximum chi-squared test value. Generalized Additive Models 
(GAMs) (Hastie and Tibshirani, 1990) for binary response were used to confirm the cut-off 























the data in order to determine the relevance of AHI and BMI in non-hypertensive 
misclassification. The outcome binary variable was "misclassified non-hypertension" (yes: for 
patients who classified themselves erroneously as non-hypertensive, no: for truly non-
hypertensive patients). The previously obtained cut-off points were used to discretize the 
continuous NC and BMI and the new categorical variables were then used as independent 
variables in the logistic regression model. The predictive ability of the resulting model was 
analysed using the Hosmer-Lemeshow goodness-of-fit test (Hosmer and Lemeshow, 1989). 
This test was used to compare the observed and expected frequencies of patients that 
misclassified themselves as non-hypertensive, based on the values of the estimated probabilities 
obtained by the logistic regression model. A high p-value would indicate that the model was 
performing well. The area under the Receiver Operating Characteristic curve (AUC) was used 
to evaluate the discriminative ability of the model.  A value of 0.50 would be obtained when a 
model discriminates no better than chance, and a value of 1.0 means perfect accuracy. 
In order to identify baseline predictors of BP control after CPAP adaptation, a univariable 
analysis was performed. The outcome variable was "uncontrolled BP" (yes: for patients with 
uncontrolled BP and no: for patients with controlled BP) and the multiple logistic regression 
model was subsequently fitted to the data. The predictive ability of the resulting model was 
analysed by the Hosmer-Lemeshow goodness-of-fit test (Hosmer and Lemeshow, 1989). A high 
p-value indicates that the model is performing well. The area under the Receiver Operating 
Characteristic curve (AUC) was used in order to evaluate the discriminative ability of the 
model. A value of 0.50 is obtained when a model discriminates no better than chance, and a 
value of 1.0 means perfect accuracy.  
Results were considered significant when α=0.05. Confidence intervals are presented when 
appropriate (95% CI). Statistical analysis was performed using the IBM SPSS Statistics (IBM 










The applicable institutional and governmental regulations concerning the ethical use of animals 
were followed, according to the NIH Principles of Laboratory Animal Care (NIH Publication 
85-23, revised 1985), the European guidelines for the protection of animals used for scientific 
purposes (European Union Directive 2010/63/EU) and the Portuguese Law nº 113/2013. 
Experimental procedures were previously approved by the Institutional Ethics Committee of the 
NOVA Medical School for animal care and use in research (Ethics approval: 21
st
 May 2011 
(study in animals submitted to CIH conditions) and 21/2013/CEFCM (study for the refinement 
of oral dosing of antihypertensive drugs in rats). 
 
Animals 
Experiments were performed in male Wistar rats (Ratus norvegicus), aged 2-3 months, and 
obtained from the NOVA Medical School animal facility. This Wistar in house colony has been 
started with animals acquired from Charles River Laboratories (Crl:WI). Animals were housed 
individually in polycarbonate cages with wire lids (Tecniplast, Buguggiate, Varese, Italy), under 
12 h light/dark cycles (8 am - 8 pm), at a room temperature 22 ± 2.0 °C and relative humidity 
60± 10%. Rats were maintained on a standard laboratory diet (SDS diets RM1) and reverse 
osmosis water, given ad libitum. Corncob bedding (Probiológica, Lisbon, Portugal) was used 
and changed once a week. Animals were Specific Pathogen Free (SPF) according to FELASA 
recommendations (Nicklas et al., 2002).  
 
Experimental protocols  
Efficacy of Carvedilol in reversing HT induced by CIH 
Drugs and chemicals 
Carvedilol (CVD) was kindly provided by Tecnimede (Sintra, Portugal; manufacturer batch: 
5334-11-015) and methylcellulose (MC) was purchased from Sigma-Aldrich (Sintra, Portugal). 
R-(+)-CVD and S-(-)-CVD were obtained from Santa Cruz Biotechnology, Inc. (Heidelberg, 
Germany). The enantiomerically pure chiral agent, (-)-menthyl chloroformate (MCF) was 
obtained from Sigma-Aldrich (Sintra, Portugal). HPLC grade solvents used in the extraction 

























Experiments were performed in thirty-one male Wistar rats, aged 2-3 months and with mean 
body weight 308.4±45.36 g.  
Three different doses were administered to investigate the long-term effects (25 days) of 
carvedilol (CVD) in an experimental model of hypertension related to CIH. Rats were randomly 
assigned and divided into five groups: Group 1 (CVD 10 mg/kg/day - CIH; n=5); Group 2 
(CVD 30 mg/kg/day - CIH; n=7); Group 3 (CVD 50 mg/kg/day - CIH; n=8); Group 4 (control 
group administered vehicle (0.5% methylcellulose (MC)); n=5); Group 5 (CVD 50 mg/Kg/day 
– Normoxia (Nx); n=6). MC 0.5% (2 ml) was used to facilitate the dissolution and absorption of 
CVD, since it is a very lipid soluble drug (Rodriguez-Perez et al., 1997). 
Animals from Groups 1, 2, 3 and 4 were gentled for 10 minutes daily for one week prior 
surgery, to minimise the discomfort related to experimental manipulation and reduce data 
variability, and were instrumented with indwelling blood pressure telemeters. Rats were 
allowed to recover for 10 days, after transmitter implantation surgery, before any measurements 
were recorded. A period of 5/6 days was then given for chamber acclimatization under 
normoxic conditions (21 O2% + 79% N2) and baseline cardiovascular data was recorded. 
Animals were then exposed to 60 days of CIH, during their sleep period, and CVD or vehicle 
administration, by gavage, started at Day 36 and lasted 25 days. Animals from Group 5 
(normoxic rats) were exposed for 60 days to normal air (21% O2 and 79% N2), in the same room 
as the CIH animals in order to experience similar conditions. Similarly, CVD administration by 
gavage started at Day 36 and lasted 25 days for the other groups. Since these rats were 
specifically used for pharmacokinetic studies, the implantation of telemetry transmitters was not 
performed. 
At the end of the experiments, 2-3 hours after drug or vehicle delivery, the rats were 
anaesthetised, by intraperitoneal injection with medetomidine (0.5mg/kg body weight; 
Domitor®, Pfizer Animal Health, Auckland, New Zealand) and ketamine (75mg/kg body 
weight; Imalgene 1000®, Mérial, Lyon, France), and cardiac puncture was performed without 
thoracotomy, with a 20 G needle with a 10 mL syringe, to collect blood for further 
quantifications. The animals were then euthanized with an intracardiac overdose of sodium 
pentobarbital (Eutasil®, Ceva Animal Health, Libourne, France), and the death was confirmed 
by cervical dislocation. 
Rats were weighed at baseline and once a week during the entire study. The amount of 
carvedilol was adjusted weekly to ensure the doses of 10, 30 and 50 mg/Kg/day (p.o.). CVD 
was weighed daily, immediately before administration, dissolved in the vehicle and labelled 





to the animals on approximately the same schedule (9:00 to 9:30 am), always after BP 
measurement and before the exposure to CIH conditions. Control animals received equivalent 
daily oral gavage volumes (2 mL). All rats underwent a 7 day handling acclimatization period 
and were handled daily for a period of 2 minutes each by the same individual and accustomed to 
the gavage position, in a different animal room. Gavage was performed using a sterile 
polypropylene feeding tube (gauge 15; tip diameter: 3 mm; length: 78 mm; Instech 
Laboratories, Inc., USA) in order to reduce the risk of trauma, perforation and cross 
contamination (Morton et al., 2001). 
 
 
Figure 3: Experimental design of the study performed to evaluate the effects of carvedilol 
on HT related to CIH. CIH: Chronic intermittent hypoxia; HT: hypertension. 
 
Radiotelemetry  
Since hemodynamic measures are particulary prone to confounding factors (e.g. experimental 
stress due to the need for physical restraint of the animals, which leads to higher BP and heart 
rate (HR) recordings), we decided to use radiotelemetry in our experiments. This method allows 
daily recording of mean arterial BP, systolic and diastolic BP and HR, under conscious 
physiological condition, in unrestrained laboratory animals.  
In our protocol, the animals were implanted with cylindrical shaped transmitters: model 
TA11PA-C40 (Data Sciences Corporation, St. Paul, MN, US). Output from the telemetry 
transmitters were recorded via radio frequency signals obtained through Data Acquisition 
System (Data Sciences Corporation, St. Paul, MN, US). The DSI Data Exchange Matrix is 
able to detect and forward the model and serial number of receivers (Figure 4) and the 























corrections via a digital signal to the computer, ensuring accurate pressure measurements in 
small animals when using DSI transmitters) to the Dataquest® A.R.T. system, which collects 
and maintains digital data from the receiver to the computer to optimize data integrity 
throughout the system.  
BP and HR measurements, obtained during a 10s sampling period, were averaged and recorded 
during 15 minutes daily. Baseline recordings of BP and HR were performed for 3/4 days prior 




Figure 4: DSI PhysioTel® Receivers – RPC-1 Model for Small Animals (Data Sciences 
Corporation, St. Paul, MN, US). The RPC-1 Receiver is used for monitoring animals housed in 
plastic cages that can be placed on top of the receiver. 
 
Device description 
The PA-C40, weighs 7.8g and has an initial pressure accuracy of ±3 mmHg. This device 
consists of two major components: the device body and the pressure catheter (Figure 5).  
 
Figure 5: The PA-C40 Transmitter: (A) Device Body and (B) Pressure Catheter (DSI, St. Paul, 
MN, US). 
 
The Device Body contains:  
(1) Pressure sensor: receives pressure fluctuations from the fluid-filled catheter and sends 





(2) Reusable electronic module: translates the pressure fluctuations into digitized signals 
and transmits them to a receiver and it also contains a magnetically activated switch that 
allows the device to be switched on or off); 
(3) Battery: provide the power supply for the electronics module;  
(4) Suture rib: allows the surgeon to suture the device securely in place at the implant site). 
 
The Pressure Catheter is polyurethane tubing that extends out of the device body (8 cm) and 
includes:  
(1) Non-compressible fluid: relays pressure fluctuations to the sensor);  
(2) Thin-walled section: tip of the catheter farthest from the device body that senses the 
dynamic portion of the pressure wave. It is designed to be completely inserted into the 
vessel where the desired pressure can be sensed. It contains biocompatible gel at the 
very tip, which prevents the non-compressible fluid from leaving the catheter and blood 
from clotting in the catheter tip;  
(3) Tip cover: removal section of silicone tubing that protects the catheter tip until it is 
actually inserted into the desired vessel. 
 
Surgical instrumentation 
Animals were instrumented under medetomidine (0.5mg/kg body weight (i.p.); Domitor®, 
Pfizer Animal Health) and ketamine (75mg/kg body weight (i.p.); Imalgene 1000®, Mérial, 
Lyon, France) anesthesia with indwelling blood pressure telemeters (model TA11PA-C40, Data 
Sciences Corporation, St. Paul, MN, US).  
The animals were provided with preoperative analgesia, using the opioid analgesic drug 
butorfanol (1mg/Kg/mL (s.c.); Dolorex®, Intervet International GmbH, Unterschleissheim, 
Germany), in order to ensure pain relief during and after surgery. The animal’s body 
temperature was maintained throughout the experimental procedure using a heating pad. To 
minimise corneal desiccation, the eyes were lubricated with sterile saline. In preparation for 
abdominal incision, this area was shaved with a clipper, scrubbed with a povidone-iodine 
solution (Betadine®, Mundipharma AG, Basel, Switzerland) and 70% isopropyl alcohol, and 
covered with a sterile surgical drape. The aseptic conditions of the microsurgical instruments 
were ensured by autoclaving and maintained at all times with the use of a hot bead sterilizer 
(Fine Science Tools GmbH, Heidelberg, Germany).  
The radiotelemetry transmitter was implanted aseptically into the abdominal aorta, exposed via 
a ventral midline incision in the abdominal cavity. The aorta was occluded using bulldog type 
clamps (Fine Science Tools GmbH, Heidelberg, Germany) placed immediately after renal artery 
























Figure 6: Surgical procedure for abdominal aorta cannulation with intraperitoneal cavity 
device placement (DSI, St. Paul, MN, US). 
 
A bent needle (20G, B.Braun Medical, Melsugen, Germany) was used as a catheter introducer 
and the pressure tip of the telemeter was guided beneath the needle and introduced into the 
aorta. The puncture site and the surrounding tissue were dried and a small drop of tissue 
adhesive (Vetbound, 3M Company, St Paul, MN, USA) was applied to seal the insertion point. 
The vessel clamps were carefully removed and, if there was no bleeding, the intestines were 
replaced in their original position and the abdominal cavity was flushed with warmed sterile 
saline to avoid tissue adhesion. The body of the transmitter was then placed on top of the 
intestines and secured to the abdominal muscle by closing the abdominal incision and 
incorporating the suture rib on the device into the closure, using nonabsorbable sutures 
(Surgisilk 4/0, Sutures Ltd, Wrexham Wales UK) in a simple interrupted pattern (Figure 7). 
Finally, the skin incision was closed using nonabsorbable suture (Surgisilk 4/0, Sutures Ltd 
UK).  
 
Figure 7: Intraperitoneal placement of the transmitter (DSI, St. Paul, MN, US).  
 
Thirty minutes after surgery, the anaesthesia was reversed with atipamezole (0.25mg/Kg/2mL 





environmental enrichment, to protect the wound sites and minimise stress. A heating pad on a 
low setting was provided to allow the animals to self-regulate temperature in the first hours after 
surgery. Postsurgical recovery was monitored by daily visual examination (return of normal 
postures and behaviours) and daily food and water intake. Rats were treated postoperatively for 
2-3 days with the nonsteroidal anti-inflammatory drug carprofen (5 mg/Kg/1mL (s.c.), 
Rimadyl®, Vericore Limited, Dundee, UK). 
 
CIH exposure 
Animals were kept in a eucapnic atmosphere, inside medium A-chambers (76 x 51 x 51 cm, A-
60274-P, Biospherix Ltd, NY, USA; Figure 8) with ad libitum food and water access. The 
chambers were equipped with gas injectors and sensors for oxygen (O2) and carbon dioxide 
(CO2) levels in order to ensure the accuracy of CIH cycles. Accumulation of CO2 was prevented 
by the continuous flow of the gas mixtures, by the circulation of the gases inside de chambers 
through vent holes and by the presence in the chamber of self-indicating soda lime (AnalaR 
Normapur®, VWR International BVBA, Leuven, Belgium), which absorbs the expired CO2. 
The CO2 levels inside the chambers never exceeded 1%. A silica gel (Chameleon® C 2-6 mm, 
VWR International BVBA, Leuven, Belgium) container was also placed inside the chambers in 
order to absorb water. Oxygen concentration inside the chambers was controlled using 100% 
nitrogen (N2) and 100% O2 via electronically regulated solenoid switches in a three-channel gas 
mixer, which gradually lowered the oxygen in the chamber from 21% to 5% O2 (OxyCycler AT 
series, Biospherix Ltd, NY, USA; Figure 8). O2 was purchased as regular gas bottles (Gasin, 
Portugal), while N2 was generated from the air using pressure swing adsorption technology via a 
high output nitrogen generator (Nitrogen 15 Plus, PSA Technology, Sysadvance, Maia, 
Portugal; Figure 8). 
 
 
Figure 8: Typical Oxycycler AT Series System (Biospherix Ltd, NY, USA) setup.  
 
The chambers were infused with 100% N2 for 3.5 min to briefly reduce the O2 concentration to 























of the next CIH cycle. Each CIH cycle lasted 10.5 min and the rats were exposed during their 
sleep period (light period of light/dark cycle) to 5.6 CIH cycles/h, 10.5 h/day, for 60 days. 
During the remaining hours of the day, the chambers were ventilated with a constant flow of 
room air to keep oxygen levels at 21% (Figure 9).  
 
Figure 9: Graphical representation of oxygen levels inside the CIH chambers. Boxes 
represent the periods of chambers infusion with 100% N2 or O2 and correspond to one CIH cycle (10.5 
min). Exposure to CIH occurred 10.5 h/day, for 60 days during rats sleep period. CIH: Chronic 
intermittent hypoxia; Nx: normoxia. 
 
Blood sampling 
Blood was collected to vacutainer tubes containing EDTA (ethylenediaminetetraacetic acid), for 
plasma sampling, kept on ice and immediately centrifuged at 3000 rpm (4 °C) for 10 min. 
Plasma samples were stored at −80 °C until analysed. 
 
High-performance liquid chromatography (HPLC) analysis 
R-(+)-CVD and S-(-)-CVD plasma concentrations were determined by HPLC, using a minor 
modification of the method described by Peccinini and colleagues (Peccinini et al.., 2008). 
Briefly, R-(+)-CVD and S-(-)-CVD were dissolved in methanol yielding stock solutions of 1 
mg/mL. Calibration samples were prepared by adding known amounts of the diluted stock 
solution to rat plasma, and covered a range of 10 - 300 ng/mL. Subsequently, calibration and 
plasma samples (250 μL) were spiked with 12.5 μL of an aqueous solution of 0.1M sodium 
hydroxide and extracted with 3 mL chloroform, for 20 minutes, in a vertical shaker. After 
centrifugation (1800 g, 4 ºC, 4 min), the organic phase was evaporated to dryness at 60 ºC in a 
Speed-Vac concentrator (Labconco, Kansas City, MO, USA). The resulting residue was 
reconstituted in 50 μL of 0.1 M sodium hydroxide, and 50 μL of the chiral reagent MCF, at 1% 
concentration in dichloromethane (v/v), was added. The mixture was shaken in a vortex for 2 





chloroform for 10 min in a vertical shaker. A new centrifugation was performed and the organic 
phase was evaporated to dryness. Finally, the residue obtained was reconstituted in 50 μL of the 
mobile phase and 30 μL was injected into the HPLC. Plasma samples were diluted in the mobile 
phase whenever appropriate. 
HPLC (Schimadzu, Kyoto, Japan) was performed using a solvent delivery pump (model LC 9-
A), autosampler (model 7725i; fluorescence detector: model RF 10AXL), and a column oven 
(model CTO-10AS VP). The stationary phase was a column (250 x 4 mm; particle size: 5 μm; 
LiChrospher 100 RP-18; Merck, New Jersey, USA) protected by a guard-column (4 x 4mm; 
particle size: 5 μm; LiChrospher 100 RP-18e; Merck, New Jersey, USA). The mobile phase 
consisted of a mixture of 0.25N acetate buffer (pH 3, adjusted with acetic acid) and methanol 
(27:73 v/v) at a flow rate of 1mL/min, at 25º C. Both solutions were degassed for 15 min by 
sonication (VWR, Carnaxide, Portugal). The excitation wavelength was 285 nm and the 
emission wavelength 680 nm. Data acquisition and processing were performed using Shimadzu 
Class VP 7.X software. 
 
Voluntary oral administration as an alternative method to gavage 
Drugs and chemicals 
Carvedilol at 10 mg/kg kindly provided by Tecnimede (Sintra, Portugal; manufacturer batch: 
5334-11-015) and losartan at 10 mg/kg, from Cinfa, S.A (generic, Pamplona, Navarra, Spain), 
were mixed with the three vehicles and administered to the animals. Analytical standards of 
carvedilol and losartan, for HPLC analysis, and methylcellulose (MC) were purchased from 
Sigma-Aldrich (Sintra, Portugal).  
 
Experimental design 
Experiments were performed in forty-one male Wistar rats, aged 2-3 months and with mean 
body weight 283 ±5.0 g. 
Three different vehicles were tested for long-term oral administration (14 days) of two 
antihypertensive drugs (carvedilol: non-cardioselective beta blocker; losartan: angiotensin II 
receptor (type AT1) antagonist). Based on their consistency, palatability and previous reports 
(Abelson et al., 2012; Goldkuhl et al., 2010; Jacobsen et al., 2011; Kalliokoski et al., 2011; 
Isaksson et al., 2011; Corbett et al., 2012), nut paste (NUT, Nutella ®, Ferrero Ibérica SA, 
Llobregat, Spain), peanut butter (PB, Skippy ®, Unilever, London, UK) and sugar dough (SD, 
SweetArt ®, Entertraining Lda, Lisboa, Portugal) were used. NUT ingredients include sugar, 
vegetable oil, hazelnuts (13%), skim milk powder (8.7%), fat-reduced cocoa powder (7.4%), 























content is 7.1%; fat content 30.3% and sugars content is 54.7%. PB is composed of roasted 
peanuts, sugar, hydrogenated vegetable oils and salt. The caloric content is 26.10 kJ/g; protein 
content is 22.2%; fat content 49.4% and carbohydrate content is 23.8%. Finally, SD presents as 
ingredients sugar, cornstarch, glucose, vegetable fat, vegetable gums, stabilizer E420, 
preservatives E202, dye E102 and E131. The caloric content is 16.50 kJ/g; protein content is 
3.5%; fat content 6.6% and carbohydrate content is 86.6%. 
Rats were randomized following weaning into six groups of six rats each: group 1 (NUT - 28 
days + NUT with 10 mg/kg/day carvedilol - 14 days); group 2 (PB - 28 days + PB with 10 
mg/kg/day carvedilol - 14 days); group 3 (SD - 28 days + SD with 10 mg/kg/day carvedilol - 14 
days); group 4 (NUT with 10 mg/kg/day losartan - 14 days); group 5 (PB with 10 mg/kg/day 
losartan - 14 days); group 6 (SD with 10 mg/kg/day losartan - 14 days) and two groups of five 
rats each: group 7 (10 mg/kg/day losartan administered by oral gavage - 14 days) and group 8 
(10 mg/kg/day carvedilol administered by oral gavage – 14 days). 
All rats used to test voluntary administration  (groups 1 to 6) underwent a 2-day acclimatization 
period, during which they were fed 0.5 g of the respective vehicle once daily, in order to 
minimize neophobia (Abelson et al., 2012) and avoid incomplete ingestion incidents. Drug or 
vehicles deliveries would be considered incomplete when any trace of vehicle was found in 
either Petri dish, side of the cage or in bedding, after the first hour. 
In the first set of experiments (groups 1, 2 and 3) the vehicles were administered without drug 
for 28 days (in addition to the acclimatization period) in order to determine whether rats would 
voluntarily ingest them for such period of time and also to test the vehicles effect on blood 
glucose level and serum lipid profile. These animals were further used to test voluntary oral 
administration of carvedilol for additional 14 days. The vehicles were weighed, mixed with the 
respective amount of drug and offered to the animals in 92x16 mm polystyrene Petri dishes 
(Sarstedt AG & Co, Germany). The Petri dishes were placed vertically, attached with adhesive 
tape to the inner cage wall (Figure 10).  
The vehicles, alone or mixed with the drug, were daily given to the animals at approximately 
the some schedule (11:00 to 12:00 am). The administration schedule as well as the ingestion 
profile (1- complete; 2- incomplete) and the time between vehicle and vehicle/drug mixture 
delivery and consumption (1- within 5 minutes or less; 2-between 5 minutes and 1 hour; 3- > 1 







Figure 10: Method for voluntary ingestion of carvedilol and losartan with three different 
vehicles: nut paste (A); peanut butter (B) and sugar-dough (C). (1) Carvedilol or losartan powder 
weighted directly over vehicle. (2) Vehicle-drug mixture shaped into a ball ready for delivery. (3) Rats 
ingesting vehicle-drug mixture from the polystyrene Petri dish placed vertically in the cage. 
 
The animals of groups 7 and 8 underwent a 7 days handling acclimatization period. Rats were 
handled daily for a period of 2 minutes each by the same individual and accustomed to the 
gavage position, in a different animal facility procedures room. Handling training and gavage 
were performed at the same schedule (11:00 to 12:00 am) as for voluntary administration.  
Gavage was performed using a stainless steel gavage feeding needle, curved and with round tip 
(gauge 16; tip diameter: 3 mm; length: 75 mm; Fine Science Tools, California, USA). 
Rats were weighed at baseline and once a week during the entire study. The amounts of 
carvedilol and losartan were adjusted weekly to ensure a daily dose of 10 mg/kg. Drugs were 
prepared daily, immediately before administration, when to be given either by gavage or along 
with vehicle. For gavage, Losartan was dissolved in reverse osmosis water (2 mL) and 
carvedilol in MC 0.5% (2 mL). When drugs were administered along with vehicle, the required 
amount of drug for each rat was mixed with 0.5 g of the respective vehicle. In the first set of 
experiments (groups 1, 2 and 3), water intake was measured weekly and blood glucose level and 
serum lipid profile were monitored, 2-3 hours after vehicle administration, at baseline, day 14 
and day 28. 
At the end of the experiments, 2-3 hours after drug delivery, rats were anaesthetised, by 
intraperitoneal injection with medetomidine (0.5mg/kg body weight; Domitor®, Pfizer Animal 
Health) and ketamine (75mg/kg body weight; Imalgene 1000®, Mérial, Lyon, France), and 























were then euthanized with an intracardiac overdose of sodium pentobarbital, and the death was 
confirmed by cervical dislocation. 
 
Blood sampling 
Tail vein sampling: In groups 1, 2 and 3, blood samples were collected from the tail vein of 
conscious animals at baseline, day 14 and day 28. Rats were placed in a conventional plastic 
restrainer (n° 554-BSRR, Plas-Labs, Lansing, Michigan, USA), at a room temperature 24-27ºC.  
A scalpel blade was used to make an incision in the lateral tail vein. Around 100 μL of blood 
was collected from each animal, using a capillary tube (Hirschmann Laborgerate, Eberstadt, 
Germany), to eppendorfs and kept on ice. This procedure was also used for collecting two blood 
drops for glucose quantification. After collection, bleeding was stopped by compression for a 
few seconds and cleaned with iodopovidone. Serum samples were centrifuged in a microfuge at 
3000 rpm (4º C) for 10 minutes, immediately decanted and stored at −80 °C until analysis. 
According to prior recommendations, the restrainer was washed and dried after each use to 
prevent pheromonally induced stress (Parasuraman et al., 2010).  
Cardiac puncture: Blood collection was performed without thoracotomy with a 20 G needle 
with a 10 mL syringe. For plasma sampling, approximately 3 mL of blood was collected to 
vacutainer tubes containing EDTA (ethylenediaminetetraacetic acid), kept on ice and 
immediately centrifuged at 3000 rpm (4 °C) for 10 min. Plasma samples were decanted prior to 
storage at −80 °C until analysis. 
 
Measurement of blood glucose level and serum lipid profile 
Blood glucose level was determined in mg/dl using a digital glucometer (Precision Xceed®, 
Abbott diabetes care Ltd, Oxon, UK). The serum levels of triglyceride (TGL), total cholesterol 
(TC), high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein- cholesterol 
(LDL-C) were determined spectrophotometrically (Rx Daytona analyser, Randox Laboratories 
Ltd, UK), using enzymatic colorimetric assay kits (Randox Laboratories Ltd, UK). The results 
were expressed in mg/dL.  
 
High-performance liquid chromatography (HPLC) analysis  
Since all rats refused to ingest the mixture of carvedilol with the three different vehicles, we 
only set up a method for the quantification of losartan. Losartan plasma concentrations were 
determined by HPLC, using a minor modification of the method described by Yeung et al. 
(Yeung et al., 2000). Briefly, losartan was dissolved in methanol yielding a stock solution of 1 
mg/mL. Calibration samples were prepared by adding known amounts of the diluted stock 





(200 μL) were extracted with 3 mL of ethyl acetate. After centrifugation (3000 rpm, 4 ºC, 10 
min), the organic phase was evaporated to dryness at 60 ºC in a Speed-Vac concentrator 
(Labconco, Kansas City, MO, USA). The resulting residue was reconstituted in 150 μL of 
mobile phase and 100 μL was injected into HPLC. 
HPLC was accomplished by using a solvent delivery pump (model LC 9-A; Schimadzu, Kyoto, 
Japan), autosampler (model 7725i; Schimadzu, Kyoto, Japan, UV-VIS spectrophotometric 
detector (model SPD-6 AV; Schimadzu, Kyoto, Japan.), column (250 x 4 mm; particle size: 5 
μm; LiChrospher 100 RP-18; Merck, New Jersey, USA) protected by a guard-column (4 x 
4mm; particle size: 5 μm; LiChrospher 100 RP-18e; Merck, New Jersey, USA) and a column 
oven (model CTO-10AS VP; Schimadzu, Kyoto, Japan). Data acquisition and processing were 
performed using Shimadzu Class VP 7.X software. The mobile phase consisted of solution A - 
methanol: acetonitrile: sodium dihydrogen phosphate monohydrate buffer (10mM; pH 3; 
50:10:40; v/v/v) and solution B - methanol. All HPLC solvents were purchased from VWR 
International (Carnaxide, Portugal). Prior analysis, both solutions were degassed for 15 min by 
sonication (VWR, Carnaxide, Portugal). The elution program consisted of an isocratic flow of A 
solution for (9.5 min), followed by a linear gradient A:B (20:80 (v/v); 2.5 min), an isocratic step 
A:B (20:80; 4 min) and finally return to initial conditions in 2 min. The analytical run was 




Data are presented as the mean ± standard error of the mean (SEM). Unpaired t-test and 
Kruskal-Wallis test with Dunn´s multiple comparisons test were used, whenever appropriate, to 
evaluate the effect of CIH, CVD or MC 0.5% on the cardiovascular parameters. A comparison 
of CVD S/(R+S) plasma ratios between normoxic and CIH groups was performed using 
unpaired Student t-test. One-way ANOVA with Bonferroni's multiple comparison test and one-
way analysis of variance with Tukey’s multiple comparison tests were used, whenever 
appropriate, to evaluate the vehicles effect on glycaemia and lipid profile. The two-way 
repeated-measures ANOVA with post hoc comparison test was used to compare the vehicle 
effect on mean animal body weights and water intake, along the 28 days of experiments. 
Comparison in losartan plasma concentrations between vehicle groups was performed using 
one-way ANOVA with Dunnett's multiple comparison post hoc tests, using gavage as control. 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., version 






















































































SECTION 1  
Section 1 presents the key results from the clinical studies carried out in the Department of 
Pneumology II, Centro Hospitalar Lisboa Norte (Hospital Pulido Valente), EPE. 
 
The results obtained in this section originated one publication in Blood Pressure Monitoring 
and a manuscript that is currently accepted for publication in Advances in Experimental 
Medicine and Biology. The main findings of these works are listed bellow: 
 
Neck circumference and body mass index as independent predictors of hypertension 
misclassification in patients suspected of having obstructive sleep apnea. 
Diogo LN, Pinto P, Bárbara C, Monteiro EC, Papoila AL. Blood Press Monit. 2015 
Feb;20(1):8-15. doi: 10.1097/MBP.0000000000000080. 
 
1) 43.4% (53/122) of the patients misclassified themselves as non-hypertensive (see Table 
1, page 64). 
2) Patients that misclassified themselves as non-hypertensive presented significantly 
higher values of ABPM variables and anthropometric characteristics, compared to truly 
non-hypertensive patients (see Table 1 and 2, pages 64 and 65). 
3) The cut points that best discriminate these two groups of patients were 27 Kg/m2 and 39 
cm for BMI and NC, respectively (see Figure 3, page 66). 
4) BMI and NC were identified as independent predictors of hypertension 
misclassification in patients suspected of OSA (see Table 3, page 66). 
 
The association between antihypertensive medication and blood pressure control in 
patients with obstructive sleep apnea.  
Diogo LN, Pinto P, Bárbara C, Papoila AL, Monteiro EC. Adv Exp Med Biol (in press). 
 
1) The prevalence of new diagnoses of OSA among those patients that attended the 
outpatient consultation of the CHLN sleep unit was 78.2% (283/362) (see Figure 1, 
page 72). 
2) 63.9% (205/321) of the patients included were diagnosed with both OSA and 
hypertension (see Figure 1, page 72). 
3) One hundred and fifty-five (155/205) patients were under antihypertensive medication 
and 31 different antihypertensive regimens were found (see Table 3, page 76).  
4) 57.5% (95/155) of patients under antihypertensive medication had uncontrolled BP. 
5) BP control is independent of both the antihypertensive regimen and the number of 




6) The lack of association between antihypertensive regimens and the number of 
antihypertensive drugs and BP control remained after CPAP adaptation (see Table 4, 
page 77). 
7) A decrease in median night-time systolic and diastolic BP was observed after CPAP 
adaptation (see Table 5, page 78). However, this decline was not enough to allow 
reclassification from uncontrolled to controlled BP in a substantial number of patients 
under AHDs.  
8) Male gender, moderate/severe and non-dipper patients were independently associated 






















































































THE ASSOCIATION BETWEEN ANTIHYPERTENSIVE MEDICATION AND BLOOD PRESSURE 
CONTROL IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA 
LUCÍLIA N DIOGO1*, PAULA PINTO2, CRISTINA BÁRBARA2, ANA L PAPOILA1, 3 AND EMÍLIA C MONTEIRO1 
1CEDOC, NOVA Medical School / Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, 
Portugal. 2Serviço de Pneumologia II, Centro Hospitalar Lisboa Norte (CHLN)-Hospital Pulido Valente, 1600-190 
Lisboa, Portugal 3 CEAUL, 1749-016 Lisboa, Portugal.  
 
Background: Obstructive sleep apnea and hypertension are closely related diseases. The lowering effect 
of continuous positive airway pressure (CPAP) on blood pressure (BP) control is modest and concomitant 
antihypertensive therapy is still required. However, the best antihypertensive regimen for BP control in 
patients with OSA remains unknown. We aimed to investigate a hypothetical association between 
ongoing antihypertensive medication and blood pressure control (BP) rates in patients with OSA, in order 
to identify the most effective antihypertensive regimen prescribed in current treatment practice. 
Methods: We conducted a prospective observational study in a cohort of 205 patients with OSA and 
hypertension who underwent a sleep study and 24-h ambulatory blood pressure monitoring (ABPM). 
Ongoing antihypertensive medication profile was recorded. Logistic regression models were used to 
investigate the association between antihypertensive regimen and BP control, before (n=205) and, when 
applicable, after continuous positive airway pressure (CPAP) adaptation (n=90). Results: According to 
current guidelines and antihypertensive medication and/or 24h ABPM, 63.9% (205/321) of the patients 
were diagnosed with OSA and hypertension. One hundred and fifty-five (155/205) were under 
antihypertensive medication and 31 different antihypertensive regimens were found. However, the 
antihypertensive regimens and the number of antihypertensive drugs were not associated with BP control 
(p=0.847;p=0.991). After CPAP adaptation, a decrease in median night-time systolic and diastolic BP 
was observed (p=0.001;p=0.006). Nevertheless, the lack of association between antihypertensive 
regimens and the number of antihypertensive drugs and BP control remained (p=0.864;p=0.800). 
Conclusions: Our findings confirm that although CPAP improves nocturnal BP, this improvement is not 
enough to warrant a suitable 24h-BP control. This study shows, for the first time, that BP control is 
independent of both antihypertensive regimen and number of antihypertensive drugs and that none of the 
currently available antihypertensive drugs have been shown to be effective for the control of BP in 
patients with OSA. Trial registration: ClinicalTrials.gov: NCT01803815.  
Keywords: ambulatory blood pressure monitoring; antihypertensive drugs; blood pressure; 
continuous positive airway pressure; hypertension and obstructive sleep apnea.  
*Corresponding author: Lucilia Neves Diogo, PharmD, MSc, Faculdade de Ciências Médicas, 






Obstructive sleep apnea is a highly prevalent 
sleep-related breathing disorder, briefly 
characterized by repetitive episodes of airflow 
cessation (apnea) or airflow reduction 
(hypopnea) in the upper airways during sleep. 
Although OSA has been associated with several 
cardiovascular conditions, it has been more 
etiologically connected to hypertension [1] and 
the link between OSA and hypertension is now 
well established and supported by different 
findings [2, 3]. Epidemiological data have 
shown that the prevalence of hypertension 
among patients with OSA is undoubtedly high 
and estimated to be around 50%. Likewise, it is 
also reported that 30-40% of hypertensive 
patients have OSA [4]. Moreover, OSA is 
renowned as a frequent secondary cause of 
hypertension [5, 6] and one of the major clinical 
conditions that favours poorly controlled 
hypertension [7]. More recently, OSA has been 
identified as an independent risk factor for 
hypertension [8] and as the most common 
condition associated with resistant hypertension 
[9]. However, the underlying mechanisms of 
hypertension-related OSA remain partially 
unclear and the best targets for the control of BP 
in these patients have not yet been established. 
Continuous Positive Airway Pressure (CPAP) is 
considered the gold standard treatment for 
symptomatic OSA patients, due to its 
effectiveness in reducing the apnea-hypopnea 
index (AHI), sleepiness, cardiovascular 
morbidity and mortality and in improving the 
quality of life [10]. The effectiveness of CPAP 
on blood pressure (BP) control is still 
controversial [4, 8, 11-16] and CPAP seems to 
be insufficient to sustain BP control by itself; 
therefore, the use of antihypertensive drugs 
(AHD) is unavoidable. In fact, the findings from 
a recent study revealed that, in non-sleepy, 
hypertensive, OSA patients, the long-term use 
of CPAP is not associated with lower BP values 
or a need for less AHD for BP control [17].  
In spite of this, data on antihypertensive drug 
regimens in patients with OSA are scarce and 
specific therapeutic guidelines for the 
pharmacological treatment of hypertension in 
these patients remain absent. Moreover, the 
effects of antihypertensive agents on OSA 
patients are not consistent [18] and there are 
limited data on whether a specific AHD 
regimen has any positive effect on the control of 
OSA [19]. Thus, more studies are requested in 
order to identify first-line AHD regimens for 
optimal BP control in this particular group of 
hypertensive patients [19, 20].  
The main goal of this prospective cohort study 
was to investigate a hypothetical association 
between ongoing antihypertensive (AH) 
regimens and BP control rates in patients with 
OSA, before and after CPAP adaptation. We 
were also interested in identifying other 
variables that could provide information about 
BP control after CPAP adaptation. Additionally, 
we intended to investigate the phenotypic 
characteristics and, specifically, the patterns of 





Three hundred and sixty-nine consecutive 
patients clinically suspected of having OSA, 
aged above 18 years, who were attending their 
first visit at the Centro Hospitalar Lisboa Norte, 
EPE (CHLN) Sleep Unit, following referral by 















were assessed for eligibility. Patient inclusion 
started in April 2010 and was completed in July 
2012. Exclusion criteria included severe 
psychiatric disease or an inability to understand 
the information required for informed consent, 
apnea-hypopnea index <5 events/hour and no 
diagnosis of hypertension. In order to fully 
accomplish the goal of the study, additional 
inclusion criteria were subsequently defined. 
Only patients with a CPAP mean daily use of at 
least 4 hours and ambulatory 24-h ABPM 
recordings, performed at baseline and 1-3 
months after checking CPAP adherence, were 
considered eligible for the study of the 
association between antihypertensive regimens 
and BP control after CPAP adaptation (Figure 
1).  
All patients were fully informed about the study 
and gave written consent in accordance with the 
Declaration of Helsinki. The study protocol was 
previously approved by Centro Hospitalar 
Lisboa Norte’s Ethics Committee. 
 
Study Design  
At baseline (first visit) all patients were invited 
to undergo an overnight polysomnography, 24-h 
ambulatory blood pressure monitoring (ABPM) 
and completed a data collection form that 
included ongoing medication profile 
registration.  
Once the diagnosis of OSA and hypertension 
was established, the criteria for treatment with 
CPAP confirmed and baseline ABPM measured 
(second visit), patients were scheduled for 
CPAP titration.  
Four to five weeks after CPAP adaptation (third 
visit), the device data were checked and patients 
with a CPAP mean daily use of at least 4 hours 
were scheduled for repeated 24-h ABPM. At 
this time, particular attention was paid to ensure 
that patients had not changed their 
antihypertensive medication since the first 
evaluation. If any changes in either type of 
medication or dose had occurred, the patient 
was excluded from the study. 
The main outcome variables were blood 
pressure (BP) control rates (controlled and 
uncontrolled) in patients undergoing 
antihypertensive medication. 
  
Data collection form and clinical 
assessment 
Socio-demographic and anthropometric data, as 
well as smoking habits, comorbidities and 
ongoing medication profiles, were registered.  
All patients were assessed for weight, height, 
neck circumference (NC) and waist 
circumference (WC) using standardised 
protocols. Body mass index (BMI) was 
calculated as body weight in kilograms divided 
by the square of height in metres: kg/m
2
. NC 
was measured at the level of the cricothyroid 
membrane, with the patients’ head positioned in 
the Frankfort horizontal plane and WC was 
assessed at the level of umbilicus; both were 
recorded using a flexible non-stretchable 
measuring tape. 
Regarding smoking habits, patients were 
classified as non-smoker, ex-smoker, and 
smoker (defined as those who smoke at least 
one cigarette per day over the previous year).  
Comorbidities, with special focus on 
hypertension, were assessed. Hypertension was 
defined as self-reported hypertension (answer 
“yes” to the question “Have you ever been told 
by a doctor that you have high blood 
pressure?”) or the use of antihypertensive 
medication. Information about diabetes mellitus, 
dyslipidaemia, arrhythmias, asthma, chronic 




depression and anxiety, history of 
cardiovascular disease and hypothyroidism was 
also collected.  
The ongoing medication profile (drug name 
(International Non-proprietary Name: INN) and 
dose) was recorded using the “Brown-Bag” 
medication review (a method in which patients 
are asked to bring all of their medications to 
each visit) [21]. We analysed the use of 
antihypertensive drugs by regimen: 1-with 
angiotensin-converting enzyme inhibitors 
(ACEi); 2-with angiotensin II receptor blockers 
(ARAs); 3-with β-blockers; and 4-others 
(including diuretics and calcium channel 
blockers), and the number of antihypertensive 
drugs (1-one, monotherapy; 2-two or more, 
polytherapy) included in each patient regimen. 
In all patients, antihypertensive drugs were 
taken for at least six months without changing 







Figure 1: Flowchart of study protocol.  
Of the 369 patients consecutively included, 68 were patients with no diagnosis of OSA and 48 with no diagnosis of 
hypertension. The ABPM and/or sleep recordings were missing for 48 patients due to technical problems or because 
they did not attend the ABPM (n=41) or sleep study (n=7). Forty had no indication for CPAP therapy. One hundred and 
sixty-five were scheduled for CPAP adaptation; however, 7 refused CPAP, CPAP data were missing in 6 patients and 
51 had no compliance. Of the 369, only the data from 90 patients were used to investigate the association between 
ongoing AH regimen and blood pressure control rates after CPAP adaptation. AHI: Apnea-Hypopnea Index; ABPM: 

















Patients underwent an overnight in-laboratory 
polysomnography (PSG) or, as an alternative 
for the diagnosis of OSA in patients with a high 
pre-test probability of moderate to severe OSA, 
a cardiorespiratory sleep study [22]. In-
laboratory polysomnographic studies were 
performed using a multichannel polygraph 
(Model Embla S7000, Embla Systems Inc., 
Broomfield, CO, USA) and ambulatory 
recordings were made using a validated portable 
digital recording unit (type 3) with sensors for 
the registration of airflow, saturation, 
respiratory movements of the chest, body 
position and snoring sounds (Embletta PDS 
device; Embla Systems Inc., Broomfield, CO, 
USA). Sleep recordings were manually scored, 
based on standard criteria [22], by trained 
technicians. Apnea was defined as a complete 
upper airway obstruction (reduction in airflow 
>80%) for at least 10s and hypopnea as a 
discernible reduction of airflow between 70% 
and 20% of the preceding period of stable 
breathing, for 10s or more. The number of 
apneas and hypopneas per hour of sleep was 
calculated and, for both in-laboratory and 
ambulatory recordings, the apnea-hypopnea 
index (AHI) was calculated. Respiratory effort 
related arousals (RERAs), scored in laboratory 
polysomnography sleep staging, were not 
considered in order to minimise the differences 
in results provided by the two diagnostic 
approaches. OSA was categorised according to 
current AHI cut-offs of <5 (non-diagnostic), 5 ≥ 
and < 15 (mild), 15 ≥ and < 30 (moderate) and 
≥ 30 (severe) [22, 23]. 
 
Twenty-four-hour ambulatory blood 
pressure monitoring (ABPM) 
Twenty-four hour ABPM was performed at 
baseline, on a different day to that of the sleep 
evaluation, and 1-3 months after CPAP 
adaptation. All participants were instructed to 
continue their usual daily activities. Screening 
BP measurements were performed in 
accordance with the recommendations of the 
European Society of Hypertension (ESH) 
guidelines [5], using appropriately-sized arm 
cuff, on the non- dominant arm, with a non-
invasive portable validated BP recorder 
(Spacelabs Model 90217; Spacelabs Healthcare, 
Redmond, WA, USA). The equipment was 
programmed for cuff inflation every 20 minutes 
during the daytime period and every 30 minutes 
during the night-time. Daytime and night-time 
were individually predetermined depending on 
the participants’ usual awake and sleep 
schedule. The data were considered valid when 
a minimum of 70% of the measurements were 
recorded without errors. BP recordings were 
analysed for the overall 24-hour period, daytime 
and night-time periods. Additionally, 24 h BP 
profile was assessed and patients were classified 
as showing a dipping or a non-dipping profile. 
A dipping profile was defined as a reduction in 
the average systolic and diastolic BP at night 
that was higher than 10% compared to daytime 
values. The data were analysed by an 
experienced cardio-respiratory technician. 
Uncontrolled BP was defined according to ESC 
and ESH guidelines [6]. BP was considered 
uncontrolled for systolic BP (SBP) values of 
135 mm Hg or above, diastolic BP (DBP) 
values of 85 mm Hg or above, or both during 
daytime and systolic BP (SBP) values of 120 
mm Hg or above, diastolic BP (DBP) values of 
70 mm Hg or above, or both during night time 
[6]. Isolated nocturnal hypertension was 




thresholds for ABPM, as night-time SBP values 
of 120 mm Hg or DBP of 70 mm Hg or above, 
and isolated daytime hypertension as diurnal 
SBP of 135 mm Hg or DBP of 85 mm Hg or 
above. When both conditions were present, 
subjects were classified as having combined 
day-night hypertension [6]. 
 
Continuous Positive Airway Pressure 
(CPAP) therapy 
CPAP titration was performed using self-
adjusting CPAP devices (autoCPAP) (REMstar 
PR1 Auto, S8 AutoSet Spirit- Resmed Ltd), 
AutoSet Spirit S9 - Resmed Ltd). During the 
initial setup of the machine, the minimum 
(Pmin: 4 cm H2O) and maximum (Pmax: 16 cm 
H2O) pressures were set. All patients were 
followed-up 4-5 weeks after CPAP adaptation, 
in order to check for any side effects or 
problems with the treatment and, if required, for 
CPAP pressure adjustment. CPAP adherence 
was assessed from the device counter. Data 
were analysed by experienced technicians using 
appropriate software.  
 
Statistical Analysis 
An exploratory analysis was carried out for all 
variables. Categorical data were expressed as 
frequencies and percentages, and continuous 
variables as mean or median, standard deviation 
(SD) or inter-quartile range (25th percentile-
75th percentile). Welch’s t-test was used as an 
adaptation of Student’s t-test whenever unequal 
variances were obtained. Wilcoxon test and 
Sign test were used to compare ABPM data 
measured at baseline and after CPAP 
adaptation. The McNemar test was applied to 
compare the proportion of uncontrolled patients 
before and after CPAP adaptation. 
In order to identify baseline predictors of BP 
control after CPAP adaptation, a univariable 
analysis was performed. The outcome variable 
was "uncontrolled BP" (yes: for patients with 
uncontrolled BP and no: for patients with 
controlled BP) and the multiple logistic 
regression model was subsequently fitted to the 
data. The predictive ability of the resulting 
model was analysed by the Hosmer-Lemeshow 
goodness-of-fit test [24]. A high p-value 
indicates that the model is performing well. The 
area under the Receiver Operating 
Characteristic curve (AUC) was used in order to 
evaluate the discriminative ability of the model. 
A value of 0.50 is obtained when a model 
discriminates no better than chance, and a value 
of 1.0 means perfect accuracy.  
Results were considered significant when 
α=0.05. Confidence intervals are presented 
when appropriate (95% CI). Statistical analysis 
was performed using the IBM SPSS Statistics 
(IBM Corp., Released 2012. IBM SPSS 
Statistics for Windows, Version 21.0. Armonk, 
NY: IBM Corp.). 
 
RESULTS 
Patients Characteristics and ABPM data 
Patients (n=369) were mainly male (65.9%), 
Caucasian (95.7%), with a mean age of 55.9 
(SD=13.1) years. From all of the enrolled 
patients, 321 presented complete ABPM and 
sleep data (n=48 missing data). According to 
current guidelines and to antihypertensive 
medication and/or 24h ABPM, 63.9% (205/321) 
of them were diagnosed with OSA and 
hypertension (Figure 1).  
In these patients, median apnea-hypopnea index 
was 20.0/h (P25=10.2/h, P75=32.6/h) and 















30.2% (62/205) and 30.7% (63/205) presented 
mild, moderate and severe OSA, respectively.  
Table 1 shows key patient characteristics 
summarized according to BP control (controlled 
n=60/205, 29.3% and uncontrolled n=145/205, 
70.7%). No differences were found between 
these two groups regarding anthropometric 
variables and smoking habits. The most 
prevalent self-reported comorbidities for 
hypertensive OSA patients were: dyslipidaemia 
(63.4%), depression/anxiety (23.9%), diabetes 
(22.0%) and hyperuricaemia (10.7%). 
ABPM data, attained at baseline, are described 
in Table 2. From the 145 uncontrolled patients, 
20 (13.8%) presented isolated diurnal 
hypertension, 52 (35.9%) isolated nocturnal 
hypertension and 73 (50.3%) both diurnal and 
nocturnal hypertension. 
 
Table 1: Hypertensive OSA patient characteristics at baseline 
Variable 
All patients 





Age, years 59.0 (11.6)  62.2 (10.4) 57.7 (11.8) 0.012 
Ψ
 
Gender, male (%) 149 (72.7) 40.0 (66.7) 109 (75.2) 0.214 
&
 
Race, Caucasian (%) 196 (95.6) 60 (100.0) 136 (93.8) 0.061 * 
BMI, kg/m
2
 31.0 (5.0) 31.5 (6.2) 30.8 (4.5) 0.420 
#
 
Neck circumference, cm 42.2 (3.8) 42.1 (4.1) 42.2 (3.8) 0.822 
Ψ
 
Waist circumference, cm 109.6 (12.1) 110.1 (13.5) 109.4 (11.5) 0.727 
Ψ
 
Smoking habits    0.305 
&
 
 Non-smokers (%) 111 (54.1) 31 (51.7) 80 (55.2)  
 Former smokers (%) 76 (37.1) 26 (43.3) 50 (34.5)  
 Current smokers (%) 18 (8.8) 3 (5.0) 15 (10.3)  
Number of comorbidities >2 
(%)ϕ 





 159 (77.6) 59 (98.3) 100 (69.0) <0.001
&
 
Data are presented as mean (SD: standard deviation), median (interquartile range: P25, P75) or number (%). 





Welch’s t test 
& 
Chi-squared test * Fisher’s exact test; OSA: obstructive sleep apnea; BMI: body mass index; AH: antihypertensive drugs; AHI: apnea-
hypopnea index. 
 








24-h ABPM (mmHg):     
 Mean 24-h BP 94.0 (86.0, 98.0) 83.0 (80.0, 85.8) 96.0 (93.0, 101.0) <0.001
Ψ
 
 Daytime systolic BP  129.0 (121.0, 139.0) 119.5 (111.3, 124.0) 135.0 (127.5, 144.0) <0.001
Ψ
 
 Daytime diastolic BP  79.0 (72.0, 85.0) 71.5 (67.0, 75.0) 83.0 (78.0, 88.0) <0.001
Ψ
 
 Night-time systolic BP  118.0 (107.5, 128.0) 105.5 (97.3, 109.0) 124.0 (115.5, 131.5) <0.001
Ψ
 
 Night-time diastolic BP 69.0 (62.0, 75.0) 61.0 (57.0, 64.0) 72.0 (67.0, 77.0) <0.001
Ψ
 
24h-BP profile:      
 Non-dipper systolic (%) 108 (52.7) 21 (35.0) 87 (60.0) 0.001 
&
 
 Non-dipper diastolic (%) 79 (38.5) 12 (20.0) 67 (46.2) <0.001
&
 
Data are presented as median (interquartile range: P25, P75) or number (%). 
Ψ
 Mann-Whitney test  
& 
Chi-squared test ; OSA: obstructive sleep apnea; ABPM: 





Patterns of antihypertensive drugs use 
Of the 205 hypertensive OSA patients, 155 were 
under antihypertensive medication. The 
antihypertensive medication profile found in 
controlled and uncontrolled groups, respectively, 
was: 19 (31.7%) and 30 (20.7%) patients under 
monotherapy and 41 (68.3%) and 65 (44.8%) 
patients under regimens that included two or 
more antihypertensive drugs. 
Thirty-one different antihypertensive regimens 
were found for hypertensive OSA patients (Table 
3). 
 
Table 3: Antihypertensive regimens in patients with OSA  
Antihypertensive Regimen 
Hypertensive OSA patients  
n=155 
Combination of ARBs + diuretics 28 (18.1) 
Monotherapy with ACEi 21 (13.5) 
Monotherapy with ARBs 14 (9.0) 
Combination of ACEi + diuretics 10 (6.5) 
Combination of CCB + diuretics + ARBs 8 (5.2) 
Combination of ARBs + CCB 8 (5.2) 
Monotherapy with CCB 7 (4.5) 
Combination of BB + diuretics + ARBs 6 (3.9) 
Monotherapy with BB 5 (3.2) 
Combination of BB + ACEi 4 (2.6) 
Combination of CCB + ACEi 4 (2.6) 
Combination of CCB + diuretics + ACEi 4 (2.6) 
Monotherapy with diuretic 3 (1.9) 
Combination of BB + diuretics  3 (1.9) 
Combination of BB + diuretics + ACEi 3 (1.9) 
Combination of BB + diuretics + ARBs + ACEi 3 (1.9) 
Combination of CCB + BB 3 (1.9) 
Combination of CCB + BB + diuretics + ACEi 3 (1.9) 
Combination of ARBs + diuretics + ACEi 2 (1.3) 
Combination of CCB + diuretics + ARBs + ACEi 2 (1.3) 
Combination of CCB + diuretics + ACEi 2 (1.3) 
Combination of CCB + BB + ARBs  2 (1.3) 
Combination of CCB + diuretics + BB 2 (1.3) 
Combination of BB + ARBs 1 (0.6) 
Combination of two BB 1 (0.6) 
Combination of CCB + diuretics 1 (0.6) 
Combination of CCB + two diuretics + ACEi 1 (0.6) 
Combination of CCB + diuretics + ARBs + BB 1 (0.6) 
Combination of CCB + two diuretics + ACEi + BB 1 (0.6) 
Combination of two CCB + ACEi + BB 1 (0.6) 
Data are presented as number (%). OSA: obstructive sleep apnea; AH: antihypertensive drugs; ACEi: angiotensin-converting enzyme inhibitors; ARBs: 
angiotensin II receptor blockers; BB: beta-blockers; CCB: calcium channel blockers 
 
Association between AH regimens and BP 
control 
In this section, we performed a univariable 
analysis in order to investigate whether there is 
an AH regimen associated with a better BP 
control. No association was found between the 
number of antihypertensive drugs and the 
antihypertensive regimens and BP control 
(p=0.991 and p=0.847, respectively) (Table 4).  
Besides AH regimens and number of AHD, the 
analysed variables were age (p=0.012), gender 
(p=0.214), BMI (p=0.420), neck circumference 
(p=0.822), waist circumference (p=0.727), 
smoking habits (p=0.305), number of 
comorbidities (p=0.082) and OSA severity 















were selected for the multivariable analysis. 
However, none of these variables remained in the 
multivariable model. 
Aware of the importance assigned by the 
clinicians to OSA severity and obesity in the 
management of OSA patients, analysis of the 
association between the number of AHD and BP 
control was additionally performed in severe 
OSA patients with a BMI ≥30 kg/m
2
 and in 
mild/moderate OSA patients with a BMI <30 
kg/m
2
. In the subgroup of severe OSA patients 
with BMI ≥30 kg/m
2
 (n=28), we found no 
statistical differences in BP control between 
patients undergoing polytherapy and 
monotherapy (p= 0.689): 44.4% (8/18) of 
patients under polytherapy and 30.0% (3/10) 
under monotherapy, respectively, presented 
controlled BP. In the subgroup of mild/moderate 
OSA patients with a BMI <30 kg/m
2
 (n=51), 
there is an indication that the number of patients 
with controlled BP is higher (p=0.064) in those 
under monotherapy (69.2% (9/13)) than in those 
under polytherapy (39.5%(15/38)).  
Table 4: Association between anti-hypertensive regimens/ number of anti-hypertensive drugs and 
BP Control at baseline and after CPAP adaptation 










Number of AH   0.991
&
   0.800
&
 
  One 19/49 (38.8) 30/49 (61.2)  9/22 (40.9) 13/22 (59.1)  
  Two or more 41/106 (38.7) 65/106 (61.3)  24/52 (46.2) 28/52 (53.8)  
AH regimens   0.847
&
   0.864* 
  With ACEi 16/39 (41.0) 23/39 (59.0)  8/21 (38.1) 13/21 (61.9)  
  With ARBs 24/58 (41.4) 34/58 (58.6)  11/25 (44.0) 14/25 (56.0)  
  With BB 5/13 (38.5) 8/13 (61.5)  1/2 (50.0) 1/2 (50.0)  
  Others 15/45 (33.3) 30/45 (66.7)  13/26 (50.0) 13/26 (50.0)  
Data are presented as number (%). 
& 
Chi-squared test * Fisher’s exact test  
CPAP: continuous positive airway pressure; AH: antihypertensive drugs; ACEi: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor 
blockers; BB: beta-blockers 
 
Effect of combined CPAP use and 
antihypertensive medication on BP 
control 
From the 369 patients that were initially 
included, only 90 fulfilled the inclusion criteria 
and were eligible to investigate the association 
between ongoing AH regimen and hypertension 
control rates after CPAP adaptation. Regarding 
ABPM data measured at baseline and after 
CPAP adaptation (Table 5), no significant 
differences were found between daytime systolic 
and diastolic BP (p=0.156 and p=0.132, 
respectively). 
As expected, a decrease in median night-time 
systolic (median=4.5 mmHg) and diastolic BP 
(median=3.5 mmHg) was observed (p=0.001 and 
p=0.006) after CPAP adaptation. Nevertheless, 
this decline was not enough to allow 
reclassification from uncontrolled to controlled 
BP in a substantial number of patients under 
AHD (p=0.332). In fact, of the 46/74 (62.2%) 
uncontrolled patients at baseline, only 11/74 




adaptation. For patients under no AHD 
(n=16/90), an improvement in BP control was 
observed in 8 patients (p=0.008). 
After CPAP, the lack of association between 
antihypertensive regimens and the number of 
antihypertensive drugs and BP control remained 
(p=0.864 and p=0.800) (Table 4).
Table 5: ABPM data at baseline and after CPAP adaptation of patients with OSA, hypertension and 
CPAP mean daily use ≥ 4 hours (n=90) 
Variable Baseline After CPAP adaptation p
 Ψ
 
 Daytime systolic BP  128.5 (121.5, 138.0) 127.5 (119.0, 135.0) 0.156
#
 
 Daytime diastolic BP  79.0 (70.8, 84.0) 76.5 (71.0, 83.0) 0.132
Ψ
 
 Night-time systolic BP  118.5 (107.0, 129.0) 114.0 (106.8, 123.5) 0.001
#
 
 Night-time diastolic BP 69.0 (61.0, 74.0) 65.5 (60.0, 72.0) 0.006
Ψ
 
Data are presented as median (interquartile range: P25, P75) 
Ψ
 Wilcoxon test 
#
 Sign Test   CPAP: continuous positive airway pressure; ABPM: ambulatory blood 
pressure monitoring; BP: blood pressure. 
 
Baseline predictors of uncontrolled BP 
after CPAP adaptation 
Since no association was found between AHD 
regimens and BP control in OSA patients, we 
looked for baseline variables that could predict 
BP control after CPAP adaptation. A 
multivariable model was fitted considering the 
outcome “uncontrolled BP” after a previous 
univariable study. For the final model, OSA 
severity and BP dipper/non-dipper profile and 
gender were considered. Regarding OSA 
severity, the odds ratio was calculated after the 
aggregation of moderate and severe categories. 
Mild severity, dipper profile and female gender 
were considered the reference categories. The 
results showed that at baseline, male gender, 
moderate/severe and non-dipper patients were 
independently associated with uncontrolled BP 
after CPAP adaptation (OR: 2.5, 95% CI: 0.9-
7.2, p=0.087; OR: 3.8, 95% CI: 1.2-12.4, 
p=0.028; OR: 3.5, 95% CI: 1.4-8.9, p=0.007) 
(Table 6). The model demonstrated a good 
predictive (Hosmer-Lemeshow p-value=0.776) 
and acceptable discriminative (AUC=0.74; 95% 
CI: 0.64-0.85) performance. 
 
Table 6: Multivariable analysis in which gender, OSA severity and 24-h BP profile at baseline were 
identified as independent predictors of BP control after CPAP adaptation (n=90) 
 
OR 
95% C.I. for OR 
p-value 
 Lower Upper 
OSA severity 
Reference category= mild 
3.8 1.2 12.4 0.028 
24h BP profile 
Reference category= dipper 
3.5 1.4 8.9 0.007 
Gender 
Reference category= female 
2.5 0.9 7.2 0.087 

















The prevalence of new diagnoses of OSA 
among those patients that attended the 
outpatient consultation of CHLN sleep unit was 
78.2% (283/362). According to current 
guidelines and to antihypertensive medication 
and/or 24h ABPM, 63.9% (205/321) of them 
were diagnosed with both OSA and 
hypertension. At baseline, 31 different 
antihypertensive regimens were found for OSA 
patients. Regarding BP control, 57.5% of 
patients under antihypertensive medication had 
uncontrolled BP (95/155). The antihypertensive 
regimens and the number of antihypertensive 
drugs were not associated with BP control. 
After CPAP adaptation, the lack of association 
between antihypertensive regimens and the 
number of antihypertensive drugs and BP 
control remained, but we found that CPAP 
significantly improved BP control in patients 
under no AH medication. In a multivariable 
study, gender, OSA severity and 24h-BP profile 
were independently associated with 
uncontrolled BP after CPAP adaptation. 
Therefore, it can be stated that the risk of being 
uncontrolled is higher for males with 
moderate/severe OSA and a non-dipper BP 
profile, confirming the relevance of OSA in the 
pathophysiology of hypertension. In summary, 
these results provided evidence that this type of 
hypertension needs to be managed as a specific 
entity and that none of the currently available 
AH regimens have been shown to be 
particularly effective to control BP in patients 
with OSA.  
We performed a real life study and, to the best 
of our knowledge, this is the first that has 
described the pattern of AH medication and 
evaluated the hypothetical association between 
ongoing antihypertensive regimen and BP 
control rates in patients with OSA.  
In general, our sample matches a typical 
population of OSA patients. Actually, the high 
prevalence of new diagnoses of OSA, indicating 
that patients are being well-referred, as well as 
the distribution of OSA severity found in CHLN 
sleep consultation, is similar to those reported 
by other authors [25, 26]. The anthropometric 
baseline characteristics that were found are in 
line with those that have been previously 
described in the literature [27]. Additionally, 
these patients tend to present a higher number of 
comorbidities, mostly a high prevalence of 
hypertension, when compared to non-OSA 
patients [8, 25, 28]. The prevalence of 
hypertension among patients with OSA is 
estimated to be around 50% [4]. Our study 
revealed a higher prevalence of hypertension in 
OSA patients, probably due to the use of ABPM 
for the diagnosis of this disease. In addition to 
the high prevalence of hypertension, ABPM 
data revealed that, regarding 24h-BP profile, 
OSA patients showed a non-dipper systolic 
profile, which has already been reported [29-
31]. The high prevalence of uncontrolled BP 
(70.7%; 145/205) and underdiagnosed 
hypertension (24.4%; 50/205) among these 
patients has also been similarly reported [2, 32, 
33]. In a past study that included 59 patients 
who were not known to be hypertensive, 
hypertension was found in 42% of patients 
using clinical measurement and 76% using 
ABPM [34]. 
As far as we know, this is the first study to 
describe the pattern of AH medication in OSA 
patients. The high number of different AH 
regimens found (n=31) is symptomatic of the 
difficulty controlling BP in these patients, and 




matter, and also underlines the importance of 
the main question addressed in the present 
work. The number of patients with regimens 
that included two or more AH drugs (n=106) is 
impressive, and emphasises the difficulty in 
achieving BP control and the close relationship 
between OSA and resistant hypertension [35-
38].  
Despite the large number of studies involving 
OSA patients, only a few have investigated the 
efficacy of different AHD and, in general, are 
individual drug studies. Most of them have 
focused on evaluating the lowering-BP effect of 
AHD and did not assess whether this decrease 
leads to an augmentation of the number of 
controlled hypertensive patients. Moreover, the 
validity of some of these results is limited due to 
the very low casuistry of the samples. 
Nevertheless, their findings allow some 
conclusions. First, drugs that block the 
sympathetic stimulation of β1-adrenergic 
receptors seem to be the most effective AHD, 
since the β1-specific antagonist atenolol was the 
most effective AHD tested (in comparison with 
isradipine, hydrochlorothiazide, spirapril, 
amlodipine, enalapril and losartan) in two 
comparative studies [39, 40], and nebivolol [41] 
was also effective in patients with OSA. On the 
other hand, the angiotensin-converting enzyme 
inhibitors (e.g. cilazapril and enalapril) lowered 
BP effectively [42], but not as significantly as 
beta-blockers [40, 43]. The angiotensin II 
receptor blocker valsartan had a similar anti-
hypertensive effect to nebivolol [41]. 
Spironolactone (competitive aldosterone 
antagonist) has been remarkably effective in 
treating resistant hypertension [44]; however, its 
effectiveness has not been evaluated in patients 
with OSA to date. Moreover, since only severe 
OSA has been associated with increased 
angiotensin II and aldosterone (moderate OSA 
was usually associated with normal levels of 
these agonists), rennin-angotensin–aldosterone 
(RAA) blockers had a modest anti-hypertensive 
effect in mild/moderate OSA [45]. Finally, 
thiazide diuretics have not been very effective in 
OSA patients without fluid retention [40]. Also, 
important data are missing, e.g. how many OSA 
patients are controlled under monotherapy with 
beta-blockers (BB), angiotensin-converting 
enzyme inhibitors (ACEi) and angiotensin II 
receptor blockers (ARB’s)? How many OSA 
patients remained uncontrolled despite the use 
of two or more AH drugs? What should be the 
second drug added to BB or RAA blockers? 
How do individual AHD behave when included 
in an AH regimen? In addition, the impact of 
these studies in clinical practice is unknown, as 
epidemiological studies designed to investigate 
the AH medication profile in OSA patients are 
missing. In addition, the more recent 
recommendations for the management of 
patients with OSA and hypertension are 
inconclusive regarding the use of AHD and 
recognise the lack of strong evidence for the 
establishment of a first-line AH regimen for 
these patients [20]. Other authors sustain the 
idea that since there is no clear evidence for 
preference for a specific class of AHD, the 
selection should primarily be guided by the 
patient’s cardiometabolic profile and associated 
comorbidities (e.g. obesity, metabolic 
syndrome, diabetes mellitus and cardiovascular 
diseases) [19]. Moreover, these authors 
recommend that, due to the lack of relevant 
trials focused on the use of associations of AHD 
in OSA patients, the choice should rely on 
current hypertension guidelines and the adverse 
effects of AHD need to be contemplated as well 















clinicians based their therapeutic decisions on 
these assumptions. 
Surprisingly, in our population, the most 
commonly prescribed AHD were diuretics and 
RAA blockers. However, the number of OSA 
patients using these AHD with uncontrolled BP 
was significantly high. In fact, 61.2% (30/49) 
and 61.3% (65/106) of patients under a 
monotherapy and polytherapy regimens, 
respectively, were uncontrolled. This evidence 
suggests that the increase in the number of 
antihypertensive drugs is not apparently relevant 
in OSA patients. If the low efficacy of 
polytherapy in controlling BP is linked to OSA 
severity, the difference between the efficacy of 
monotherapy and polytherapy in severe patients 
would be higher in the subgroup of severe 
patients with BMI ≥30 kg/m
2
, which was not the 
case.  
On the other hand, before CPAP adaptation, no 
associations were found between AH regimens 
and number of AHD and BP control. These 
findings suggest that none of the current AHD, 
either alone or in association, have been shown 
to be effective enough to control BP. 
Additionally, the number of AHD included in a 
specific regimen seems not to be relevant to the 
control of BP in patients with OSA.  
In the study performed after CPAP adaptation, 
we decided to include only patients who were 
adherent with CPAP therapy for at least 4 hours 
per night on average, as this is a threshold that is 
often used to define minimum acceptable CPAP 
use. According to the suggestion of a past study, 
patients in these conditions of CPAP use had an 
appreciable decrease in the incidence of 
hypertension [16]. Additionally, the beneficial 
effect of nasal CPAP therapy on BP seems to be 
closely associated with the presence of 
untreated or resistant hypertension, with OSA 
severity (more pronounced in severe OSA) and 
with patient compliance to CPAP [2]. 
Therefore, it would be expected that the 
combined effect of CPAP and AHD on BP 
control was more pronounced than the isolated 
effect of AHD. However, the lack of association 
between AH regimens and BP control remained 
after CPAP adaptation, which suggests the 
slight effect of CPAP in controlling BP. These 
findings are consistent with the results of 
several past studies [4, 11-13]. Börgel et al. [33] 
revealed that the absence of antihypertensive 
drugs is an independent predictor for the 
lowering effect of CPAP therapy on systolic and 
diastolic BP. Furthermore, Dernaika et al. 
reported that the effects of CPAP therapy on BP 
regulation appear to be less evident in 
hypertensive patients under a drug regimen [46]. 
In our patient population, eight of the sixteen 
patients who were not on AH medication, after 
CPAP adaptation there BP became controlled. 
Both results suggest that an earlier diagnosis of 
hypertension related to OSA is more important 
than the AH regimen selection. 
Moreover, the effect of CPAP on lowering BP 
was clearly more significant in nocturnal BP, 
mainly in nocturnal SBP. Anyway, however 
important, this effect was not enough to reach 
the intended purpose for these patients, since it 
did not allow the reclassification from 
uncontrolled to controlled BP. In fact, despite 
some authors [47] having reported the beneficial 
effect of CPAP in preventing the bursts of 
sympathetic activity present at the end of each 
respiratory event, in our case, the hypothetical 
reduction in sympathetic activity was not 
associated with an appreciable decrease in 
diurnal BP. Consequently, in patients with 
OSA, more important than studying the effect of 




combined effect of CPAP and AH medication. 
The study performed by Dernaika et al. [46] 
evaluated the long-term effects of CPAP 
therapy on BP in patients with OSA and 
resistant hypertension. The results revealed that 
CPAP permitted the de-escalation of 
antihypertensive treatment in 71% of patients 
with resistant hypertension, but did not 
significantly alter the antihypertensive regimen 
in the controlled group. However, in our 
opinion, the study of Dernaika et al. [46] 
presents two main drawbacks. First, the study 
did not characterize the different AH 
associations (it only referred to the number of 
patients that were undergoing a specific AHD 
class) and second, it did not evaluate the 
efficacy of each class on BP control. The same 
limitations were found in the study of Börgel et 
al. [33], which was performed to evaluate the 
interaction between BP-lowering effects of 
CPAP and AHD. Additionally, Pépin et al. [48] 
designed a study to assess the respective 
efficacy of CPAP and valsartan (ARBs) in 
reducing BP hypertensive patients with OSA 
that had never been treated for either condition 
and speculated that the combined effect of both 
therapies on BP control might be additive in 
patients in whom hypertension is still 
uncontrolled by specific AH drugs. However, 
they did not quantify the combined effect of 
CPAP and valsartan. They found that valsartan 
induced a four-fold higher decrease in mean 24h 
BP than CPAP [48]. Thus, the results of our 
pilot study revealed, for the first time, that none 
of the current AH regimens are superior to the 
others, either alone or when combined with 
CPAP, in promoting BP control, and underlines 
that new AHD drugs for this particular 
population are definitely needed.  
Finally, gender, OSA severity and 24 h BP 
profile at baseline were identified as 
independent predictors of BP control after 
CPAP adaptation. Our results show that male 
patients with an AHI higher than 15 events/hour 
of sleep and patients with a non-dipper profile 
had a three-fold increased odds of presenting 
uncontrolled BP after CPAP adaption. Although 
Robinson et al. [49] did not identify OSA 
severity as a predictor of the fall in 24h mean 
BP with CPAP treatment, the impact of this 
decrease in BP control remains unknown. In a 
more recent small study, male gender, Epworth 
sleepiness scale, BMI, smoking, alcohol use and 
baseline 24h mean BP were identified as 
independent predictors of a decrease in 24h 
mean BP after CPAP adaptation [50]. The 
apparent controversy of whether or not OSA 
severity is a predictor of the beneficial effect of 
CPAP in lowering BP could be explained by the 
differences in the outcome variable analysed. In 
our perspective, uncontrolled BP (present study) 
is a stronger and more relevant clinical outcome 
than the decrease in 24h-mean BP values.  
 
Limitations 
We are conscious about some limitations of our 
study. First, our sample should ideally be larger 
and provided from more than a single centre, in 
order to avoid referral bias. However, our centre 
could be considered representative of the 
general OSA population because we found 
similar characteristics to those described in the 
literature. The huge variability in AHD regimen 
found in the present work together with the 
sample size, does not allow us to identify the 
best AHD regimen for these patients. 
Additionally, the results of this exploratory 
study strongly suggest that none of the available 















control in OSA patients. Therefore, the impact 
of a much larger epidemiological study could be 
also limited and, in our opinion, the search for 
new therapeutic strategies will be more useful. 
Additionally, despite the use of a “Brown-Bag” 
medication review in order to record patients 
ongoing medication profile, data regarding 
adherence to AH drug treatment (before and 
after inclusion) were checked only based on 
self-reported adherence and were not confirmed 
by a “pill-count” method or other. However, this 
variable does not invalidate the study, since it is 
common to all patients. Since the differences 
between efficacies within each class are not well 
documented, the evaluation of each drug per se 
was not considered relevant. Therefore, the 
analysis was conducted taking into account the 
regimens of AH drugs with higher prevalence. 
Nevertheless, the added value of the present 
study is the evaluation of the efficacy of AH 
regimens commonly used in these patients 
instead of analysing the effect of a specific 
AHD. Despite these drawbacks, our results 
provide new insights into the need for 
innovative AHD to treat OSA patients. 
 
CONCLUSIONS 
In conclusion, the findings of the present 
work suggest, for the first time, that none of 
the currently available antihypertensive 
drugs, either alone or in association, have 
been shown to be effective enough to control 
BP in these patients, either before or after 
CPAP. BP control is independent of both the 
antihypertensive regimen and the number of 
antihypertensive drugs and the increase in the 
number of AHD does not appear to be relevant 
to control BP in patients with OSA. Our results 
also confirm that although CPAP improves 24h-
BP profile, it is not enough to warrant a suitable 
BP control in patients with OSA. Moreover, the 
finding that there is a significant improvement 
in BP control in patients under no AHD, after 
CPAP adaptation, suggest that an earlier 
diagnosis of hypertension related to OSA is 
more relevant than the AH regimen selection, 
probably because the available AH regimens are 
useful to prevent but not able to completely 
revert hypertension. Finally, male, 
moderate/severe and non-dipper patients, at 
baseline, had three-fold increased odds of being 
uncontrolled after CPAP adaptation. 
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SECTION 2  
 
Section 2 presents the key results from the experimental studies carried out at Nova Medical 
School (animal facility labs) and Chronic Diseases Research Center (CEDOC). 
Please note that although the second study has been designed to test the viability of oral 
voluntary administration, for long-term delivery of both carvedilol and losartan, the animals 
systematically refused to ingest the mixture of carvedilol with the three different vehicles. For 
that reason, we decided to submit for publication only the results of losartan. Moreover, 
carvedilol had to be delivered by gavage in the first study since carvedilol voluntary oral 
administration systematically failed. Data regarding carvedilol voluntary oral administration 
will be discussed later in the Discussion Chapter.  
 
The results obtained in this section originated two manuscripts that are currently in submission 
and accepted for publication in JAALAS, respectively. The main findings of these works are 
listed bellow: 
 
Efficacy of carvedilol in reversing hypertension induced by chronic intermittent hypoxia 
in rats. 
Diogo LN, Pereira SA, Faustino I, Nunes AR, Afonso RA, Santos AI, Monteiro EC (in 
submission). 
 
1) CIH significantly increased MAP, diastolic and systolic BP in our animal model. No 
effect was observed for HR (see Figure 3, page 97). 
2) No reduction in mean arterial pressure was observed with the doses of 10, 30 and 50 
mg/Kg of CVD (see Figure 5, page 99). 
3) All doses of CVD promoted a significant decrease in HR (see Figure 6, page 100). 
4) The ratios S/(R+S) of CVD enantiomers between rats exposed to CIH and normoxic 
conditions were different (see Figure 8, page 101). 
5) Animals exposed to CIH and treated with 50 mg/kg/day of CVD presented higher R-
(+)-CVD and S-(-)-CVD plasma concentrations than normoxic animals treated with the 
same dose, although this difference did not reach statistical significance. 
 
Losartan voluntary oral administration – a less stressful approach in rats  





1) Blood glucose levels were reduced by NUT administration and PB induces increased 
levels of triglycerides and total cholesterol (see Figures 2, 3 and 4, pages 118, 119 and 
120).  
2) SD group presented a higher concentration of losartan when compared with gavage 
group, without changing lipid and glucose profiles (see Figure 5, page 121).  
3) The three vehicles are viable for daily single dose voluntary ingestion of losartan, from 
which SD proved to be the best alternative.  
4) SD is better suited than gavage for losartan oral daily administration.  
5) Voluntary ingestion proved to be an effective method for a controlled daily dose 




















EFFICACY OF CARVEDILOL IN REVERSING HYPERTENSION INDUCED BY CHRONIC 
INTERMITTENT HYPOXIA IN RATS  
 
Lucília N Diogoa*, Sofia A Pereiraa, Ana R Nunesa, Inês V Faustinoa, Ricardo A Afonsoa,b, 
Ana I Santosb and Emília C Monteiroa 
aCentro de Estudos de Doenças Crónicas, CEDOC, NOVA Medical School / Faculdade de Ciências Médicas, 
Universidade Nova de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal b Department of 
Physiology, NOVA Medical School / Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo dos 
Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. 
 
Background and Aim: Animal models of chronic intermittent hypoxia (CIH) mimic the HT observed in 
patients with OSA. Antihypertensive drugs were used in these models to address the physiological 
mechanism but not to revert established hypertension. We aimed to investigate the efficacy of carvedilol, 
a nonselective beta-blocker with intrinsic anti- α1-adrenergic activity and antioxidant properties in a rat 
model of CIH-induced hypertension. The variability of carvedilol enantiomers in plasma concentrations 
was also evaluated. Methods: Male Wistar rats with indwelling blood pressure telemeters were exposed 
during their sleep period to 5.6 CIH cycles/h, 10.5 h/day, for 60 days. Carvedilol administration, by 
gavage, began on Day 36 of the CIH period and lasted 25 days. Animals specifically used for 
pharmacokinetic studies were exposed for 60 days to normal air (21% O2 and 79% N2), in the same room 
as the CIH animals. R-(+)-CVD and S-(-)-CVD plasma concentrations were determined by HPLC. 
Statistical analysis was performed using GraphPad Prism and statistical significance for all tests was set 
at the level of p<0.05. Results: CIH significantly increased diastolic and systolic blood pressure (p<0.05, 
for all variables) by 25.7 and 21.6 mmHg respectively, while no effect was observed for HR in our animal 
model. Despite the doses of 10, 30 and 50 mg/Kg of CVD promoted a significant reduction in HR 
(p<0.05, for all doses), no decrease in arterial pressure was observed. The S/(R+S) ratio of CVD 
enantiomers was lower (p<0.05) in rats exposed to CIH than in animals under normoxic conditions. 
Conclusions: Together our results suggest that the blockade of the sympathetic nervous system together 
with the putative pleiotropic effects of carvedilol was not able to revert hypertension induced by CIH.  
Despite finding that CIH induced pharmacokinetic changes in the R/(R+S) ratio, they are not apparently 
responsible for the lack of efficacy of carvedilol in reversing this particular type of hypertension.  
Key words: antihypertensive drugs, beta-blockers, carvedilol, chronic intermittent hypoxia, telemetry.  
*Corresponding author: Lucilia Neves Diogo, PharmD, MSc, NOVA Medical School / Faculdade de 






Chronic intermittent hypoxia (CIH) is a feature 
that is present in sleep-disordered breathing, 
namely in obstructive sleep apnea (OSA). 
Although OSA has been associated with 
numerous cardiovascular conditions, it has been 
more etiologically connected to systemic 
hypertension (Kapa et al., 2008). The 
mechanisms involved in the pathogenesis of HT 
can be summarised in relation to two main 
pathways: sympathetic nervous system 
stimulation mediated mainly by activation of 
carotid body chemoreflexes and/or asphyxia, 
and the systemic effects of CIH (for a review 
see Diogo and Monteiro, 2014).  
The effects of antihypertensive agents on OSA 
patients are not consistent and it is imperative to 
identify preferred compounds for adequate BP 
control in this group of patients (Parati et al., 
2013). Studies aimed at investigating the 
antihypertensive effect of antihypertensive 
drugs (AHDs) in animal models of CIH are 
scarce, however, and were not designed to 
respond to pharmacological issues (Allahdadi et 
al., 2008; Belaidi et al., 2009; da Silva et al., 
2011; Del Rio et al., 2010; Fenik et al., 2012; 
Fletcher et al., 1999; Hung et al, 2013; Kanagy 
et al., 2001; Knight et al., 2013; Kumar et al., 
2006; Moya et al., 2014; Soukhova O’Hare et 
al., 2008; Troncoso Brindeiro et al., 2007). 
AHDs have been used solely as 
pharmacological tools to address physiological 
mechanisms and to prevent HT (Diogo and 
Monteiro, 2014). Although individual drug 
studies, performed in humans, find that the 
blockade of β1- adrenergic receptors (e.g. 
atenolol, carvedilol, nebivolol and metoprolol) 
might be helpful (Heitmann et al., 2010; Kario 
et al., 2014; Kraiczi et al., 2000; Mayer et al., 
1990; Pelttari et al., 1998) in reversing HTA 
related to OSA, to the best of our knowledge, no 
experimental study has yet been designed to 
evaluate the long-term effects of carvedilol 
(CVD) or other beta-adrenergic blocking 
agents.  
CVD is a non-selective beta-blocker with 
intrinsic anti-α 1-adrenergic activity and with 
recognised antioxidant properties. The broad 
range of its adrenergic inhibition seems to offer 
advantages over other beta-adrenergic blocking 
agents (DiNicolantonio and Hackam, 2012). 
This antihypertensive drug is administered 
orally as a racemic mixture of two enantiomers 
and its beta-blocking activity is the result of the 
S- enantiomer, while its alpha-blocking activity 
is the result of both R- and S-enantiomers 
(Peccinini et al., 2008).  
We aimed to investigate, in a rat model of CIH- 
induced hypertension, the efficacy of carvedilol 
in reducing both BP parameters and heart rate. 
Secondly, we sought to explore the effects of 
CIH on the pharmacokinetics profile of 
carvedilol, in order to test the hypothesis that IH 
changes carvedilol pharmacokinetics, 
compromising or enhancing their efficacy. 
Together these experiments might contribute to 
attaining more specific information concerning 
carvedilol use in HT related to OSA. 
 
MATERIAL AND METHODS 
Drugs and chemicals 
CVD was kindly provided by Tecnimede 
(Sintra, Portugal; manufacturer batch: 5334-11-
015) and MC was purchased from Sigma-
Aldrich (Sintra, Portugal). R-(+)-CVD and S-(-
)-CVD were obtained from Santa Cruz 















The enantiomerically pure chiral agent, (-)-
menthyl chloroformate (MCF) was obtained 
from Sigma-Aldrich (Sintra, Portugal). HPLC 
grade solvents used in the extraction procedure 
and for the mobile phase of the 
chromatographic system were obtained from 
VWR (Lisbon, Portugal). 
 
Animals  
Experiments were performed in thirty-one male 
Wistar rats (Ratus norvegicus), aged 60-75 
days, with mean body weight 308.4 45.36 g, 
obtained from the NOVA Medical School 
animal facility. Animals were housed 
individually in polycarbonate cages with wire 
lids (Tecniplast, Buguggiate, Varese, Italy), 
under 12 h light/dark cycles (8 am - 8 pm), at a 
room temperature 22 ± 2.0 °C and relative 
humidity 60± 10%. Rats were maintained on a 
standard laboratory diet (SDS diets RM1) and 
reverse osmosis water, given ad libitum. 
Corncob bedding (Probiológica, Lisbon, 
Portugal) was used and changed once a week. 
Animals were Specific Pathogen Free (SPF) 
according to FELASA recommendations 
(Nicklas et al., 2002).  
A growth curve for body weight gain in the first 
180 days was obtained with daily weights from 
three hundred and fifty seven male Wistar rats 
born in the NOVA Medical School animal 
facility. Animals from the colony were 
randomly weighed, inside the animal rooms, for 
a period of one year until a sample of 25 (91 to 
180 days) or 50 (1-90 days) weights per day 
was achieved. The experimental groups in the 
present report were not part of the colony 
growth chart. 
The applicable institutional and governmental 
regulations concerning ethical use of animals 
were followed, according to the NIH Principles 
of Laboratory Animal Care (NIH Publication 
85-23, revised 1985), the European guidelines 
for the protection of animals used for scientific 
purposes (European Union Directive 
2010/63/EU) and Portuguese Law nº 113/2013. 
Experimental procedures were previously 
approved by the Institutional Ethics Committee 
of the NOVA Medical School for animal care 




Three different doses were administered to 
investigate the long-term effects (25 days) of 
CVD in an experimental model of hypertension 
related to CIH. Rats were randomly assigned 
and divided into five groups: Group I (CVD 10 
mg/kg/day - CIH; n=5); Group 2 (CVD 30 
mg/kg/day - CIH; n=7); Group 3 (CVD 50 
mg/kg/day - CIH; n=8); Group 4 (control group 
administered vehicle (0.5% methylcellulose 
(MC)); n=5); Group 5 (CVD 50 mg/Kg/day – 
Nx; n=6). MC 0.5% (2 mL) was used to 
facilitate the dissolution and absorption of 
CVD, since it is a very lipid soluble drug, 
(Rodriguez-Perez et al., 1997). 
Animals from Groups 1, 2, 3 and 4 were gentled 
for 10 minutes daily for one week prior surgery, 
to minimise the discomfort related to 
experimental manipulation and reduce data 
variability, and were instrumented with 
indwelling blood pressure telemeters. Rats were 
allowed to recover for 10 days, after transmitter 
implantation surgery, before any measurements 
were recorded. A period of 5/6 days was then 
given for chamber acclimatization under 
normoxic conditions (21 O2% + 79% N2) and 




Animals were then exposed to 60 days of CIH, 
during their sleep period, and CVD or vehicle 
administration, by gavage, started at day 36 and 
lasted 25 days. Animals from Group 5 
(normoxic rats) were exposed for 60 days to 
normal air (21% O2 and 79% N2), in the same 
room as the CIH animals in order to experience 
similar conditions. Similarly, CVD 
administration by gavage started at Day 36 and 
lasted 25 days for the other groups. Since these 
rats were specifically used for pharmacokinetic 
studies, the implantation of telemetry 
transmitters was not performed. 
At the end of the experiments, 2-3 hours after 
drug or vehicle delivery, the rats were 
anaesthetised, by intraperitoneal injection with 
medetomidine (0.5mg/kg body weight; 
Domitor®, Pfizer Animal Health, Auckland, 
New Zealand) and ketamine (75mg/kg body 
weight; Imalgene 1000®, Mérial, Lyon, 
France), and cardiac puncture was performed 
without thoracotomy, with a 20 G needle with a 
10 mL syringe, to collect blood for further 
quantifications. The animals were then 
euthanized with an intracardiac overdose of 
sodium pentobarbital (Eutasil®, Ceva Animal 
Health, Libourne, France), and the death was 
confirmed by cervical dislocation. 
Rats were weighed at baseline and once a week 
during the entire study. The amount of 
carvedilol was adjusted weekly to ensure the 
doses of 10, 30 and 50 mg/Kg/day (p.o). CVD 
was weighed daily, immediately before 
administration, dissolved in the vehicle and 
labelled individually for each rat. CVD 
dissolved in 0.5% MC (2 mL) or vehicle alone 
was given daily to the animals on approximately 
the same schedule (9:00 to 9:30 am), always 
after BP measurement and before exposure to 
CIH conditions. Control animals received 
equivalent daily oral gavage volumes (2 mL). 
All rats underwent a 7 day handling 
acclimatization period and were handled daily 
for a period of 2 minutes each by the same 
individual and accustomed to the gavage 
position, in a different animal room. Gavage 
was performed using a sterile polypropylene 
feeding tube (gauge 15; tip diameter: 3 mm; 
length: 78 mm; Instech Laboratories, Inc., USA) 
in order to reduce the risk of trauma, perforation 
and cross contamination (Morton et al., 2001). 
 
Surgical instrumentation 
Animals were instrumented under 
medetomidine (0.5 mg/kg body weight (i.p.); 
Domitor®, Pfizer Animal Health) and ketamine 
(75 mg/kg body weight (i.p.); Imalgene 1000®, 
Mérial, Lyon, France) anaesthesia with 
indwelling blood pressure telemeters (model 
TA11PA-C40, Data Sciences Corporation, St. 
Paul, MN), allowing daily recording of mean 
arterial BP, systolic and diastolic BP and heart 
rate (HR). The animals were provided with 
preoperative analgesia, using the opioid 
analgesic drug butorfanol (1mg/Kg/mL (s.c.); 
Dolorex®, Intervet International GmbH, 
Unterschleissheim, Germany), in order to 
ensure pain relief during and after surgery. The 
animal’s body temperature was maintained 
throughout the experimental procedure using a 
heating pad. To minimise corneal desiccation, 
the eyes were lubricated with sterile saline. In 
preparation for abdominal incision, this area 
was shaved with a clipper, scrubbed with a 
povidone-iodine solution (Betadine®, 
Mundipharma AG, Basel, Switzerland) and 
70% isopropyl alcohol, and covered with a 















the microsurgical instruments was ensured by 
autoclaving and maintained at all times with the 
use of a hot bead sterilizer (Fine Science Tools 
GmbH, Heidelberg, Germany).  
The radiotelemetry transmitter was implanted 
aseptically into the abdominal aorta, exposed 
via a ventral midline incision in the abdominal 
cavity. The aorta was occluded using bulldog 
type clamps (Fine Science Tools GmbH, 
Heidelberg, Germany) placed immediately after 
renal artery bifurcation and immediately before 
femoral artery bifurcation. A bent needle (20G, 
B.Braun Medical, Melsugen, Germany) was 
used as a catheter introducer and the pressure 
tip of the telemeter was guided beneath the 
needle and introduced into the aorta. The 
puncture site and the surrounding tissue were 
dried and a small drop of tissue adhesive 
(Vetbound, 3M Company, St Paul, MN, USA) 
was applied to seal the insertion point. The 
vessel clamps were carefully removed and, if 
there was no bleeding, the intestines were 
replaced in their original position and the 
abdominal cavity was flushed with warmed 
sterile saline to avoid tissue adhesion. The body 
of the transmitter was then placed on top of the 
intestines and secured to the abdominal muscle 
by closing the abdominal incision and 
incorporating the suture rib on the device into 
the closure, using non-absorbable sutures 
(Surgisilk 4/0, Sutures Ltd, Wrexham Wales 
UK) in a simple interrupted pattern. Finally, the 
skin incision was closed using non-absorbable 
sutures (Surgisilk 4/0, Sutures Ltd UK).  
Thirty minutes surgery, the anaesthesia was 
reversed with atipamezole (0.25 mg/Kg/2mL 
(i.p); Antisedan®, Orion Pharma, Espoo, 
Finland). All animals were individually housed, 
with environmental enrichment, to protect the 
wound sites and minimise stress. A heating pad 
on a low setting was provided to allow the 
animals to self-regulate temperature in the first 
hours after surgery. Postsurgical recovery was 
monitored by daily visual examination (return 
of normal postures and behaviours) and daily 
food and water intake. Rats were treated 
postoperatively for 2-3 days with the 
nonsteroidal anti-inflammatory drug carprofen 
(5 mg/Kg/1mL (s.c), Rimadyl®, Vericore 
Limited, Dundee, UK). 
 
Chronic intermittent hypoxia (CIH) 
exposure 
Animals were kept in a eucapnic atmosphere, 
inside medium A-chambers (76 x 51 x 51 cm, 
A-60274-P, Biospherix Ltd, NY, USA) with ad 
libitum food and water access. The chambers 
were equipped with gas injectors and sensors 
for oxygen (O2) and carbon dioxide levels 
(CO2) in order to ensure the accuracy of CIH 
cycles. Accumulation of CO2 was prevented by 
the continuous flow of the gas mixtures, the 
circulation of the gases inside de chambers 
through vent holes and by the presence in the 
chamber of self-indicating soda lime (AnalaR 
Normapur®, VWR International BVBA, 
Leuven, Belgium), which absorbs the expired 
CO2. The CO2 levels inside the chambers never 
exceeded 1%. A silica gel (Chameleon® C 2-6 
mm, VWR International BVBA, Leuven, 
Belgium) container was also placed inside the 
chambers in order to absorb water. Oxygen 
concentration inside the chambers was 
controlled using 100% nitrogen (N2) and 100% 
O2 via electronically regulated solenoid 
switches in a three-channel gas mixer, which 
gradually lowered the oxygen in the chamber 




Biospherix Ltd, NY, USA). The chambers were 
infused with 100% N2 for 3.5 min to briefly 
reduce the O2 concentration to 5%, and then 
with 100% O2 for 7 min to restore oxygen to 
ambient levels of 21%, until the start of the next 
CIH cycle. Each CIH cycle lasted 10.5 min and 
the rats were exposed during their sleep period 
to 5.6 CIH cycles/h, 10.5 h/day, for 60 days. 
During the remaining hours of the day, the 
chambers were ventilated with a constant flow 
of room air to keep oxygen levels at 21%. O2 
was purchased as regular gas bottles (Gasin, 
Portugal), while N2 was generated from the air 
using pressure swing adsorption technology via 
a high output nitrogen generator (Nitrogen 15 
Plus, PSA Technology, Sysadvance, Maia, 
Portugal).  
 
Collection of radiotelemetry data 
Output from the telemetry transmitters was 
recorded via radio frequency signals obtained 
through the Data Acquisition System from Data 
Sciences International (DSI, St. Paul, Minn.). 
BP and HR measurements, obtained during 10 
seconds sampling periods, were averaged and 
recorded for 15 minutes daily. Baseline 
recordings of BP and HR were performed for 
5/6 days prior to CIH exposure. 
 
Blood sampling  
For plasma sampling, blood was collected to 
vacutainer tubes containing EDTA 
(ethylenediaminetetraacetic acid), kept on ice 
and immediately centrifuged at 3000 rpm (4 °C) 
for 10 min. Plasma samples were stored at −80 
°C until analysed. 
 
High-performance liquid chromatography 
(HPLC) analysis  
R-(+)-CVD and S-(-)-CVD plasma 
concentrations were determined by HPLC, 
using a minor modification of the method 
described by Peccinini and colleagues 
(Peccinini et al., 2008). Briefly, R-(+)-CVD and 
S-(-)-CVD were dissolved in methanol yielding 
stock solutions of 1 mg/mL. Calibration 
samples were prepared by adding known 
amounts of the diluted stock solution to rat 
plasma and covered a range of 10 - 300 ng/mL. 
Subsequently, calibration and plasma samples 
(250 μL) were spiked with 12.5 μL of an 
aqueous solution of 0.1M sodium hydroxide 
and extracted with 3 mL chloroform, for 20 
minutes, in a vertical shaker. After 
centrifugation (1800 g, 4 ºC, 4 min), the organic 
phase was evaporated to dryness at 60 ºC in a 
Speed-Vac concentrator (Labconco, Kansas 
City, MO, USA). The resulting residue was 
reconstituted in 50 μL of 0.1 M sodium 
hydroxide and 50 μL of the chiral reagent MCF, 
at 1% concentration in dichloromethane (v/v), 
was added. The mixture was shaken in a vortex 
for 2 min. After adding 250 μL of water, 
carvedilol diastereoisomers were extracted with 
3 mL chloroform for 10 min in a vertical 
shaker. A new centrifugation was performed 
and the organic phase was evaporated to 
dryness. Finally, the residue obtained was 
reconstituted in 50 μL of the mobile phase and 
30 μL was injected into the HPLC. Plasma 
samples were diluted in the mobile phase 
whenever appropriate. 
HPLC (Schimadzu, Kyoto, Japan) was 
accomplished by using a solvent delivery pump 
(model LC 9-A), autosampler (model 7725i; 















column oven (model CTO-10AS VP). The 
stationary phase was a column (250 x 4 mm; 
particle size: 5 μm; LiChrospher 100 RP-18; 
Merck, New Jersey, USA) protected by a guard-
column (4 x 4mm; particle size: 5 μm; 
LiChrospher 100 RP-18e; Merck, New Jersey, 
USA). The mobile phase consisted of a mixture 
of 0.25N acetate buffer (pH 3, adjusted with 
acetic acid) and methanol (27:73 v/v) at a flow 
rate of 1mL/min, at 25º C. Both solutions were 
degassed for 15 min by sonication (VWR, 
Carnaxide, Portugal). The excitation 
wavelength was 285 nm and the emission 
wavelength 680 nm. Data acquisition and 
processing were performed using Shimadzu 
Class VP 7.X software. 
 
Statistics 
Data are presented as mean ± standard error of 
the mean (SEM). Unpaired t-test and Kruskal-
Wallis test with Dunn´s multiple comparisons 
test were used, whenever appropriate, to 
evaluate the effect of CIH, CVD or MC 0.5% 
on the cardiovascular parameters. A comparison 
of CVD S/(R+S) plasma ratios between 
normoxic and CIH groups was performed using 
unpaired Student t-test. Statistical analysis was 
performed using GraphPad Prism (GraphPad 
Software Inc., version 5.01, San Diego, CA). 
Statistical significance for all tests was set at the 
level of p<0.05. 
 
RESULTS 
Effect of CIH on body weight 
To study the effect of CIH on body weight we 
started by characterising the NOVA Medical 
School colony growth curve for body weight 
gain. Male Wistar rats (n=357) were weighed 
daily, on a calibrated scale, and plotted as 
shown in Figure 1. From Day 1 to Day 90 each 
average point was obtained with 50 weights, 
and from Day 91 to Day 180 with 25 weights. 
This growth curve allowed the comparison 
between rats exposed to CIH and age-matched 
male Wistar rats obtained from the NOVA 
Medical School animal facility.  
The mean body weight of the animals at 
baseline (60-75 day-old animals; n=20) was 
325±9.9 g, which fits the expected body weight 
for animals of this age (338±7.6 g) in this 
population (Figure 1; line A; p=0.4072).  Rats 
exposed to 35 days of CIH (95-110 day-old 
animals; n=20) weighed (351±9.1 g) 
significantly less (p<0.0001) compared with 
age-matched healthy male Wistar rats (424±1.8 
g) from the NOVA Medical School animal 
facility (Figure 1; line B). This growth 
retardation was also observed at the end of the 
25-day period of both CIH exposure and CVD 
administration (120-135 day-old animals; n=20; 
358±9.4 g; Figure 1; line C), since the mean 
value of the colony was 452±3.4 g at the same 











Figure 1: Effect of CIH on body weight in comparison with the growth curve for body weight gain of male Wistar rats 
(n=357) born in the NOVA Medical School animal facility. Filled lines indicate the mean body weight of the experimental 
animals: (A) at baseline (60-75 day-old animals; n=20); (B) exposed to 35 days of CIH (95-110 day-old animals; n=20) 
and (C) administered with CVD for 25 days and submitted to 60 days of CIH (n=20). Data are expressed as 
mean±SEM. **** p<0.0001 Unpaired t-test. CIH: chronic intermittent hypoxia; CVD: carvedilol. 
 
Effect of CIH on blood pressure and 
heart rate 
Blood pressure and heart rate were measured in 
the 6 days before  (normoxic period) and 
throughout the 35 days of CIH exposure. Figure 
2 shows raw BP and HR data obtained daily 
during the experimental protocol. 
Since at the onset of CIH the BP values were 
not yet stabilised and hypertension induced by 
CIH was essentially observed after the second 
week of exposure (Figure 2A), we decided to 
exclude the data attained during the first seven 
days of CIH exposure from the statistical 
analysis, for both BP and HR.  
Animals exposed to 35 days of CIH exhibited 
significantly higher mean arterial blood pressure 
(Nx: 100.9±2.195 mmHg vs. CIH: 126.1±4.231 
mmHg; p<0.001), diastolic BP (87.4±2.37 
mmHg vs. CIH: 113.1±4.913 mmHg; p<0.001) 
and systolic BP (115.7±2.523 mmHg vs. CIH: 
137.3±2.216 mmHg; p<0.0001) relative to their 
own baseline values (normoxic period) (Figure 
3A, B and C). No changes in mean HR were 
observed during CIH exposure (Figure 3D; Nx: 


















Figure 2: Grouped data showing the daily average recordings of (A) MAP, systolic BP, diastolic BP; and (B) heart rate 
of rats submitted to CIH for 35 days (n=20). BP: blood pressure; bpm: beats per minute; CIH: chronic intermittent 
hypoxia; HR: heart rate; MAP: mean arterial blood pressure; Nx: normoxia. 
 
 
Figure 3: Effect of CIH on (A) mean arterial blood pressure; (B) systolic blood pressure; (C) diastolic blood pressure 
and (D) heart rate, in male Wistar rats (n=20). Data are expressed as mean±SEM. *** p<0.001 and **** p<0.0001 
Unpaired t-test. BP: blood pressure; bpm: beats per minute; CIH: chronic intermittent hypoxia; MAP: mean arterial 
blood pressure; Nx: normoxia. 
 
Effect of CVD on blood pressure and 
heart rate 
 
Figure 4 summarises the mean arterial blood 




with MC 0.5% (control-vehicle group), obtained 
daily during the experimental protocol (n=5). In 
this group, no differences were found in mean 
arterial blood pressure (117.9±0.721 mmHg vs. 
119±0.54 mmHg), systolic BP (132±0.894 
mmHg vs. 133.6±0.585 mmHg), diastolic BP  
 
(104±0.456 mmHg vs. 105.5±0.576 mmHg) and 
HR (379.9±5.208 bpm vs. 370.1±4.343 bpm) 
between the 35 days of CIH exposure and 25 




Figure 4: Grouped data showing the daily average recordings of  (A) MAP; and (B) heart rate of rats administered 
with MC 0.5% for 25 days and submitted to 60 days of CIH (control-vehicle group; n=5). CIH: chronic intermittent 
hypoxia; MAP: mean arterial blood pressure; MC: methylcellulose; Nx: normoxia. 
 
We tested three different doses of CVD (10, 
30 and 50 mg/kg) and no decrease in mean 
arterial pressure was observed (Figure 5). 
Curiously, daily administration of CVD 30 
mg/kg produced a slight increase in mean 
arterial pressure (Figure 5; 121.4±0.852 
mmHg (CIH) vs. 125.4±0.841 mmHg 
(CIH+CVD 30); p<0.05), diastolic 
(104.5±0.762 mmHg (CIH) vs. 108.8±0.623 
mmHg (CIH+CVD 30); p<0.001) and 
systolic BP 140.2±0.684 mmHg (CIH) vs. 
144.7±0.735 mmHg (CIH+CVD 30); 
p<0.001). No significant changes in 
diastolic (121.0±1.928 mmHg (CIH) vs. 
122.6±1.371 mmHg (CIH+CVD 50)) or 
systolic BP 157.0±1.404 mmHg (CIH) vs. 
154.7±2.369 mmHg (CIH+CVD 50)) were 
observed for the dose of 50 mg/Kg. The 
dose of 10 mg/Kg evoked a slight increase 
in diastolic BP (119.2±0.9161 mmHg (CIH) 
vs. 129.3±1.679 mmHg (CIH+CVD 10); 
p<0.001) while no effect was observed for 
systolic BP 146.2±0.901 mmHg (CIH) vs. 

















Figure 5: Effect of CVD (A) 10 mg/kg (n=5); (B) 30 mg/kg (n=7) and (C) 50 mg/kg (n=8) daily administration (25 days) 
on mean arterial blood pressure of rats submitted to 60 days of CIH. Data are expressed as mean±SEM. * p<0.05, ** 
p<0.01 and *** p<0.001 Kruskal-Wallis test with Dunn´s multiple comparisons test. CIH: chronic intermittent hypoxia; 
CVD: carvedilol; MAP: mean arterial blood pressure; Nx: normoxia. 
 
In contrast, all doses of CVD promoted a 
significant decrease in mean HR (403.8±4.808 
bpm (CIH) vs. 353.3±4.950 bpm (CIH+CVD 
10), p<0.0001; 384.4±4.501 bpm (CIH) vs. 
346.1±3.729 bpm (CIH+CVD 30), p<0.0001; 
400.2±3.461 bpm (CIH) vs. 339.4±7.601 bpm 
(CIH+CVD 50), p<0.0001) compared with 
values obtained during the 35 days of CIH 
exposure, consistent with its beta-blocking 






Figure 6: Effect of CVD (A) 10 mg/kg (n=5); (B) 30 mg/kg (n=7) and (C) 50 mg/kg (n=8) daily administration (25 days) 
on heart rate of rats submitted to 60 days of CIH. Data are expressed as mean±SEM. * p<0.05 and **** p<0.0001 
Kruskal-wallis test with Dunn´s multiple comparisons test. Bpm: beats per minute; CIH: chronic intermittent hypoxia; 
CVD: carvedilol; Nx: normoxia. 
 
R-(+)-carvedilol and S-(-)-carvedilol 
plasma concentrations 
R-(+)-CVD and S-(-)-CVD plasma 
concentrations were determined in Groups 3 
and 5. The chromatograms of R-(+)-CVD and 
S-(-)-CVD in rat plasma samples are presented 
in Figure 7.  
In both groups, the level of R-(+)-CVD was 
higher than S-(-)-CVD. Animals exposed to 
CIH for 60 days and treated with 50 mg/kg/da-y 
of CVD (Group 3) presented higher R-(+)-CVD 
(941.9 284.4 ng/mL) and S-(-)-CVD 
(436.0 85.01 ng/mL) plasma concentrations 
than normoxic animals (531.6 54.52 ng/mL and 
358.6 44.11 ng/mL, respectively), although this 
difference did not reach statistical significance.  
The ratios S/(R+S) of CVD enantiomers 
between rats exposed to CIH (0.3214 0.0216) 
and normoxic conditions (0.3883 0.0144) were 
different (Figure 8; p<0.05), however, the levels 
of R-(+)-CVD + S-(-)-CVD obtained in CIH 
exposed rats (1378.0±328.9) were not 
statistically different from the ones measured in 



















Figure 7: The HPLC chromatograms resulting from derivatization with MCF of (A) blank rat plasma; (B) calibration 
sample – rat plasma spiked with 100 ng/mL of R-(+)-CVD and S-(-)-CVD; (C) plasma sample of a rat exposed to 
chronic intermittent hypoxia treated with 50 mg/Kg/day of racemic CVD and (D) plasma sample of a normoxic rat 
treated with 50 mg/Kg/day of the racemic CVD. 
 
Figure 8: Ratio S(-)-carvedilol / (R(+)-carvedilol + S(-)-carvedilol) in rats exposed to normoxia (Nx n=6) and chronic 
intermittent hypoxia (CIH; n=8) treated with 50 mg/Kg/day of racemic carvedilol (CVD). Data are expressed as 
mean±SEM. Unpaired student t-test * p<0.05. Nx: normoxia; CIH: chronic intermittent hypoxia. 
 
DISCUSSION 
We hypothesised that CVD, an antihypertensive 
drug with α1- and β-adrenoceptor antagonist 
activity, would be effective in reducing both BP 
and HR, since it is broadly consensual that 
sympathetic activation and oxidative stress 




HT related to OSA (Sunderram and 
Androulakis, 2012). We found that CIH 
significantly increased MAP, diastolic and 
systolic BP in our animal model, while no effect 
was observed for HR. Although doses of 10, 30 
and 50 mg/Kg of CVD promoted a significant 
reduction in HR, no decrease in mean arterial 
pressure was observed. Interestingly, we also 
found that CIH changed the plasma 
concentrations of CVD enantiomers however, 
the lower ratios S/(R+S) of CVD enantiomers 
observed in rats exposed to CIH do not 
apparently explain the lack of efficacy of CVD 
in reversing this particular type of hypertension.  
The animal model used in the present work 
mimics the intermittent hypoxic episodes that 
occur chronically in patients suffering from 
OSA. Obesity is a major cause of airway 
obstruction in these patients but it is also 
postulated that OSA can trigger reflex 
mechanisms that favour the development of 
metabolic syndrome in these patients 
(Mannarino et al., 2012). Our model allows us 
to separate the mechanical and hypercapnic 
components of obstruction from the effect of 
intermittent hypoxia itself.  Several authors 
have reported weight loss in CIH-exposed rats 
when compared with control rats (Silva and 
Schreihofer et al., 2011; Soukhova-O’Hare et 
al., 2008; Totoson et al., 2013; Zoccal et al., 
2008). Singh and Sevamurthy suggested that the 
weight loss observed after CIH exposure is due 
to a reduction in food intake (Singh and 
Sevamurthy, 1993). More recently, other 
authors measured daily food intake and reported 
that the reduced body weight gain in CIH rats 
was not associated with reduced food 
consumption but related to a significantly 
higher metabolism and energy expenditure 
(Fenik et al., 2012). In addition to reporting the 
weight loss, our results showed, for the first 
time, that CIH induces a deviation in the weight 
changes observed in age-matched Wistar rats, 
leading to a significant retardation of body 
growth. This finding suggests that intermittent 
hypoxia by itself does not contribute to 
maintaining an overweight status in obese 
patients with OSA. The effect of CIH on body 
weight deserves further study in obese animals. 
CIH is now established as the dominant model 
of sleep apnea. Generally, this model makes use 
of specific ventilated chambers in which the 
animals are housed and cyclically exposed 
either to normoxia/hypoxia or room air to 
mimic the most relevant consequences of OSA 
(Diogo and Monteiro, 2014). In our protocol, 
rats were housed in cages placed inside medium 
A-chambers that were large enough to prevent 
air jet stress-induced changes in cardiovascular 
parameters and also to allow the rats to be 
housed in groups during the extended period of 
CIH exposure in order to decrease stress levels. 
Our paradigm of CIH in rats roughly 
corresponds to sleep apnea lasting for more than 
two years in humans, which matches the clinical 
practice of OSA diagnosis. In humans, an 
apnea-hypopnea index (AHI) bellow 5 
events/hour of sleep is under the physiological 
range (Berry et al., 2012). A paradigm of 5.6 
cycles/h of exposure to CIH in rats, even with 
correction for higher metabolic activity in 
animals (Germack et al., 2002), is below the 
AHI cut-offs for moderate OSA (>15 
events/hour of sleep). 
Animal models of CIH diverge in some aspects, 
such as the animal species involved, the severity 
of hypoxia, the number of hypoxic episodes per 















exposure (exposure duration), and CO2 
manipulation (for a review see Diogo and 
Monteiro, 2014). Anyway they are unanimous 
in reporting the development of mild 
hypertension (Allahdadi et al., 2005; Bathina et 
al., 2013; Campen et al., 2005; Chen et al., 
2005; Dyavanapalli et al., 2014; Fletcher et al., 
2000; Kanagy et al., 2001; Knight et al., 2011; 
Lai et al., 2006; Lin et al., 2007; Liu et al., 
2013; Sharpe et al., 2013; Silva and 
Schreihofer, 2011; Schulz et al., 2014; 
Soukhova-O'Hare et al., 2008; Tahawi et al., 
2001; Totoson et al., 2013; Zoccal et al., 2009). 
In agreement with these reports, CIH 
significantly increased mean arterial pressure, 
diastolic and systolic BP in our animal model, 
highlighting once again the major role of CIH in 
the development of hypertension.  
The effects of CIH on HR result from a balance 
between sympathetic nervous system 
overactivation and baroreflex control. Our 
results are in line with previous studies that 
described no changes in HR (Dyavanapalli et 
al., 2014; Knight et al., 2011; Soukhova-
O’Hare et al., 2008; Zoccal et al., 2009) and 
match the lower rate of variability that has been 
described for patients with OSA (Trimer et al., 
2014).  Apparently, CIH does not impair the 
baroreflex control of HR. Increases in HR were 
only observed in a study performed with 
anesthetised rats exposed to CIH for 90 days 
(Lin et al., 2007).  In humans, baroreflex 
control of HR was reported to be lower in obese 
than non-obese awake humans and improved 
after weight reduction (Grassi et al., 1998). 
Since our animal model is lean this is also 
consistent with the absence of HR changes.  
After validation of our rat model of 
hypertension related to OSA, we decided to test 
CVD since sympathetic activation and oxidative 
stress play an important role in the 
pathophysiology of hypertension related to OSA 
and, beta-blockers have not yet been tested in 
this animal model. Studies investigating the 
antihypertensive effect of drugs on animal 
models are scarce and drugs have been used 
solely as pharmacological tools to address 
physiological mechanisms (for a review see, for 
example, Diogo and Monteiro, 2014). The 
experiments evaluate prevention, but not the 
effectiveness of treatment. Other limitations of 
the pharmacological approaches included in 
these works are the absence of dose-response 
curves and comparison of the effectiveness of 
different drugs in the same animal model. 
Aware of these drawbacks, our study was 
planned to first induce hypertension and then 
evaluate the efficacy of cumulative doses of 
CVD because the translation of the results 
obtained with simultaneous induction of 
hypertension and drug administration to humans 
is not relevant.  
In humans, β -blockers have been used 
empirically to treat HT in OSA patients.  
Several studies were designed to evaluate the 
efficacy of atenolol (Kraiczi et al., 2000; Salo et 
al., 1999; Pelttari et al., 1998), metoprolol 
(Mayer et al., 1990) and nebivolol (Heitmann et 
al., 2010). To the best of our knowledge, only 
one study was performed to evaluate the effects 
of CVD in OSA patients (Kario et al., 2014). 
This study compares a bedtime dose of 
nifedipine, a calcium channel blocker with CVD 
in the sleep BP profile (Kario et al., 2014). It 
found that the BP lowering effects of nifedipine 
on the mean and minimum sleep systolic BP 
were stronger than those of carvedilol, but the 




specifically to the hypoxia stimuli than 
nifedipine. In general, these drug studies found 
that the blockade of β-adrenergic receptors 
during short periods (one to six weeks) might be 
helpful in reducing BP but none has established 
BP control as an endpoint. The evidence was 
not consistent, however, because some studied 
reported decreases in night-time BP while 
others only in daytime BP. These studies were 
performed in AHDs non-naïve patients with 
several comorbidities and do not allow us to 
distinguish between the beneficial effect of 
beta-blockers against the acute sympathetic 
overactivity triggered by obstruction and their 
effects on the mechanisms triggered by hypoxia 
itself (for a review see Diogo and Monteiro, 
2014). Studies in humans are also limited by the 
inability to identify the chronicity of OSA and 
hypertension in each patient. This can interfere 
with drug efficacy, assuming that the 
mechanisms involved in hypertension induced 
by OSA might be time-dependent. For instance, 
it has been proposed that IH is able to induce a 
renal hormetic response: short-term IH induces 
a protective response against the renal oxidative 
damage, but long-term IH exposure induces a 
damaging effect on the kidneys (Sun et al., 
2012). 
The doses of CVD tested (10, 30 and 50 
mg/kg/day) were selected based on previous 
studies performed in different models of 
hypertension (Bertera et al., 2012a; Bertera et 
al., 2012b; Chen et al., 2013; Di Verniero et al., 
2010; Rodriguez-Perez et al., 1997). The lack of 
efficacy of CVD cannot be attributed to the 
doses because they were effective in reducing 
HR in our model, in reducing BP in other 
models of HT and are higher than the doses 
administered to humans (12.5-50 mg). 
CVD was daily administered by gavage, the 
most widely used method for the precise oral 
dosing of rodents. This method can, however,  
elicit a stress response, and it has been shown 
that any source of external stress on rodents can 
significantly increase heart rate and blood 
pressure, effects that persist for around 3 hours 
(Brown et al., 2000; Bonnichsen et al., 2005; 
Kramer et al., 2000; Balcombe et al., 2004). 
Aware of this fact we administered CVD only 
after monitoring BP parameters and the 
measurements were made on the day after 
administration and before exposure to IH 
conditions.  
Carvedilol is a lipophilic third generation β-
blocking agent, and it is assumed that it easily 
crosses the blood-brain barrier. Several 
advantages have been claimed for third 
generation agents over the traditional β-
blockers. First, drugs such as CVD exhibit a 
broad range of adrenergic inhibition, blocking 
postsynaptic β1, β2 and α1 receptors and 
presynaptic β2 receptors (DiNicolantonio and 
Hackam, 2012). Secondly, unlike traditional 
agents, CVD promotes vasodilatation through 
different mechanisms, which translate into a 
more favourable hemodynamic profile 
compared to non-vasodilating beta-blockers 
(Rath et al., 2012). In addition to its alpha-
adrenergic receptor blocking properties, it has 
been suggested that CVD-induced increased 
nitric oxide (NO) plasma levels (Afonso et al., 
2006; Vanhoutte and Gao, 2013) and 
antioxidant properties (Rath et al., 2012; 
Feuerstein and Ruffolo, 1995) could also 
contribute to the vasorelaxation and subsequent 
reduction in vascular resistance evoked by 
CVD. CVD is also noted as a suppressor of the 















al., 1997), as a drug with antiproliferative 
actions (Cheng et al., 2001) and with beneficial 
effects on vascular and cardiac structural 
remodelling (Bakris, 2009; Chen et al., 2013), 
endothelial dysfunction (Feuerstein and 
Ruffolo, 1995) and progression of target organ 
damage (Bakris, 2009). Finally, CVD also has a 
calcium channel blocking effect by inhibiting 
voltage-dependent L-type Ca2+ in vascular 
smooth muscle cells (Nakajima et al., 2003), 
inhibits the rennin-angiotensin system (Cheng et 
al., 2001) by blocking β1 receptors and 
enhances the plasma concentration of atrial 
natriuretic peptide (Cheng et al., 2001). 
Since these pleiotropic effects of CVD match 
the pathophysiological mechanisms described 
for CIH (for a review see Diogo & Monteiro, 
2014), the lack of efficacy of carvedilol in 
reversing hypertension induced by CIH was 
unexpected.  
The finding that the three doses of CVD 
promoted a significant decrease in HR 
confirmed that the lack of antihypertensive 
efficacy couldn’t be attributed to the absence of 
beta-blocking activity.  
Another explanation could be that CIH might 
change the pharmacokinetic profile of CVD, 
compromising their antihypertensive efficacy. 
Carvedilol is clinically administered as a 
racemic mixture in which nonselective beta-
adrenoreceptor blocking activity is present in 
the S-(-) enantiomer and alpha-adrenergic 
blocking activity is present in both R-(+) and S-
(-) enantiomers at equal potency (Peccinini et 
al., 2008). A decrease in HR without no effects 
on BP might thus be explained by a selective 
increase in the levels of S-(-)-CVD. There is 
some evidence that hypoxic conditions can 
broadly change drug clearance (Chen et al., 
2013; Gao et al., 2013; Vij et al., 2012) or drug 
effects (Nunes et al., 2010). 
In the present work, we found, for the first time, 
that CIH changes CVD pharmacokinetics by 
mechanisms that deserve further exploration, 
however, the lower ratio S/(R+S) observed in 
rats submitted to CIH could not easily explain 
the lack of hypotensive effects. 
Another putative explanation for the lack of 
efficacy of carvedilol is that the blockade of the 
sympathetic nervous system along with all the 
pleiotropic properties of CVD, might not be 
enough to reverse hypertension induced by CIH. 
From a broad perspective, we can speculate that 
the majority of CVD effects were produced in 
experiments that planned to address only one 
variable involved in the pathophysiology of 
hypertension and some in acute conditions. Few 
studies of hypertension with the chronic 
administration of CVD have been performed in 
rat models. In a model of hypertension induced 
by unilateral renal artery narrowing (Chen et al., 
2013), CVD (20 mg/kg/day) administered by 
gavage for 8 weeks, caused a significant and 
sustained reduction of SBP apparent in the first 
two weeks of treatment, but it was not able to 
completely reverse the hypertensive effect of 
the surgical procedure. In hypertension induced 
by renal ablation (5/6), only rats receiving doses 
of 10 and 20 mg/Kg/day of CVD (but not of 5 
mg/Kg/day) exhibited significant decreases in 
SBP apparent at week five of treatment 
(Rodriguez-Perez et al., 1997). These findings, 
together with the lack of efficacy of CVD found 
in our animal model, support the theory that 
mechanisms other than this type of renal 
damage are involved in hypertension induced 




Finally, it has been described that CIH leads to 
an increased stiffness and reduced vessel wall 
distensibility (Phillips et al., 2006) and induces 
significant renal inflammation and fibrosis. 
(Sun et al., 2012). We can therefore postulate 
that CIH induces structural changes in vessels, 
renal tubules, etc., that are not targeted by CVD.  
 
CONCLUSION 
In conclusion, the lack of efficacy of CVD in 
reversing hypertension induced by CIH in our 
animal model suggests that the blockade of 
sympathetic nervous system alone does not 
seem to be the best strategy for reversing 
established hypertension in sleep apnea 
conditions. Sympathetic overactivity may be an 
early step in the mechanism leading to more 
permanent effects due to prolonged sympathetic 
overactivity or through local effects of recurrent 
IH that are not reversed by drugs such as CVD. 
This study also pointed out, for the first time, 
that CIH changes CVD pharmacokinetics 
through mechanisms that deserve further 
exploration. Drugs that have proved to be useful 
in essential hypertension treatment should thus 
be tested in studies specifically designed for 
secondary hypertension induced by CIH.  
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RATS 
Lucília N Diogoa*, Inês V Faustinoa, Ricardo A Afonsoa,b, Sofia A Pereiraa, Emília C 
Monteiroa and Ana I Santosb 
aCentro de Estudos de Doenças Crónicas, CEDOC, NOVA Medical School / Faculdade de Ciências Médicas, 
Universidade Nova de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal b Department of 
Physiology, NOVA Medical School / Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo dos 
Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. 
 
ABSTRACT 
Gavage is a widely performed technique for daily dosing in laboratory rodents. Although it is effective, 
gavage comprises a sequence of potentially stressful procedures for laboratory animals that may 
constitute bias for the experimental results, especially when the drugs to be tested interfere with stress 
dependent parameters. We aimed to test suitable vehicles for drug delivery by voluntary ingestion. Male 
Wistar rats (2-3 months) were used to test nut paste (NUT), peanut butter (PB) and sugar dough (SD) as 
vehicles for long-term voluntary oral administration of losartan, an angiotensin II receptor blocker. 
Vehicles were administered 28 days without drug in order to assess the glucose level and serum lipid 
profile. Losartan was mixed with vehicles and offered to the animals or administered by gavage (14 days) 
for subsequent quantification of losartan plasma levels by HPLC. After a 2-day acclimatization period, all 
animals voluntarily ate the vehicles, either alone or mixed with losartan. Blood glucose levels were 
reduced by NUT administration (p<0.01). PB induces increased levels of triglycerides and total 
cholesterol (p<0.05). SD group presented a higher concentration of losartan when compared with gavage 
group (p<0.01), without changing lipid and glucose profiles. Our results showed that the three vehicles 
are viable for daily single dose voluntary ingestion of losartan, from which SD proved to be the best 
alternative.  Drug bioavailability was not reduced, suggesting that voluntary ingestion is highly effective 
for chronic oral administration of losartan. The results presented herein point to a welfare-based 
refinement for drug administration in laboratory rodents.  
 
Key words: gavage; voluntary oral administration; losartan; nut paste; sugar dough; peanut butter. 
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Oral drug administration as a single daily dose 
in animal models is commonly done with water-
diluted drugs, gavage or voluntary ingestion. 
Gavage is widely performed for precise oral 
dosing in rodents. It is commonly used in 
efficacy and toxicity studies, as well as drug 
discovery. This technique, applicable in 
conscious animals, is a rapid and efficient mean 
of accurately delivering fixed doses of the drug 
to be tested (Turner et al., 2012). However, 
gavage comprises a sequence of procedures 
potentially stressful for laboratory animals.  
Removing the animal from the cage, manually 
restraint and insertion of a flexible or rigid 
dosing cannula into the esophagus in direction 
to the stomach (Atcha et al., 2010; Brown et al., 
2000), cause high levels of stress even in 
trained animals. Additionally, there are also 
welfare issues related to the use of gavage when 
it is done by inexperienced people and/or in 
long-term studies (Huang-Brown and Guhad, 
2002). Indeed, gastro-esophageal aspiration and 
pulmonary injury represent recurrent 
complications of gavage dosing of rodents that 
may be triggered by technical gavage errors 
(Damsch et al., 2011). Moreover, the use of 
gavage for different drugs and vehicles can 
elicit a significant stress response in a vehicle- 
and dose volume-dependent fashion (Brown et 
al., 2000).  
When testing antihypertensive drugs it becomes 
crucial to ensure the selection of a non-invasive 
and stress-free method for drug delivery, since 
it has been shown that any source of external 
stress on rodents can significantly increase heart 
rate and blood pressure (Brown et al., 2000; 
Bonnichsen et al., 2005; Kramer et al., 2000; 
Balcombe et al., 2004) and therefore contribute 
for confounding the experimental results.  
Several alternatives to gavage, performed with 
less human interference, have been tested in the 
last years. Administration of a drug mixed with 
an attractive vehicle, by voluntary ingestion, 
seems to be an effective method for drug 
administration in a non-invasive way (Goldkuhl 
et al., 2008; Jacobsen et al., 2011). In previous 
attempts to refine the gavage procedure, nut 
paste has been successfully used for analgesic 
drugs delivery (Abelson et al., 2012; Goldkuhl 
et al., 2008; Jacobsen et al., 2011; Kalliokoski 
et al., 2011) and shown to be a promising 
option for estrogen administration (Isaksson et 
al., 2011). Other alternatives included the use of 
transgenic dough diet-pill dosing method 
(Walker et al., 2012), flavored gelatin 
preparation - “jello” (Flecknell et al., 1998), 
sugar cookie dough (Corbett et al., 2012), 
honey (Kuster et al., 2012) and syringe-feeding 
technique (Atcha et al., 2010).  
In our study we used nut paste (NUT), peanut 
butter (PB) and sugar dough (SD) as drug 
vehicles due to their palatability, consistency 
and previously reported results. We aimed to 
investigate the suitability of these vehicles for 
voluntary oral administration and, additionally, 
if they can be used as an alternative method to 
gavage, for chronic administration of losartan to 
laboratory rats. We hypothesized that low 
amounts of these vehicles, even when 
administered to rats during a long period of 
time, will not induce relevant changes in blood 
glucose or lipid profiles, while efficiently 
delivering the tested drug, as assessed by 
losartan serum concentration.  Accordingly, we 
further hypothesized that the serum 















voluntary ingestion would be at least as high as 
with gavage. 
 
MATERIAL AND METHODS 
Animals 
Experiments were performed in forty-one male 
Wistar rats (Rattus norvegicus L.), aged 2-3 
months, with mean body weight 283 5.0 g, 
obtained from the NOVA Medical School 
animal facility. This Wistar in house colony has 
been started with animals acquired from Charles 
River Laboratories (Crl:WI). Animals were 
housed individually in polycarbonate cages with 
wire lids (Tecniplast, Buguggiate, Varese, 
Italy), under 12 h light/dark cycles (8 am - 8 
pm), at a room temperature 22 ± 2.0 °C and 
relative humidity 60± 10%. Rats were 
maintained on standard laboratory diet (SDS 
diets RM1) and reverse osmosis water, given ad 
libitum. Corncob bedding (Probiológica, 
Lisbon, Portugal) was used and changed once a 
week. Animals were Specific Pathogen Free 
(SPF) according to FELASA recommendations 
(Nicklas et al., 2002).  
Applicable institutional and governmental 
regulations concerning ethical use of animals 
were followed, according to the NIH Principles 
of Laboratory Animal Care (NIH Publication 
85-23, revised 1985), the European guidelines 
for the protection of animals used for scientific 
purposes (European Union Directive 
2010/63/EU) and the Portuguese Law nº 
113/2013. Experimental procedures were 
previously approved (nr. 21/2013/CEFCM) by 
the Institutional Ethics Committee of the 





Three different vehicles were tested for long-
term oral administration (14 days) of losartan, 
an antihypertensive drug (angiotensin II 
receptor (type AT1) antagonist). Based on their 
consistency, palatability and previous reports 
(Abelson et al., 2012; Goldkuhl et al., 2010; 
Jacobsen et al., 2011; Kalliokoski et al., 2011; 
Isaksson et al., 2011; Corbett et al., 2012), nut 
paste (NUT, Nutella ®, Ferrero Ibérica SA, 
Llobregat, Spain), peanut butter (PB, Skippy ®, 
Unilever, London, UK) and sugar dough (SD, 
SweetArt ®, Entertraining Lda, Lisboa, 
Portugal) were used. NUT ingredients include 
sugar, vegetable oil, hazelnuts (13%), skim milk 
powder (8.7%), fat-reduced cocoa powder 
(7.4%), soy lecithin (emulsifier) and vanillin 
(flavoring). The caloric content is 21.75 kJ/g; 
protein content is 7.1%; fat content 30.3% and 
sugars content is 54.7%. PB is composed of 
roasted peanuts, sugar, hydrogenated vegetable 
oils and salt. The caloric content is 26.10 kJ/g; 
protein content is 22.2%; fat content 49.4% and 
carbohydrate content is 23.8%. Finally, SD 
presents as ingredients sugar, cornstarch, 
glucose, vegetable fat, vegetable gums, 
stabilizer E420, preservatives E202, dye E102 
and E131. The caloric content is 16.50 kJ/g; 
protein content is 3.5%; fat content 6.6% and 
carbohydrate content is 86.6%. 
Rats were randomized following weaning into 
six groups of six rats each: group 1 (NUT - 28 
days); group 2 (PB - 28 days); group 3 (SD - 28 
days); group 4 (NUT with 10 mg/kg/day 
losartan - 14 days); group 5 (PB with 10 
mg/kg/day losartan - 14 days); group 6 (SD 




group of five rats: group 7 (10 mg/kg/day 
losartan administered by oral gavage - 14 days). 
All rats used to test voluntary administration  
(groups 1 to 6) underwent a 2-day 
acclimatization period, during which they were 
fed 0.5 g of the respective vehicle once daily, in 
order to minimize neophobia (Abelson et al., 
2012) and avoid incomplete ingestion incidents. 
Drug or vehicles deliveries would be considered 
incomplete when any trace of vehicle was found 
in either Petri dish, side of the cage or in 
bedding, after the first hour. 
In the first set of experiments (groups 1, 2 and 
3) the vehicles were administered without drug 
for 28 days (in addition to the acclimatization 
period) in order to determine whether rats 
would voluntarily ingest them for such period 
of time and also to test the vehicles effect on 
blood glucose level and serum lipid profile. The 
vehicles were weighed, mixed with the 
respective amount of drug and offered to the 
animals in 92x16 mm polystyrene Petri dishes 
(Sarstedt AG & Co, Germany). The Petri dishes 
were placed vertically, attached with adhesive 
tape to the inner cage wall (Figure 1). The 
vehicles, alone or mixed with the drug, were 
daily given to the animals at approximately the 
some schedule (11:00 to 12:00 am). The 
administration schedule as well as the ingestion 
profile (1- complete; 2- incomplete) and the 
time between vehicle and vehicle/drug mixture 
delivery and consumption (1- within 5 minutes 
or less; 2-between 5 minutes and 1 hour; 3- > 1 
hour) were recorded.  
The animals of group 7 underwent a 7 days 
handling acclimatization period. Rats were 
handled daily for a period of 2 minutes each by 
the same individual and accustomed to the 
gavage position, in a different animal facility 
procedures room. Handling training and gavage 
were performed at the same schedule (11:00 to 
12:00 am) as for voluntary administration.  
Gavage was performed using a stainless steel 
gavage feeding needle, curved and with round 
tip (gauge 16; tip diameter: 3 mm; length: 75 
mm; Fine Science Tools, California, USA). 
Rats were weighed at baseline and once a week 
during the entire study. The amounts of losartan 
were adjusted weekly to ensure a daily dose of 
10 mg/kg. Losartan was prepared daily, 
immediately before administration, when to be 
given either by gavage or along with vehicle. 
For gavage, Losartan was dissolved in reverse 
osmosis water (2 mL). When Losartan was 
administered along with vehicle, the required 
amount of drug for each rat was mixed with 0.5 
g of the respective vehicle. In the first set of 
experiments (groups 1, 2 and 3), water intake 
was measured weekly and blood glucose level 
and serum lipid profile were monitored, 2-3 
hours after vehicle administration, at baseline, 

















Figure 1: Method for voluntary ingestion of losartan with three different vehicles: nut paste (A); peanut butter (B) and sugar-
dough (C). (1) Losartan powder weighted directly over vehicle. (2) Vehicle-drug mixture shaped into a ball ready for delivery. (3) 
Rats ingesting vehicle-drug mixture from the polystyrene Petri dish placed vertically in the cage. 
 
At the end of the experiments, 2-3 hours after 
drug delivery, rats were anesthetized, by 
intraperitoneal injection with medetomidine 
(0.5mg/kg body weight; Domitor®, Pfizer 
Animal Health) and ketamine (75mg/kg body 
weight; Imalgene 1000®, Mérial, Lyon, 
France), and cardiac puncture was performed to 
collect blood for further drug quantification. 
The animals were then euthanized by an 
intracardiac overdose of sodium pentobarbital, 




Tail vein sampling: In groups 1, 2 and 3, blood 
samples were collected from the tail vein of 
conscious animals at baseline, day 14 and day 
28. Rats were placed in a conventional plastic 
restrainer (n° 554-BSRR, Plas-Labs, Lansing, 
Michigan, USA), at a room temperature 24-
27ºC.  A scalpel blade was used to make an 
incision in the lateral tail vein. Around 100 μL 
of blood was collected from each animal, using 
a capillary tube (Hirschmann Laborgerate, 
Eberstadt, Germany), to eppendorfs and kept on 
ice. This procedure was also used for collecting 
two blood drops for glucose quantification. 
After collection, bleeding was stopped by 
compression for a few seconds and cleaned with 
iodopovidone. Serum samples were centrifuged 
in a microfuge at 3000 rpm (4º C) for 10 
minutes, immediately decanted and stored at 
−80 °C until analysis. According to prior 
recommendations, the restrainer was washed 
and dried after each use to prevent 
pheromonally induced stress (Parasuraman et 




Cardiac puncture: Blood collection was 
performed without thoracotomy with a 20 G 
needle with a 10 mL syringe. For plasma 
sampling, approximately 3 mL of blood was 
collected to vacutainer tubes containing EDTA 
(ethylenediaminetetraacetic acid), kept on ice 
and immediately centrifuged at 3000 rpm (4 °C) 
for 10 min. Plasma samples were decanted prior 
to storage at −80 °C until analysed. 
 
Measurement of blood glucose level and 
serum lipid profile 
Blood glucose level was determined in mg/dl 
using a digital glucometer (Precision Xceed®, 
Abbott diabetes care Ltd, Oxon, UK). The 
serum levels of triglyceride (TGL), total 
cholesterol (TC), high-density lipoprotein-
cholesterol (HDL-C) and low-density 
lipoprotein- cholesterol (LDL-C) were 
determined spectrophotometrically (Rx Daytona 
analyser, Randox Laboratories Ltd, UK), using 
enzymatic colorimetric assay kits (Randox 
Laboratories Ltd, UK). The results were 
expressed in mg/dL.  
 
HPLC analysis  
Losartan plasma concentrations were 
determined by HPLC (High-performance liquid 
chromatography), using a minor modification of 
the method described by Yeung and colleagues 
(Yeung et al., 2000). Briefly, losartan was 
dissolved in methanol yielding a stock solution 
of 1 mg/mL. Calibrations samples were 
prepared by adding known amounts of the 
diluted stock solution to rat plasma and covered 
a range of 1 - 10 μg/mL. Subsequently, 
calibration samples (200 μL) were extracted 
with 3 mL of ethyl acetate. After centrifugation 
(3000 rpm, 4 ºC, 10 min), the organic phase was 
evaporated to dryness at 60 ºC in a Speed-Vac 
concentrator (Labconco, Kansas City, MO, 
USA). The resulting residue was reconstituted 
in 150 μL of mobile phase and 100 μL was 
injected into HPLC. 
HPLC was accomplished by using a solvent 
delivery pump (model LC 9-A; Schimadzu, 
Kyoto, Japan), autosampler (model 7725i; 
Schimadzu, Kyoto, Japan, UV-VIS 
spectrophotometric detector (model SPD-6 AV; 
Schimadzu, Kyoto, Japan.), column (250 x 4 
mm; particle size: 5 μm; LiChrospher 100 RP-
18; Merck, New Jersey, USA) protected by a 
guard-column (4 x 4mm; particle size: 5 μm; 
LiChrospher 100 RP-18e; Merck, New Jersey, 
USA) and a column oven (model CTO-10AS 
VP; Schimadzu, Kyoto, Japan). Data 
acquisition and processing were performed 
using Shimadzu Class VP 7.X software. The 
mobile phase consisted of solution A - 
methanol: acetonitrile: sodium dihydrogen 
phosphate monohydrate buffer (10mM; pH 3; 
50:10:40; v/v/v) and solution B - methanol. All 
HPLC solvents were purchased from VWR 
International (Carnaxide, Portugal). Prior 
analysis, both solutions were degassed for 15 
min by sonication (VWR, Carnaxide, Portugal). 
The elution program consisted of an isocratic 
flow of A solution for (9.5 min), followed by a 
linear gradient A:B (20:80 (v/v); 2.5 min), an 
isocratic step A:B (20:80; 4 min) and finally 
return to initial conditions in 2 min. The 
analytical run was performed with a mobile 
phase flow rate 0.8mL/min, at 25º C and 
detection wavelength of 230 nm. 
 
Drugs 
Losartan at 10 mg/kg, from Cinfa, S.A (generic, 















three vehicles and administered to the animals. 
Analytical standards of losartan, for HPLC 
analysis, were purchased from Sigma-Aldrich 
(Sintra, Portugal).  
 
Statistical Analysis 
All data are represented as mean ± standard 
error of the mean (SEM). One-way ANOVA 
with Bonferroni's multiple comparison test and 
one-way analysis of variance with Tukey’s 
multiple comparison test were used, whenever 
appropriate, to evaluate the vehicles effect on 
glycaemia and lipid profile. The two-way 
repeated-measures ANOVA with post hoc 
comparison test was used to compare the 
vehicle effect on mean animal body weights and 
water intake, along the 28 days of experiments. 
Comparison in losartan plasma concentrations 
between vehicle groups was performed using 
one-way ANOVA with Dunnett's multiple 
comparison post hoc test, using gavage as 
control. Statistical analysis was performed using 
GraphPad Prism (GraphPad Software Inc., 
version 5.01, San Diego, CA). Statistical 




Vehicles and vehicles-drug mix ingestion 
During the 2-day acclimatization period the 
vehicles were made available in the cages as 
shown in figure 1. Animals of groups 1 and 4 
were offered nut paste (NUT), 2 and 5 peanut 
butter (PB) and 3 and 6 sugar dough (SD). The 
time between vehicle presentation and complete 
consumption was less than 1 hour in groups 1, 
2, 4 and 5. Five animals from group 3 and four 
from group 6 took more than 1 hour in the first 
day but in the second day all animals took less 
than 1 hour to eat the SD. After the 
acclimatization period, all animals of groups 1, 
2 and 3, voluntarily ingested the vehicles. The 
time between vehicle delivery and its 
consumption was five minutes or less, for all 
cases. No incomplete drug ingestion incidents 
were observed after the acclimatization period 
(groups 4, 5 and 6). Furthermore, ingestion of 
the vehicle-drug mixture was immediate (less 
than 5 minutes) for all animals.  
 
Physiological data, blood glucose levels 
and lipid profile  
There was no vehicle effect on mean animal 
body weights and water intake, throughout the 
28 days of experiments (p>0.05). Vehicle 
ingestion did not induce any deviation to the 
weight variation observed in animals of this age 
in this population. Weight gain was in average 
90 g for the 18 animals of groups 1, 2 and 3 and 
water intake increased in average 14.8 ml 
during the 28 days. 
Interestingly, unlike PB and SD groups, a 
significant decrease in mean blood glucose 
levels was observed along the experimental 
period for the NUT group of animals (Figure 2 
A). Moreover, at the 28-day time-point the 
mean glycaemia of NUT group was 
significantly lower than the one observed for 
the other two groups (Nut paste vs. PB: p<0.05; 
Nut paste vs. SD: p<0.01; Figure 2 D). The 
glycemic profile remained unchanged in PB and 
SD groups (p>0.05) (Figure 2 B and C). 
Regarding the lipid profile, serum levels of total 
cholesterol gradually increased in both NUT 
(p<0.05; baseline vs. 28 days) and PB (p<0.05; 
baseline vs. 28 days) groups (Figure 3 A and 




(p>0.05) in SD group (Figure 3 C). Anyway, 
the mean total cholesterol levels of the three 
groups at both 14-day and 28-day time points 
were not significantly different (p>0.05) (Figure 
3 D). In the SD group, a non-significant 
increase (p>0.05) in serum triglycerides 
concentrations was observed during the 28 days 
(Figure 4 C). The PB group showed the same 
tendency but this time the increase was 
statistically significant (p<0.05; baseline vs. 28 
days; p<0.01 14 days vs. 28 days; Figure 4 B). 
Serum triglycerides values remained unchanged  
(p>0.05) in the NUT administration (Figure 4 
A). Once again, the mean total triglycerides 
concentrations of the three groups at both 14-
day and 28-day time points were not 
significantly different (p>0.05) (Figure 4 D). 
Decreased levels of HDL-C were observed at 
day 14 for both SD (p<0.01) and PB (p<0.001) 
groups. These values progressively increased 
and, at the end of the experiment, were similar 
to those observed at baseline (p>0.05: baseline 
vs. 28 days, for both groups). No differences in 
HDL-C values were found between vehicles at 
the three time points (p>0.05) and NUT did not 
affect the HDL-C levels (Figure 3 E). Finally, 
no significant changes on LDL-C values were 
observed either for NUT, PB or SD groups 
along the experimental period (Figure 3 F). 
 
 
Figure 2: Mean glycaemia values (mg/dl) in the serum of Wistar rats fed with 0.5 g of (A) Nut paste; (B) Peanut butter 
and (C) Sugar Dough vs. time (D). Comparison of the three vehicles effects on glycaemia at 14 and 28-day time points. 
Data are expressed as mean SEM; n=6 for all groups.  * p<0.05; ** p<0.01 - One-way ANOVA with Bonferroni’s 
multiple comparison test; 
#
 p<0.05 (nut paste vs. sugar dough); 
##
 p<0.01 (nut paste vs. peanut butter) – One-way 




















Figure 3: Mean total cholesterol concentrations (mg/dl) in the serum of Wistar rats fed with 0.5 g of (A) Nut paste; (B) 
Peanut butter and (C) Sugar Dough vs. time (* p<0.05; **p<0.01 - One-way ANOVA with Bonferroni’s multiple 
comparison test). Comparison of the three vehicles effects on (D) total cholesterol, (E) HDL-C and (F) LDL-C levels at 
14 and 28-day time points (One-way analysis of variance with Tukey’s multiple comparison test). Data are expressed as 






Figure 4: Mean triglycerides concentrations (mg/dl) in the serum of Wistar rats fed with 0.5 g of (A) Nut paste; (B) 
Peanut butter and (C) Sugar Dough vs. time (* p<0.05; ** p<0.01 - One-way ANOVA with Bonferroni’s multiple 
comparison test). (D) Comparison of the three vehicles effects on triglycerides levels at 14 and 28-day time points. Data 
are expressed as mean SEM (n=6 for all groups). 
 
Losartan plasma concentrations 
After 14 days of losartan daily administration 
by gavage the mean plasma concentration was 
0.9 0.09 g/mL. A slight but non-significant 
decrease of the plasma concentration of losartan 
was observed in the PB group (0.7 0.09 
g/mL). However, when losartan was given 
along with NUT, its plasma concentration 
tended to be higher than in the gavage group 
(1.3 0.15 g/mL), although this difference did 
not reach statistical significance. When SD 
vehicle was used, a significantly higher losartan 
plasma concentration was achieved (1.7 0.14 
g/mL; p<0.01 vs. gavage). These results are 
presented in Figure 5. 
 
 
















Figure 5: Losartan (LST) plasma concentrations ( g/mL), from blood collected by cardiac puncture after 14 days of 
daily ingestion, in gavage (GAV), nut paste (NUT), peanut butter (PB) and sugar dough (SD) rats. Data are expressed 





We have tested nut paste (NUT), peanut butter 
(PB) and sugar dough (SD) as potential vehicles 
for chronic losartan administration to rats in 
order to surpass the stress induced by orogastric 
forced administration (gavage). Voluntary 
ingestion proved to be an effective method for a 
controlled daily dose administration, with a 
define timetable, that is independent of handling 
and restraint procedures. Moreover, as gavage, 
this approach mimics the single-dose 
administration, widely used in human clinical 
practice. 
Male Wistar rats, aged 2-3 months and housed 
individually were used to avoid hypothetical 
effects of estrogen on blood lipids (Ganong, 
2002). Although Sharp and collaborators (Sharp 
et al., 2002) recommend that animals should be 
ideally housed in group to decrease the stress 
levels, in our study, animals were single-housed 
during all protocol in order to ensure correct 
dosage and to confirm vehicle or vehicle plus 
drug complete ingestion. The palatability of 
NUT, PB and SD showed to be attractive for the 
animals, since the animals ingested them almost 
immediately and completely. Furthermore, the 
consistency of these vehicles facilitates the 
weighing and the mixing of powder, thereby 
ensuring the accuracy of the drug dose. The 
amount of vehicle given to the animals (0.5g) 
was shown to be enough to hold the weighed 
drug, whereas still appeared attractive for the 
animals and not too large to cause significant 
metabolic changes. Offering the mixture in a 
Petri dish placed vertically inside the cage 




complete ingestion. Before it has been reported 
that placing NUT in a container on the floor of 
the cage is not recommended, since neophobic 
animals tend to burry the novel item, and thus 
mix the vehicle with the bedding material 
(Abelson et al., 2012).  
Although some authors have recommended a 
period of up to five days for animal 
acclimatization to the vehicles (Isaksson et al., 
2011), in our study, two days proved to be 
enough time to ensure that there was no 
neophobic behavior after that. In order to reduce 
the stress levels associated with handling and 
restrained we decided to use a one-week period 
of acclimatization in the gavage group. 
Oral gavage has been recently refined from 
metal gavage needle to a sterile flexible feeding 
tube which reduces the risk of trauma, 
perforation and cross contamination, (Morton et 
al., 2001), the stress related to orogastric 
administration is not overcome by this 
approach.  
Losartan is the first orally available angiotensin-
receptor antagonist without agonist properties 
(Sica et al., 2005). Following oral 
administration, losartan is rapidly absorbed, 
reaching maximum concentrations 1–2 hours 
post-administration (Sica et al., 2005). This 
drug is freely soluble in water and the reported 
bioavailability of losartan with a 50 mg tablet is 
32.6% (Sica et al., 2005). Dose administration 
with meals slows the rate of absorption and 
reduces the area under the plasma 
concentration-time curve (AUC) of losartan and 
its metabolite by approximately 10% (Simpson 
et al., 2000). Food can have a significant effect 
on drug absorption through several 
mechanisms, including delay in gastric 
emptying, increases in splanchnic blood flow, 
and changes in gastrointestinal secretions. 
These effects can alter tablet disintegration, 
drug dissolution, and drug transit through the 
gastrointestinal tract. Facing this, we decided to 
offer the vehicle- drug mixtures at the first 
hours of light in order to ensure that drug 
ingestion took place in a period with lower 
regular food intake. The vehicle amount used 
did not show to interfere with losartan 
bioavailability. 
According to Chan and colleagues, blood 
sampling site can strongly influence a 
substantial number of routinely tested blood 
parameters such as glucose, TC, TGL and HDL-
C and highlight the need to standardize 
sampling sites, especially when repeated blood 
sampling is required (Chan et al., 2013). To 
avoid this untoward experimental bias, only 
blood collected from the tail vein, in three 
different days, was used for measurement of 
blood glucose level and serum lipid profile. 
Accordingly, no differences were observed 
among groups of animals when comparing basal 
levels, i.e., prior to gavage or vehicle 
administration. Moreover, previous studies in 
the literature showed that there are no 
significant age-related changes in glycemia 
(Ribeiro et al., 2008) or lipid profiles (Uchida et 
al., 1978) throughout the time period of our 
study. Therefore, any changes observed 
between different vehicles are caused by 
differences in the vehicles composition and not 
age-related. 
Analysis of the results suggested that NUT, PB 
and SD are possible alternatives to gavage for 
chronic administration of losartan, since their 















increased water ingestion and were all fully 
eaten by the animals. However, taken into 
account the glycemia and lipid profile, SD 
proved to be the most suitable vehicle for the 
administration of this antihypertensive drug for 
two main reasons. First, the mean plasma 
concentration of losartan was significantly 
higher than the one attained when gavage was 
used. Secondly, SD didn’t induce any 
significant change on both glycaemia and lipid 
profile along the 28 days. On the other hand, the 
use of PB seems to be the least adequate due to 
the changes on the rat’s lipid profile associated 
with a 22% reduction of losartan plasmatic 
concentration. Even though the NUT group 
showed a glycemia reduction and increased 
total cholesterol, the losartan plasma 
concentration was 29% higher than gavage. 
These results could suggest that SD maximizes 
losartan absorption, leading to a higher 
bioavailability.  
In the present study, only Cmax concentrations 
were measured. It must be highlighted that 
losartan has an extensive first-pass effect with 
an oral bioavailability of 32%, showing that 
transcelullar intestinal absorption (P-
glycoprotein) and biotransformation (CYP3A4) 
clearly impacts its bioavailability and allows 
drug-nutrients interactions.  
In our opinion, the higher losartan 
concentrations attained in sugar dough group, 
compared with gavage, might be explained by 
three different mechanisms: an absorption 
delay, an increased absorption or a lower 
biotransformation. In fact, the high content of 
sugar present in sugar dough might increase the 
rate and/or extent of drug absorption since it has 
been described that sucrose fatty acid esters 
might improve the intestinal absorption of 
poorly absorbable drugs via a transcellular and a 
paracellular pathways (Yamamoto et al., 2014). 
Additionally, it has been suggested that high 
carbohydrate content may lower CYP450 
activity, particularly when high doses are 
administered (Sonawane et al., 1988). 
Substances that leave an unpleasant odor or 
flavor could discouraged voluntary ingestion 
and compromised the success of this method. 
Thus, we suggest that a pilot study should be 
carried out in order to ensure that all rats would 
successfully ingest the drug-vehicle mixture.  
 
CONCLUSION 
The results presented in this report support that 
the use of voluntary oral administration is a 
viable alternative for chronical administration of 
a fixed dose of losartan. In fact, our results 
suggest that SD is better suited than gavage for 
losartan oral daily administration. Furthermore, 
these data provide evidence that SD is the most 
adequate vehicle for losartan administration in 
rats in order to overcome the several 
shortcomings associated to gavage. The drug 
bioavailability was not reduced, suggesting that 
this approach is an effective oral dosing method 
for chronic administration of losartan. This 
refinement might be of interest for safety 
evaluation of drugs, particularly for those which 
toxic effects are associated with stress.   
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The general discussion is divided into five informal sections. The first one summarizes the relevant 
findings of both clinical and experimental studies. Then, we describe how the present work matches 
what is already known in the literature. So, it is inevitable that there is some content overlap between 
this section and chapter IV. The next sections outline the main limitations of our work and explore 
some future perspectives concerning the management of hypertension related to obstructive sleep 
apnea. Finally, we highlight the added value and the impact of the present work to the field. 
 
Summary of relevant findings 
 
CLINICAL STUDIES 
The prevalence of new diagnoses of OSA among those patients that attended the outpatient 
consultation of CHLN sleep unit was 78.2% (283/362).  
A considerable number of patients misclassified themselves as non-hypertensive (43.4%; 53/122), 
confirming the lack of validity of self-reported hypertension and emphasizing the importance of 
ABPM in the minimization of underestimated hypertension among patients suspected of OSA. These 
patients presented significantly higher values of ABPM variables and anthropometric characteristics, 
compared to truly non-hypertensive patients (69/122). The cut points that best discriminates these two 
groups of patients were 27 Kg/m
2
 and 39 cm for BMI and NC, respectively. BMI and NC were 
identified as independent predictors of hypertension misclassification in patients suspected of OSA. So 
briefly, these findings suggest that all undiagnosed hypertensive patients referred to a sleep disorder 
centre for symptoms suggesting OSA with a BMI and NC above 27 Kg/m
2
 and 39 cm, respectively 
(patients with a high odds of misclassifying themselves as non-hypertensive), should be screened for 
hypertension, through ABPM. 
Furthermore, according to current guidelines and to antihypertensive medication and/or 24h ABPM, 
63.9% (205/321) of the patients included were diagnosed with both OSA and hypertension. At 
baseline, 31 different antihypertensive regimens were found for OSA patients. Regarding BP control, 
57.5% of patients under antihypertensive medication had uncontrolled BP (95/155). BP control is 
independent of both the antihypertensive regimen and the number of antihypertensive drugs and the 
increase in the number of AHD does not appear to be relevant to  
control BP in patients with OSA. After CPAP adaptation, the lack of association between 
antihypertensive regimens and the number of antihypertensive drugs and BP control remained, but we 
found that CPAP significantly improved BP control in patients under no AH medication. This last 
finding suggest that an earlier diagnosis of hypertension related to OSA is more relevant than the AH 
regimen selection, probably because the available AH regimens are useful to prevent but not able to 
revert structural changes associated to hypertension. In a multivariable study, gender, OSA severity 
and 24h-BP profile were independently associated with uncontrolled BP after CPAP adaptation. 






OSA and a non-dipper BP profile, confirming the relevance of OSA in the pathophysiology of 
hypertension. In summary, these results provided evidence that this type of hypertension needs to be 
managed as a specific entity and that none of the currently available AH drugs, either alone or in 
association, have been shown to be particularly effective to control BP in patients with OSA, either 
before or after CPAP adaptation. 
 
EXPERIMENTAL STUDIES 
The main purpose of our first experimental study was to investigate the efficacy of an antihypertensive 
drug, with α1- and β-adrenoceptor antagonist activity, recognized antioxidants properties and other 
pleiotropic effects, in reversing hypertension induced by CIH. We hypothesized that CVD would be 
effective in reducing both BP and HR, since it is broadly consensual that sympathetic activation and 
oxidative stress plays a relevant role in the pathophysiology of HT related to OSA (Sunderram and 
Androulakis, 2012). We found that CIH significantly increased MAP, diastolic and systolic BP in our 
animal model, while no effect was observed for HR. In addition, despite the doses of 10, 30 and 50 
mg/Kg of CVD promoted a significant reduction in HR, no decrease in mean arterial pressure was 
observed. Interestingly, we also found that CIH changes the plasma concentrations of CVD 
enantiomers however, the lower ratios S/(R+S) of CVD enantiomers observed in rats exposed to CIH 
do not apparently explain the lack of efficacy of CVD in reversing this particular type of hypertension.  
At the same time, we also have tested nut paste (NUT), peanut butter (PB) and sugar dough (SD) as 
potential vehicles for chronic antihypertensive drugs administration to rats in order to surpass the 
stress induced by orogastric forced administration (gavage). Blood glucose levels were reduced by 
NUT administration and PB induces increased levels of triglycerides and total cholesterol. SD group 
presented a higher concentration of losartan when compared with gavage group, without changing 
lipid and glucose profiles. So, our results showed that the three vehicles are viable for daily single 
dose voluntary ingestion of losartan, from which SD proved to be the best alternative. In fact, our data 
suggest that SD is better suited than gavage for losartan oral daily administration and provide evidence 
that SD is the most adequate vehicle for losartan administration in rats in order to overcome the 
several shortcomings associated to gavage. Since drug bioavailability was not reduced, voluntary 
ingestion proved to be an effective method for a controlled daily dose administration, with a defined 
timetable, that is independent of handling and restraint procedures. Moreover, as gavage, this 
approach mimics the single-dose administration, widely used in human clinical practice.  
 
How the present work fits what is already known? 
 
CLINICAL STUDIES 


















in patients suspected of OSA. Although self-reported data is often more economically feasible and 
readily available compared to BP monitoring, our findings show that these reports may not provide 
truthful information. Such inaccuracy will surely lead to an underestimation of hypertension 
prevalence if ABPM recordings are not taken into account. In OSA patients, this imprecision may 
have serious consequences since therapeutic decision-making (e.g. CPAP application) is based, in part, 
on the presence of cardiovascular disease, namely hypertension. For this reason, the validity of self-
reported hypertension is highly questionable and should not replace any type of BP monitoring. 
However, the conclusions regarding this issue are far from unanimous and the number of variables that 
have been found to be associated with the accuracy of self-reported high BP is considerable (Mentz et 
al., 2012).  
Twenty-four-hour ABPM data showed that the frequency of systolic or diastolic non-dipping pattern is 
significant in misclassified non-hypertensive (MNH) patients. It is known that the lack of pressure fall 
at night, one of the major features of the 24-h BP profile in OSA patients (Hla et al., 2008), is itself 
associated with a poor cardiovascular prognosis (Dolan et al., 2009). Furthermore, Loredo et al. 
(2004) showed that an absence of nocturnal dip in BP correlated inversely with the indices of sleep 
fragmentation (Loredo et al., 2004), and changes on sleep architecture may be responsible for daytime 
hypersomnolence, the prime feature of OSA (Baguet et al., 2009). Thus, clinical observation of 
dipping or non-dipping profiles is extremely relevant, mainly for patients clinically suspected of 
having OSA.  
ABPM also revealed that most MNH patients presented isolated nighttime HT or both daytime and 
night-time hypertension. In a study performed by Burr et al. (2006), night-time BP was identified as 
the strongest predictor of cardiovascular mortality  (Burr et al., 2006). Thus, the early recognition of 
nocturnal features, mainly recognized through the use of ABPM, is unquestionably relevant to 
improve the long-term outcomes of OSA patients.  
Currently, BP measured in a clinical setting is considered the reference method for the general 
population, including patients with OSA (Baguet et al., 2009). Nevertheless, office BP measurement is 
affected by major problems such as the white-coat effect, observer bias, limited reproducibility and the 
intrinsic inaccuracy of the auscultatory technique. Moreover, this method is unable to collect 
information on physiological BP variability and nocturnal BP (Parati et al., 2012). Consequently, 
office readings frequently lead to both overestimation and underestimation of hypertension, since BP 
could be apparently normal in the office but elevated outside the office, especially during the night-
time period (Parati et al., 2012) or vice versa. Home BP monitoring (HBPM) has been proposed as an 
alternative to office BP measurements or ABPM. Like ABPM, this method allows the registration of 
BP values during a patient’s normal activities, avoiding the white-coat effect; however such recordings 
are limited to short periods of time. Additionally, HBPM is unable to provide detailed information on 
BP during night-time, precisely when OSA episodes occur. These limitations are overcome when 






possibility of collecting a large number of BP measurements, since real BP is reflected more 
accurately by repeated measurements. In addition, ABPM allows the evaluation of BP profile over 24 
hours and therefore can detect the variability in circadian rhythms and identify patients with abnormal 
patterns of nocturnal BP (Parati et al., 2012). Furthermore, the findings of a previous study have 
shown that the use of 24-h ABPM allowed the diagnosis of twice as much hypertension than did 
clinical measurement and therefore ABPM might be of particular significance in the hypertension 
diagnosis of OSA patients (Baguet et al., 2005). Moreover, there is strong evidence that the predictive 
value for major cardiovascular events is better with ABPM than with clinical measurement (Burr et 
al., 2008). Another study supports the idea that ABPM should be mandatory for the routine diagnosis 
of hypertension for those at risk for masked hypertension (Phillips et al., 2012). This recognized 
cardiovascular entity is closely associated with OSA and adverse outcomes (Baguet et al., 2008).  In 
brief, due to the specific features of OSA-related hypertension, ABPM seems to be the preferred 
method for BP measurement in patients suspected of having OSA.  
Although ABPM should ideally be performed in all patients with suspected OSA, this type of BP 
measurement is time- and labour-intensive as well as an expensive diagnostic tool and consequently is 
not routinely used. Given these limitations, we tried to find an alternative tool that would allow the 
identification of patients that misclassify themselves as non-hypertensive. Since anthropometric 
measurements (BMI, NC and WC) have been shown to predict OSA (Davies et al., 1992; Proimos et 
al., 2012) and other cardiovascular diseases (Preis et al., 2010; Vallianou et al., 2013), we decided to 
investigate the ability of these features to predict the misclassification of hypertension.  
Our results showed that patients with undiagnosed hypertension and a BMI above 27 Kg/m
2
 and an 
NC higher than 39 cm had three-fold and two-fold higher odds, respectively, of misclassifying 
themselves as non-hypertensive than patients with a lower BMI or AHI. The optimal BMI cut-off 
point that was found to predict the misclassification of hypertension was lower than the recommended 
cut-off point to predict OSA (30 Kg/m
2
) (Friedman et al., 1999) and in the range of that recommended 
for global cardiovascular risk (25–29.9 Kg/m
2
) (Expert Panel on the Identification, Evaluation, and 
Treatment of Overweight in Adults, 1998). Concerning NC, the same cut-off point was found at 39 cm 
for both genders, and this value was similar to the ones described for OSA prediction and 
cardiovascular disease risk (Preis et al., 2010; Soylu et al., 2012).  
Additionally, we performed a real life study in order to investigate a hypothetical association between 
ongoing antihypertensive regimens and BP control rates in patients with OSA, before and after CPAP 
adaptation. 
In general, our sample matches a typical population of OSA patients. Actually, the high prevalence of 
new diagnoses of OSA, indicating that patients are being well referred, as well as the distribution of 
OSA severity found in CHLN sleep consultation, is similar to those reported by other authors 


















found are in line with those that have been previously described in the literature (Friedman et al., 
1999). Additionally, these patients tend to present a higher number of comorbidities, mostly a high 
prevalence of hypertension, when compared to non-OSA patients (Fletcher et al., 1985; Lavie et al., 
2000; Marin et al., 2012). The prevalence of hypertension among patients with OSA is estimated to be 
around 50% (Calhoun, 2010). Our study revealed a higher prevalence of hypertension in OSA 
patients, probably due to the use of ABPM for the diagnosis of this disease. In addition to the high 
prevalence of hypertension, ABPM data revealed that, regarding 24h-BP profile, OSA patients showed 
a non-dipper systolic profile, which has already been reported (Davies et al., 2000; Hla et al., 2008). 
The high prevalence of uncontrolled BP (70.7%; 145/205) and underdiagnosed hypertension (24.4%; 
50/205) among these patients has also been similarly reported (Börgel et al., 2000; Baguet et al., 2009; 
Lavie and Hoffstein, 2001). In a past study that included 59 patients who were not known to be 
hypertensive, hypertension was found in 42% of patients using clinical measurement and 76% using 
ABPM (Baguet et al., 2005). 
As far as we know, this is the first study to describe the pattern of AH medication in OSA patients. 
The high number of different AH regimens found (n=31) is symptomatic of the difficulty in 
controlling BP in these patients, and of the lack of consensus and guidelines in this matter, and also 
underlines the importance of the main question addressed in the present work. The number of patients 
with regimens that included two or more AH drugs is impressive, and emphasises the difficulty in 
achieving BP control and the close relationship between OSA and resistant hypertension (Pedrosa et 
al., 2011; Pimenta et al., 2013).  
Despite the huge number of studies involving OSA patients, only a few have investigated the efficacy 
of different AHD and, in general, are individual drug studies. Most of them have focused on 
evaluating the lowering-BP effect of AHD and did not assess whether this decrease leads to an 
augmentation of the number of controlled hypertensive patients. Moreover, the validity of some of 
these results is limited due to the very low casuistry of the samples and by the incapacity to identify 
the chronicity of OSA and hypertension in each patient. This can interfere with the drug efficacy, 
assuming that the mechanisms involved in hypertension induced by OSA might be time-dependent. 
For instance, it has been proposed that IH is able to induce a renal hormetic response, i.e.: short-term 
IH induces a protective response against the renal oxidative damage, but long-term IH exposure 
induces a damage effect on the kidney (Sun et al., 2013). Nevertheless, their findings allow some 
conclusions. First, drugs that block the sympathetic stimulation of β1-adrenergic receptors seem to be 
the most effective AHD, since the β1-specific antagonist atenolol was the most effective AHD tested 
(in comparison with isradipine, hydrochlorothiazide, spirapril, amlodipine, enalapril and losartan) in 
two comparative studies (Kraiczi et al., 2000; Pelttari et al., 1998), and nebivolol (Heitmann et al., 
2010) was also effective in patients with OSA. On the other hand, the angiotensin-converting enzyme 






significantly as beta-blockers (Kraiczi et al., 2000; Mayer et al., 1990). The angiotensin II receptor 
blocker valsartan had a similar anti-hypertensive effect to nebivolol (Heitmann et al., 2010). 
Spironolactone (competitive aldosterone antagonist) has been remarkably effective in treating resistant 
hypertension (Pimenta et al., 2008); however, its effectiveness has not been evaluated in patients with 
OSA to date. Moreover, since only severe OSA has been associated with increased angiotensin II and 
aldosterone (moderate OSA was usually associated with normal levels of these agonists), rennin-
angotensin–aldosterone (RAA) blockers had a modest anti-hypertensive effect in mild/moderate OSA 
(Ziegler et al., 2011). Finally, thiazide diuretics have not been very effective in OSA patients without 
fluid retention (Kraiczi et al., 2000). Also, important data are missing, e.g. how many OSA patients 
are controlled under monotherapy with beta-blockers (BB), angiotensin-converting enzyme inhibitors 
(ACEi) and angiotensin II receptor blockers (ARB’s)? How many OSA patients remained 
uncontrolled despite the use of two or more AH drugs? What should the second drug added to BB or 
RAA blockers be? How do individual AHD behave when included in an AH regimen? In addition, the 
impact of these studies in clinical practice is unknown, as epidemiological studies designed to 
investigate the AH medication profile in OSA patients are missing. In addition, the more recent 
recommendations for the management of patients with OSA and hypertension are inconclusive 
regarding the use of AHD and recognise the lack of strong evidence for the establishment of a first-
line AH regimen for these patients (Parati et al., 2013). Other authors sustain the idea that since there 
is no clear evidence for preference for a specific class of AHD, the selection should primarily be 
guided by the patient’s cardiometabolic profile and associated comorbidities (e.g. obesity, metabolic 
syndrome, diabetes mellitus and cardiovascular diseases) (Tsioufis et al., 2010). Moreover, these 
authors recommend that, due to the lack of relevant trials focused on the use of associations of AHD in 
OSA patients, the choice should rely on current hypertension guidelines and the adverse effects of 
AHD need to be contemplated as well (Tsioufis et al., 2010). Our study was designed assuming that 
clinicians based their therapeutic decisions on these assumptions. 
Surprisingly, in our population, the most commonly prescribed AHD were diuretics and RAA 
blockers. However, the number of OSA patients using these AHD with uncontrolled BP was 
significantly higher. In fact, 61.2% (30/49) and 61.3% (65/106) of patients under a monotherapy and 
polytherapy regimens, respectively, were uncontrolled. This evidence suggests that the increase in the 
number of antihypertensive drugs is not apparently relevant in OSA patients. If the low efficacy of 
polytherapy in controlling BP was linked to OSA severity, the difference between the efficacy of 
monotherapy and polytherapy in severe patients would be higher in the subgroup of severe patients 
with BMI ≥30 kg/m
2
, which was not the case.  
On the other hand, before CPAP application, no associations were found between AH regimens and 
number of AHD and BP control. These findings suggest that none of the current AHD, either alone or 


















AHD included in a specific regimen seems not to be relevant to the control of BP in patients with 
OSA.  
In the study performed after CPAP adaptation, we decided to include only patients who were adherent 
with CPAP therapy for at least 4 hours per night on average, as this is a threshold that is often used to 
define minimum acceptable CPAP use. According to the suggestion of a past study, patients in these 
conditions of CPAP use had an appreciable decrease in the incidence of hypertension (Barbé et al., 
2012). Additionally, the beneficial effect of nasal CPAP therapy on BP seems to be closely associated 
with the presence of untreated or resistant hypertension, with OSA severity (more pronounced in 
severe OSA) and with patient compliance to CPAP (Baguet et al., 2009). Therefore, it would be 
expected that the combined effect of CPAP and AHD on BP control was more pronounced than the 
isolated effect of AHD. However, the lack of association between AH regimens and BP control 
remained after CPAP adaptation, which suggests the slight effect of CPAP in controlling BP. These 
findings are consistent with the results of several past studies (Alajmi et al., 2007; Calhoun, 2010; 
Ziegler et al., 2011). Börgel et al. (2004) revealed that the absence of antihypertensive drugs is an 
independent predictor for the lowering effect of CPAP therapy on systolic and diastolic BP (Börgel et 
al., 2004). Furthermore, Dernaika et al. (2009) reported that the effects of CPAP therapy on BP 
regulation appear to be less evident in hypertensive patients under a drug regimen (Dernaika et al., 
2009). In our case, eight of the sixteen patients that were on no AH medication switched from 
uncontrolled to controlled after CPAP adaptation. Both results suggest that an earlier diagnosis of 
hypertension related to OSA is more important than the AH regimen selection. 
Moreover, the effect of CPAP on lowering BP was clearly more significant in nocturnal BP, mainly in 
nocturnal SBP. Anyway, however important, this effect was not enough to reach the intended purpose 
for these patients, since it did not allow the reclassification from uncontrolled to controlled BP. In fact, 
despite some authors (Somers et al., 1995) having reported the beneficial effect of CPAP in preventing 
the bursts of sympathetic activity present at the end of each respiratory event, in our case, the 
hypothetical reduction in sympathetic activity was not associated with an appreciable decrease in 
diurnal BP. Consequently, in patients with OSA, more important than studying the effect of CPAP 
alone on BP reduction is evaluating the combined effect of CPAP and AH medication. The study 
performed by Dernaika et al. (2009) evaluated the long-term effects of CPAP therapy on BP in 
patients with OSA and resistant hypertension (Dernaika et al., 2009). The results revealed that CPAP 
permitted the de-escalation of antihypertensive treatment in 71% of patients with resistant 
hypertension, but did not significantly alter the antihypertensive regimen in the controlled group. 
However, in our opinion, the study of Dernaika et al. (Dernaika et al., 2009) presents two main 
drawbacks. First, the study did not characterise the different AH associations (it only referred to the 
number of patients that were undergoing a specific AHD class) and second, it did not evaluate the 






(2004), which was performed to evaluate the interaction between BP-lowering effects of CPAP and 
AHD (Börgel et al., 2004). Additionally, Pépin et al. (2010) designed a study to assess the respective 
efficacy of CPAP and valsartan (ARBs) in reducing BP hypertensive patients with OSA that had never 
been treated for either condition and speculated that the combined effect of both therapies on BP 
control might be additive in patients in whom hypertension is still uncontrolled by specific AH drugs 
(Pépin et al., 2010). However, they did not quantify the effect of the association; this study showed 
that valsartan induced a four-fold higher decrease in mean 24h BP than CPAP (Pépin et al., 2010). 
Thus, the results of our pilot study revealed, for the first time, that none of the current AH regimens 
are superior to the others, either alone or when combined with CPAP, in promoting BP control, and 
underlines that new AHD drugs for this particular population are definitely needed.  
Finally, gender, OSA severity and 24 h BP profile at baseline were identified as independent 
predictors of BP control after CPAP adaptation. Our results show that male patients with an AHI 
higher than 15 events/hour of sleep and patients with a non-dipper profile had a three-fold increased 
odds of presenting uncontrolled BP after CPAP adaption. Although Robinson et al. (2008) did not 
identify OSA severity as a predictor of the fall in 24h mean BP with CPAP treatment; the impact of 
this decrease in BP control remains unknown (Robinson et al., 2008). In a more recent small study, 
male gender, Epworth sleepiness scale, BMI, smoking, alcohol use and baseline 24h mean BP were 
identified as independent predictors of a decrease in 24h mean BP after CPAP adaptation (Yorgun et 
al., 2013). The apparent controversy of whether or not OSA severity is a predictor of the beneficial 
effect of CPAP in lowering BP could be explained by the differences in the outcome variable 
analysed. In our perspective, uncontrolled BP (present study) is a stronger and more relevant clinical 
outcome than the decrease in 24h-mean BP values.  
 
EXPERIMENTAL STUDIES 
The animal model used to investigate the efficacy of carvedilol in reversing hypertension induced by 
CIH mimics the intermittent hypoxic episodes that occur chronically in patients suffering from OSA. 
Obesity is a major cause of airway obstruction in these patients but it is also postulated that OSA can 
trigger reflex mechanisms that favour the development of metabolic syndrome in these patients 
(Mannarino et al., 2012). Our model allows us to separate the mechanical component of obstruction 
from the effect of intermittent hypoxia itself.  Several authors have reported weight loss in CIH-
exposed rats when compared with control rats (Silva and Schreihofer et al., 2011; Soukhova-O’Hare et 
al., 2008; Totoson et al., 2013; Zoccal et al., 2008). Singh and Sevamurthy (1993) suggested that the 
weight loss observed after CIH exposure is due to a reduction in food intake (Singh and Sevamurthy, 
1993). More recently, other authors measured daily food intake and reported that the reduced body 
weight gain in CIH rats was not associated with reduced food consumption but related to a 


















the weight loss, our results showed, for the first time, that CIH induces a deviation in the weight 
changes observed in age-matched Wistar rats, leading to a significant retardation of body growth. This 
finding suggests that intermittent hypoxia by itself does not contribute to maintaining an overweight 
status in obese patients with OSA. The effect of CIH on body weight deserves further study in obese 
animals. 
CIH is now established as the dominant model of sleep apnea. Generally, this model makes use of 
specific ventilated chambers in which the animals are housed and cyclically exposed either to 
normoxia/hypoxia or room air to mimic the most relevant consequences of OSA (Diogo and Monteiro, 
2014). In our protocol, rats were housed in cages placed inside medium A-chambers that were large 
enough to prevent air jet stress-induced changes in cardiovascular parameters and also to allow the rats 
to be housed in groups during the extended period of CIH exposure in order to decrease stress levels. 
Our paradigm of CIH in rats roughly corresponds to a sleep apnea lasting for more than two years in 
humans, which matches the time of OSA diagnosis in clinical practice. In humans, an apnea-hypopnea 
index (AHI) bellow 5 events/hour of sleep is under the physiological range (Berry et al., 2012). A 
paradigm of 5.6 cycles/hour of exposure to CIH in rats, even with correction for higher metabolic 
activity in animals (Germack et al., 2002), is below the AHI cut-offs for moderate OSA (>15 
events/hour of sleep). 
Animal models of CIH diverge in some aspects, such as the animal species involved, the severity of 
hypoxia, the number of hypoxic episodes per hour of sleep, the number of days of hypoxic exposure 
(exposure duration), and CO2 manipulation (for a review see Diogo and Monteiro, 2014). Anyway 
they are unanimous in reporting the development of mild hypertension (Allahdadi et al., 2005; Bathina 
et al., 2013; Campen et al., 2005; Chen et al., 2005; Dyavanapalli et al., 2014; Fletcher et al., 2000; 
Kanagy et al., 2001; Knight et al., 2011; Lai et al., 2006; Lin et al., 2007; Liu et al., 2013; Sharpe et 
al., 2013; Silva and Schreihofer, 2011; Schulz et al., 2014; Soukhova-O'Hare et al., 2008; Tahawi et 
al., 2001; Totoson et al., 2013; Zoccal et al., 2009). In agreement with these reports, CIH significantly 
increased mean arterial pressure, diastolic and systolic BP in our animal model, highlighting once 
again the major role of CIH in the development of hypertension.  
The effects of CIH on HR result from a balance between sympathetic nervous system overactivation 
and baroreflex control. Our results are in line with previous studies that described no changes in HR 
(Dyavanapalli et al., 2014; Knight et al., 2010; Soukhova-O’Hare et al., 2008; Yamamoto et al., 2013; 
Zoccal et al., 2009) and match the lower rate of variability that has been described for patients with 
OSA (Trimer et al., 2014).  Apparently, CIH does not impair the baroreflex control of HR. Increases 
in HR were only observed in a study performed with anesthetised rats exposed to CIH for 90 days (Lin 
et al., 2007).  Additionally, in humans, baroreflex control of HR was reported to be lower in obese 
than non-obese awake humans and improved after weight reduction (Grassi et al., 1998). Since our 






After validation of our rat model of hypertension related to OSA, we decided to test CVD, since 
sympathetic activation and oxidative stress play an important role in the pathophysiology of 
hypertension related to OSA. Furthermore, beta-blockers have not yet been tested in this animal model 
and in limited clinical studies they proved to be helpful to reduce BP in OSA patients. Studies 
investigating the antihypertensive effect of drugs on animal models are scarce and drugs have been 
used solely as pharmacological tools to address physiological mechanisms (for a review see, for 
example, Diogo and Monteiro, 2014). The experiments evaluate prevention but not the effectiveness 
of treatment. Other limitations of the pharmacological approaches included in these works are the 
absence of dose-response curves and comparison of the effectiveness of different drugs in the same 
animal model. Aware of these drawbacks, our study was planned to first induce hypertension and then 
evaluate the efficacy of cumulative doses of CVD because the translation of the results obtained with 
simultaneous induction of hypertension and drug administration to humans is not relevant.  
The doses of CVD tested (10, 30 and 50 mg/kg/day) were selected based on previous studies 
performed in different models of hypertension (Bertera et al., 2012a; Bertera et al., 2012b; Chen et al., 
2013; Di Verniero et al., 2010; Rodriguez-Perez et al., 1997). The lack of efficacy of CVD cannot be 
attributed to the doses because they were effective in reducing HR in our model, in reducing BP in 
other models of HT, and are higher than the doses administered to humans (12.5-50 mg). 
Carvedilol is a lipophilic third generation β-blocking agent and it is assumed that it easily crosses the 
blood-brain barrier. Several advantages have been claimed for third generation agents over the 
traditional β-blockers. First, drugs such as CVD exhibit a broad range of adrenergic inhibition, 
blocking postsynaptic β1, β2 and α1 receptors and presynaptic β2 receptors (DiNicolantonio and 
Hackam, 2012). Secondly, unlike traditional agents, CVD promotes vasodilatation through different 
mechanisms, which translates into a more favourable hemodynamic profile compared to non-
vasodilating beta-blockers (Rath et al., 2012). In addition to its alpha-adrenergic receptor blocking 
properties, it has been suggested that CVD-induced increased nitric oxide (NO) plasma levels (Afonso 
et al., 2006; Vanhoutte and Gao, 2013) and antioxidant properties (Rath et al., 2012; Feuerstein and 
Ruffolo, 1995) could also contribute to the vasorelaxation and subsequent reduction in vascular 
resistance evoked by CVD. CVD is also noted as a suppressor of the synthesis of endothelin-1 (ET-1) 
(Saijonmaa et al., 1997), as a drug with antiproliferative actions (Chen et al., 2001) and with 
beneficial effects on vascular and cardiac structural remodelling (Bakris, 2009; Chen et al., 2013), 
endothelial dysfunction (Feuerstein and Ruffolo, 1995) and progression of target organ damage 
(Bakris, 2009). Finally, CVD also has a calcium channel blocking effect by inhibiting voltage-
dependent L-type Ca2+ in vascular smooth muscle cells (Nakajima et al., 2003), inhibits the rennin-
angiotensin system (Cheng et al., 2001) by blocking β1 receptors and enhances the plasma 
concentration of atrial natriuretic peptide (Cheng et al., 2001). 


















(for a review see Diogo & Monteiro, 2014), the lack of efficacy of carvedilol in reversing hypertension 
induced by CIH was unexpected.  
The finding that the three doses of CVD promoted a significant decrease in HR confirmed that the lack 
of antihypertensive efficacy couldn’t be attributed to the absence of beta-blocking activity.  
Another explanation could be that CIH might change the pharmacokinetic profile of CVD, 
compromising their antihypertensive efficacy. Carvedilol is clinically administered as a racemic 
mixture in which nonselective beta-adrenoreceptor blocking activity is present in the S-(-) enantiomer 
and alpha-adrenergic blocking activity is present in both R-(+) and S-(-) enantiomers at equal potency 
(Peccinini et al., 2008). A decrease in HR without no effects on BP might thus be explained by a 
selective increase in the levels of S-(-)-CVD. There is some evidence that hypoxic conditions can 
broadly change drug clearance (Chen et al., 2013; Gao et al., 2013; Vij et al., 2012) or drug effects 
(Nunes et al., 2010). 
In the present work, we found, for the first time, that CIH changes CVD pharmacokinetics by 
mechanisms that deserve further exploration, however, the lower ratio S/(R+S) observed in rats 
submitted to CIH could not easily explain the lack of hypotensive effects. 
Another putative explanation for the lack of efficacy of carvedilol is that the blockade of the 
sympathetic nervous system, along with all the pleiotropic properties of CVD, might not be enough to 
reverse hypertension induced by CIH. From a broad perspective, we can speculate that the majority of 
CVD effects were produced in experiments that planned to address only one variable involved in the 
pathophysiology of hypertension, and some in acute conditions. Few studies of hypertension with the 
chronic administration of CVD have been performed in rat models. In a model of hypertension 
induced by unilateral renal artery narrowing (Chen et al., 2013), CVD (20 mg/kg/day) administered by 
gavage for 8 weeks, causes a significant and sustained reduction of SBP apparent in the first two 
weeks of treatment, but it was not able to completely reverse the hypertensive effect of the surgical 
procedure. In hypertension induced by renal ablation (5/6), only rats receiving doses of 10 and 20 
mg/Kg/day of CVD (but not of 5 mg/Kg/day) exhibited significant decreases in SBP apparent at week 
five of treatment (Rodriguez-Perez et al., 1997). These findings, together with the lack of efficacy of 
CVD found in our animal model, support the theory that mechanisms other than this type of renal 
damage are involved in hypertension induced by CIH.  
Finally, it has been reported that CIH leads to an increased stiffness and reduced vessel wall 
distensibility (Phillips et al., 2006) and induces significant renal inflammation and fibrosis (Sun et al., 
2013). We can therefore postulate that CIH induces structural changes in vessels, renal tubules, etc., 
that are not targeted by CVD.  
CVD was daily administered by gavage, since in the study that we simultaneously conducted in order 
to investigate an alternative method to gavage (oral voluntary administration) for chronic 






mixture of carvedilol with the three vehicles tested. This behaviour was probably due to the fact that 
CVD may leave a residual unpleasant odour or flavour that discourages voluntary consumption. The 
time between delivery and small amounts consumption was always superior to 1 hour, and even when 
the vehicle-CVD mixtures were left overnight the animals failed to completely eat them. Despite 
gavage is the most widely used method for the precise oral dosing of rodents, it can elicit a stress 
response, and it has been shown that any source of external stress on rodents can significantly increase 
heart rate and blood pressure, effects that persist for around 3 hours (Brown et al., 2000; Bonnichsen 
et al., 2005; Kramer et al., 2000; Balcombe et al., 2004). Aware of this fact we administered CVD 
only after monitoring BP parameters, and the measurements were made on the day after administration 
and before exposure to IH conditions.  
In the study designed to test the viability of oral voluntary administration for long-term delivery of 
CVD and losartan (angiotensin II receptor blocker), male Wistar rats, aged 2-3 months and housed 
individually were used to avoid hypothetical effects of estrogen on blood lipids (Ganong, 2002). 
Although Sharp and colleagues recommend that animals should be ideally housed in group to decrease 
the stress levels (Sharp et al., 2002), in our study, animals were single-housed during all protocol in 
order to ensure correct dosage and to confirm vehicle or vehicle plus drug complete ingestion. The 
palatability of NUT, PB and SD showed to be attractive for the animals, since all animals ingested 
them almost immediately and completely. Furthermore, the consistency of these vehicles facilitates the 
weighing and the mixing of powder, thereby ensuring the accuracy of the drug dose. The amount of 
vehicle given to the animals (0.5g) was shown to be enough to hold the weighed drug, whereas still 
appeared attractive for the animals and not too large to cause significant metabolic changes. Offering 
the mixture in a Petri dish placed vertically inside the cage proved to be an effective solution to ensure 
complete ingestion. Before it has been reported that placing NUT in a container on the floor of the 
cage is not recommended, since neophobic animals tend to burry the novel item, and thus mix the 
vehicle with the bedding material (Abelson et al., 2012).  
Although some authors have recommended a period of up to five days for animal acclimatization to 
the vehicles (Isaksson et al., 2011), in our study, two days proved to be enough time to ensure that 
there was no neophobic behaviour after that. In order to reduce the stress levels associated with 
handling and restrained we decided to use a one-week period of acclimatization in the gavage group. 
Oral gavage has been recently refined from metal gavage needle to a sterile flexible feeding tube 
which reduce the risk of trauma, perforation and cross contamination (Morton et al., 2001). However, 
the stress related to orogastric administration is not overcome by this approach.  
Unlike what it was observed for carvedilol, all rats successfully ingested losartan mixed with either 



















Losartan is the first orally available angiotensin-receptor antagonist without agonist properties (Sica et 
al., 2005). Following oral administration, losartan is rapidly absorbed, reaching maximum 
concentrations 1–2 hours post-administration (Sica et al., 2005).  This drug is freely soluble in water 
and the reported bioavailability of losartan with a 50 mg tablet is 32.6% (Sica et al., 2005). Dose 
administration with meals slows the rate of absorption and reduces the area under the plasma 
concentration-time curve (AUC) of losartan and its metabolite by approximately 10% (Simpson and 
McClellan, 2000). Food can have a significant effect on drug absorption through several mechanisms, 
including delay in gastric emptying, increases in splanchnic blood flow, and changes in 
gastrointestinal secretions. These effects can alter tablet disintegration, drug dissolution, and drug 
transit through the gastrointestinal tract. Facing this, we decided to offer the vehicle- drug mixtures at 
the first hours of light in order to ensure that drug ingestion took place in a period with lower regular 
food intake. The vehicle amount used did not show to interfere with losartan bioavailability. 
According to Chan et al. (2012), blood sampling site can strongly influence a substantial number of 
routinely tested blood parameters such as glucose, TC, TGL and HDL-C and highlight the need to 
standardize sampling sites, especially when repeated blood sampling is required (Chan et al., 2012). 
To avoid this untoward experimental bias, only blood collected from the tail vein, in three different 
days, was used for measurement of blood glucose level and serum lipid profile. Accordingly, no 
differences were observed among groups of animals when comparing basal levels, i.e., prior to gavage 
or vehicle administration. Moreover, previous studies in the literature showed that there are no 
significant age-related changes in glycemia (Ribeiro et al., 2008) or lipid profiles (Uchida et al., 1978) 
throughout the time period of our study. Therefore, any changes observed between different vehicles 
are caused by differences in the vehicles composition and not age-related. 
Analysis of the results suggested that NUT, PB and SD are possible alternatives to gavage for chronic 
administration of losartan, since their ingestion was not associated with weight gain or increased water 
ingestion and were all fully eaten by the animals. However, taken into account the glycaemia and lipid 
profile, SD proved to be the most suitable vehicle for the administration of this antihypertensive drug 
for two main reasons. First, the mean plasma concentration of losartan was significantly higher than 
the one attained when gavage was used. Secondly, SD didn’t induce any significant change on both 
glycaemia and lipid profile along the 28 days. On the other hand, the use of PB seems to be the least 
adequate due to the changes on the rat’s lipid profile associated with a 22% reduction of losartan 
plasmatic concentration. Even though the NUT group showed a glycaemia reduction and increased 
total cholesterol, the losartan plasma concentration was 29% higher than gavage. These results could 
suggest that SD maximizes losartan absorption, leading to a higher bioavailability.  
In the present study, only Cmax concentrations were measured. It must be highlighted that losartan has 






absorption (P-glycoprotein) and biotransformation (CYP3A4) clearly impacts its bioavailability and 
allows drug-nutrients interactions.  
In our opinion, the higher losartan concentrations attained in sugar dough group, compared with 
gavage, might be explained by three different mechanisms: an absorption delay, an increased 
absorption or a lower biotransformation. In fact, the high content of sugar present in sugar dough 
might increase the rate and/or extent of drug absorption since it has been described that sucrose fatty 
acid esters might improve the intestinal absorption of poorly absorbable drugs via a transcellular and a 
paracellular pathways (Yamamoto et al., 2014). Additionally, it has been suggested that high 
carbohydrate content may lower CYP450 activity, particularly when high doses are administered 
(Sonawane et al., 1988). 
Substances that leave an unpleasant odour or flavour could discouraged voluntary ingestion and 
compromised the success of this method. Thus, we suggest that a pilot study should be carried out in 
order to ensure that all rats would successfully ingest the drug-vehicle mixture.  
What are the main limitations? 
 
CLINICAL STUDIES 
We are conscious about some limitations of our clinical studies. Our sample should ideally be larger 
and provided from more than a single centre, in order to avoid referral bias. However, our centre could 
be considered representative of the general OSA population because we found similar characteristics 
to those described in the literature. Another limitation of the study was the low casuistry of women in 
our sample. However, this unbalance was expected since OSA is more prevalent among males. 
Anyway, gender was considered during the statistical analysis. The huge variability in AHD regimen 
found in the present work together with the sample size, does not allow us to identify the best AHD 
regimen for these patients. Additionally, the results of this exploratory study strongly suggest that 
none of the available AHD are clearly able to achieve adequate BP control in OSA patients. Therefore, 
the esults of a much larger epidemiological study could be also frustrating and, in our opinion, the 
search for new therapeutic strategies will be more useful.  
Additionally, despite the use of a “Brown-Bag” medication review in order to record patients ongoing 
medication profile, data regarding adherence to AH drug treatment (before and after inclusion) were 
checked only based on self-reported adherence and were not confirmed by a “pill-count” method or 
other. However, this variable does not invalidate the study, since it is common to all patients. Since the 
differences between efficacies within each class are not well documented, the evaluation of each drug 
per se was not considered relevant. Therefore, the analysis was conducted taking into account the 
regimens of AH drugs with higher prevalence. Nevertheless, the added value of the present study is 
the evaluation of the efficacy of AH regimens commonly used in these patients instead of analysing 


















for innovative AHD to treat OSA patients. 
 
EXPERIMENTAL STUDIES 
Regarding the experimental studies, one of the limitations that can be pointed out is the different 
number of animals that was allocated to each experimental group. In the first study, due to the limited 
number of age-matched animals available, we decided to allocate more animals to the group of CVD 
50 mg/kg (higher dose tested). The major arguments for this decision were: first, this group would be 
used for the pharmacokinetic study and, second, we had already noted the limited impact of the lower 
doses of CVD on BP. Furthermore, the use of only one antihypertensive drug, the absence, at the 
moment, of mechanistic data (we collected tissue samples for further analysis) to explain the negative 
results, along with the lack of catecholamines quantification and assessment of sympathetic activity 
can also be pointed as additional limitations. 
In the second study, once again, the number of animals dictated that one of the groups would have one 
less animal. Considering that the most studied and more invasive method is the gavage, we opted to 
allow this group to have only 5 animals. Nevertheless, in both studies, the standard error of the mean 
(SEM) was acceptably low in all groups, suggesting that the number of animals was also acceptable 
and statistical analysis would not be compromised. For these reasons and in light of the 3Rs approach, 
it is our opinion that additional animals would not be required to draw conclusions from both studies. 
Additionally, another drawback of the second study may have been the evaluation of single-point drug 
concentrations (Cmax) instead of using the area under the curve (AUC) approach. However, our 
HPLC method was validated for a volume of 200 μL of plasma, analyzed in duplicate. Thus tail 
puncture sampling for AUC achievement at the time point of 7 days would require the collection of at 
least 1 mL of blood that would represent approximately 6% of the total blood volume. Since such a 
volume would take one week to be recovered, we decided to perform only losartan quantification as a 
terminal single-point measure. The main argument for this decision was a simple attempt to not 
interfere with the losartan steady state and with major animal volemia during the experiments. 
What is still unknown and should be addressed? 
Theoretically, since OSA has been identified as an independent risk factor for hypertension, the first 
approach to manage HT related to OSA should be control the underlying condition i.e. avoid the 
repetitive episodes of apnea or hypopnea caused by an obstructed or collapsed upper airway during 
sleep. However, normalize the apnea-hypopnea index (AHI) is not an easy task for two main reasons. 
First, the cause of upper-airway collapse, as well as the etiology of OSA, is multifactorial. In fact, an 
appreciable number of factors is known to be linked to upper-airway collapse (e.g. reduced airway 
dilator muscle activity during sleep, upper-airway anatomy, obesity, decreased end-expiratory lung 
volume, ventilatory control instability, and rostral fluid shifts). Secondly, to date, the results of clinical 






nicotinic agents) in treating the obstruction associated to OSA have been disappointing (Veasey et al., 
2006). These pharmacological agents have not been successful in reducing significantly the AHI in 
patients with OSA (Veasey et al., 2006). Furthermore, although CPAP is considered the gold standard 
treatment for OSA due to its ability in providing pneumatic splitting of the upper airway and 
effectiveness in reducing the apnea-hypopnea index, CPAP effect seems to be not enough to sustain by 
itself BP control in patients with OSA. Besides that, CPAP presents other disadvantages (e.g. CPAP 
device needs to be used every and complains of nightmask discomfort, nasal congestion, and nose and 
throat dryness) which are able to compromise patients compliance.   
Consequently, there is consensus that HT related to OSA is gaining more relevance as an independent 
nosological condition that needs a systematic approach to identify the best therapeutic strategy. One 
major challenge is gaining an understanding of whether the blockade of the reflex pathways triggered 
by carotid body activation is sufficiently effective to control BP in itself in HT related to OSA. 
Eventually, other pathways directly stimulated by hypoxia at a cellular level should be explored in 
depth and manipulated to attain relevant clinical control of these patients.  
Moreover, the use of some new non-pharmacological approaches should also be considered for the 
management of HT related to OSA. Taken in perspective, the pathophysiology of this type of HT, 
which involves an increase in sympathetic activity, renal denervation seems to be a logical approach 
since the signalling between the kidneys and the central sympathetic nervous system is bidirectional 
and occurs through the renal afferent and efferent nerves (Böhm et al., 2013). Indeed, accumulating 
evidence indicates that the kidneys act both as a generator and a recipient of sympathetic activity: 
sympathetic afferents travel from the kidneys to the central nervous system and promote sympathetic 
nervous system overactivity in response to renal injury and, vice versa, efferent sympathetic nerves 
travel to the kidneys (Faselis et al., 2014). Moreover, sympathetic overactivity results in enhanced 
renin release, increased sodium and water reabsorption, and reduced renal blood flow and glomerular 
filtration rate (Faselis et al., 2014).  
The beneficial role of renal denervation in the management of resistant HT and other cardiovascular 
diseases has been reported and reviewed extensively (Böhm et al., 2013; Faselis et al., 2014; Grassi et 
al., 2012; Pimenta and Oparil, 2012; Tsioufis et al., 2014; Ukena et al., 2013; Urban et al., 2013). 
Moreover, Shantha and Pancholy (Shantha and Pancholy, 2014) have recently undertaken a systematic 
review of the effect of renal sympathetic denervation on AHI in patients with OSA. Curiously, they 
concluded that this approach is associated with a significant reduction in mean AHI (Shantha and 
Pancholy, 2014). However, as the authors pointed out, these results need further validation due to the 
low causal basis of the studies included in the analysis and due to the fact that only one of these 
studies was performed fully in a specific population of OSA patients; in the remaining studies, the 
diagnosis of OSA was only established after inclusion (Shantha and Pancholy, 2014). In a recent pilot 


















al., 2011). Despite the low causal basis (n=10), their findings demonstrated a significant BP decrease 
within three months, which was further enhanced at six months, exhibiting a drop pattern similar to 
clinical studies in resistant HT (Witkowski et al., 2011). Nontheless, further studies are needed to 
support this impressive effect of renal denervation and to ensure the safety of this technique for 
patients with HT related to OSA. 
Like renal denervation, carotid baroreceptor stimulation has also been proposed as a novel 
antihypertensive therapy based on the recent evidence that baroreceptors might play an important role 
even in long-term BP regulation (Grassi et al., 2012; Lovic et al., 2014; Papademetriou et al., 2011). 
The main similarities and differences between these two novel approaches have been reviewed 
extensively by a group of Italian researchers (Grassi et al., 2014; Seravalle et al., 2014). Although 
electrical baroreflex stimulation appears to be safe and effective, and might represent a useful tool for 
managing resistant HT (Lovic et al., 2014), to the best of our knowledge, the effectiveness of this 
approach has not been yet tested in models of IH. Thus, further investigation in this specific field 
would be welcome.  
In line with the pioneer study performed by Fletcher et al. (1992c) that established that carotid body 
(CB) ablation eliminated the hypertension related to CIH, McBryde et al. (2013) have shown that CB 
deafferentation, through bilateral carotid sinus nerve denervation, promotes an effective and lasting 
AH response in SHR and reduces the overactive sympathetic activity. They have also demonstrated 
that associated with renal denervation, carotid sinus nerve denervation remains effective and produces 
a cumulative response (McBryde et al., 2013). In line with these findings, they propose carotid sinus 
nerve denervation as an effective AH treatment in patients with sympathetically mediated diseases 
(McBryde et al., 2013). 
More recently, Burchell et al. have reviewed the potential of a new device for the control of arterial 
HT (Burchell et al., 2014). The ROX coupler device creates an anastomosis between the iliac artery 
and vein, diverting a calibrated amount of arterial blood into the venous system, reducing vascular 
resistance and increasing arterial compliance (Burchell et al., 2014). This non-pharmacological 
approach seems to be a promising tool in the management of patients with resistant HT due to its 
ability to provide an immediate and sustained reduction in BP (Burchell et al., 2014). The safety and 
efficacy of the ROX coupler in the treatment of this type of HT is now being evaluated in a European 
multicentre randomized study (Burchell et al., 2014). Positive results in patients with drug-resistant 
HT leave open the possibility of the use of the ROX coupler device becoming a new strategy for the 
management of HT related to OSA. 
Furthermore, drugs that have proved to be useful in essential HT treatment should be tested promptly 
in studies specifically designed for secondary HT induced by CIH. On the other hand, given the 
particularities of HT related to OSA, the recourse to tailored treatments should be considered as a 






quickly and effectively in patients with OSA as BP control is still not achievable in a significant 
proportion of these patients.  
Finally, the contribution of animal models to this approach is unquestionable in terms of avoiding the 
confounding risk factors for HT that tend to be present in OSA patients. In addition, drugs that have 
been used as pharmacological tools to understand pathophysological mechanisms should now be 
investigated regarding their efficacy in reversing HT induced by CIH. 
What are the added value and the impact of the present work to the field? 
To the best of our knowledge, this is the first work that described the pattern of AH medication and 
evaluated the hypothetical association between ongoing antihypertensive regimen and BP control 
rates, in patients with OSA. Our findings suggest, for the first time, that none of the currently available 
antihypertensive drugs, either alone or in association, shown to be effective enough to control BP in 
these patients, either before or after CPAP. Moreover, the increase in the number of AHD seems to be 
not relevant to BP control in patients with OSA. Our study was also the first to identify cut-off points 
based on anthropometric measurements that can help the discrimination between misclassified non-
hypertensive patients and truly non-hypertensive patients. These findings may contribute for a more 
selective use of ABPM, a high-cost and time- consuming diagnostic tool and therefore reduce the 
prevalence of undiagnosed hypertension among patients suspected of obstructive sleep apnea. 
Concerning the experimental studies, our results showed the lack of efficacy of carvedilol in reversing 
hypertension induced by CIH in our animal model and suggest that the blockade of sympathetic 
nervous system alone does not seem to be the best strategy for reversing established hypertension in 
sleep apnea conditions. Sympathetic overactivity may be an early step in the mechanism leading to 
more permanent effects due to prolonged sympathetic overactivity or through local effects of recurrent 
IH that are not reversed by drugs such as CVD. This study also pointed out that CIH induces 
pharmacokinetic changes in CVD although are not responsible for its lack of efficacy in reversing this 
particular type of hypertension. Together these findings open up new doors for future research to 
better understand the mechanisms underlying HT related to OSA and to seek novel therapeutic targets 
and strategies to manage this type of HT. At last, our results support that the use of voluntary oral 
administration is a viable alternative, to gavage, for chronic administration of a fixed dose of an AHD 
and also point to a welfare-based refinement for drug administration in laboratory rodents. This 
refinement might be of interest for safety evaluation of drugs, particularly for those which adverse 
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INFORMAÇÃO AO VOLUNTÁRIO DO ESTUDO 
 
A. CONTEXTUALIZAÇÃO E OBJECTIVOS DO ESTUDO 
Foi convidado a participar num estudo, da Faculdade de Ciências Médicas da Universidade Nova de 
Lisboa, intitulado: “Avaliação da terapêutica anti-hipertensora em doentes com Sindroma de Apneia 
Obstructiva do Sono”. Neste documento ser-lhe-à facultada uma breve descrição do mesmo. Esta 
informação deverá ser lida cuidadosamente e caso tenha alguma dúvida adicional deverá esclarecê-la 
com o seu médico assistente. 
A Sindroma de Apneia Obstructiva do Sono é uma morbilidade bastante frequente e que se encontra 
associada a outras patologias. É comum os doentes com apneia do sono evidenciarem hipertensão 
arterial diurna, daí que na sua maioria se encontrem medicados com fármacos anti-hipertensores. 
Neste sentido, o objectivo geral do estudo, em que o convidamos a participar, é justamente contribuir 
para a selecção, de entre os fármacos actualmente disponíveis, da terapêutica anti-hipertensora de 
eleição a implementar aos doentes com apneia do sono. 
 
B. DESCRIÇÃO DOS PROCEDIMENTOS DO ESTUDO 
O estudo irá decorrer nas consultas de Patologia do Sono efectuadas no Centro Hospitalar de Lisboa 
Norte (CHLN) e deverá envolver cerca de 100/150 participantes.  
Numa primeira fase, ser-lhe-ão solicitados os seus dados sócio-demográficos (data de nascimento, 
sexo e raça), antropométricos (peso, altura, perímetro abdominal e perímetro do pescoço) e os dados 
relativos à presença de outras patologias, para além da apneia do sono. Nesta fase ser-lhe-á ainda 
solicitado a avaliação dos seus valores de pressão arterial. Esta avaliação será efectuada em sua casa 
por um período de 24 horas. O aparelho bem como todas as informações relativas ao seu 
funcionamento ser-lhe-ão transmitidas pelo seu médico ou por um técnico de saúde. O seu médico irá, 
igualmente, solicitar-lhe a realização de um estudo do sono, cujos dados obtidos serão também 
incluídos no estudo, e que traga todos os medicamentos que constam da sua medicação actual.  
De acordo com os resultados obtidos através destes exames, o médico poderá prescrever-lhe a 
utilização de um aparelho denominado CPAP que utilizará à noite em sua casa, e a realização de nova 
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É importante que saiba que, todas as avaliações a que vai ser sujeito são realizadas por rotina na 
consulta de patologia do sono da sua unidade de saúde, e, portanto, a sua participação no estudo não 
lhe exigirá qualquer vinda adicional ao hospital.   
 
C. RISCOS E BENEFÍCIOS 
O estudo não tem qualquer risco associado uma vez que apenas lhe pedimos que nos faculte a 
informação que atrás fizemos referência, e os exames a que vai ser sujeito não são invasivos ou 
dolorosos. O seu médico assistente está isento da responsabilidade por quaisquer danos relacionados 
com a sua deslocação às consultas de patologia do sono da sua unidade de saúde. 
Relativamente aos benefícios, apesar de não haver um benefício directo ou a curto prazo para si, os 
resultados obtidos através deste estudo, poderão a longo prazo, contribuir para uma optimização da 
terapêutica anti-hipertensora em doentes com apneia do sono e, consequentemente, para um melhor 
controlo desta patologia. Pela sua participação neste estudo não lhe serão concedidos quaisquer 
benefícios financeiros.  
 
D. CONFIDENCIALIDADE 
A participação neste estudo vai ser mantida confidencial e o seu nome não será revelado a ninguém 
para além do seu médico assistente e do investigador envolvido no estudo. Todos os intervenientes no 
estudo estão sujeitos a confidencialidade. Se os resultados do estudo forem publicados em literatura 
médica, o seu nome não será em qualquer circunstância revelado. 
 
E. BASE DE PARTICIPAÇÃO 
A participação neste estudo é completamente voluntária, não sendo paga qualquer quantia pela sua 
contribuição no estudo. O seu médico assistente também não receberá nenhuma remuneração pela 
realização deste estudo. Pode recusar-se a participar ou desistir do estudo em qualquer altura, sem 
qualquer desvantagem ou perda de cuidados de saúde a que tenha direito. Qualquer dúvida que tenha 






















DECLARAÇÃO DE CONSENTIMENTO INFORMADO 
 
Declaro que li a informação anterior e compreendi o objectivo do estudo. Todas as minhas dúvidas à cerca do 
mesmo foram respondidas pelo meu médico assistente. Toda a informação verbal e escrita e as discussões 
sobre o estudo estão em Português, idioma em que sou fluente.  
Concordo que os meus dados sejam registados e mais tarde possam vir a ser utilizados para publicação dos 
resultados do estudo. Sei que a minha identificação será mantida confidencial. 
Após ter lido cuidadosamente, ter-me sido completamente explicada a informação anterior e ter reflectido, a 
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